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Umbillical cord blood hematopoietic stem and progenitor cells 
General introduction 
1.1 Scope of the thesis 
Hematopoietic stem cells (HSCs) and progenitors are a unique scientific and medical 
resource. Stem cell transplantation (SCT) has achieved significant therapeutic 
success over the last decades. While initially bone marrow (BM) HSCs were used for 
transplantation, mobilization ofHSCs into the peripheral blood (PB) and their collection 
by leukapheresis and use as clinical grafts became feasible. Umbilical cord blood (UCB) 
is a most recent source of HSCs and progenitors, which has been used to treat patients 
with hematological diseases and other severely ill patients whose immune systems 
have been decimated by high dose chemotherapy. Among the various HSC sources for 
transplantation, UCB offers a number of potential advantages: easy access, ability to 
ensure ethnic diversity among donors, low risk of transmissible infectious diseases, no 
risk to donor and no contamination by residual tumor cells. However, reconstitution 
of hematopoiesis after intensive chemotherapy and grafting of UCB cells in children 
and even more in adults, is slower as compared to the use of BM or mobilized PB 
(MPB) grafts. This is most probably due to the low number of transplanted HSCs per 
kg bodyweight. Another problem regarding UCB transplantation is that the collection 
can only take place once, so that additional grafts are not available if so required. 
Combining blood from several umbilical cords has not been felt an option in the clinical 
transplantation setting due to the possible immunological consequences, and therefore 
research has focussed on the development of techniques to increase the number ofUCB 
HSCs in laboratory incubators. 
The ability to isolate and expand cells capable of reconstituting hematopoiesis keeps 
great promise to improve the outcomes of patients treated with autologous and allogeneic 
SCT. Ex vivo expansion may broaden the SCT modality in cases where limited HSCs 
and progenitors are available and where their quality are dramatically reduced, such as 
in UCB grafts or leukapheresis samples from heavily pretreated patients. The morbidity 
caused by prolonged neutropenia leaves patients at risk to develop serious infections. 
The potential for rapid recovery after myeloablative therapy may be accelerated by ex 
vivo generation of the required numbers of the necessary cells. Expansion studies may 
alternatively contribute to the development of culture conditions that permit efficient 
gene transfer into primitive HSCs without their concurrent differentiation-induced loss. 
These studies may also aid in purging stem cell transplants of contaminated tumor cells 
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in an autologous setting for example by specific molecular targeting of tumor cells using 
immunotoxins directed specifically against cancer cell antigens. Finally, another clinical 
application could be the generation of immunologically active cells such as natural killer 
or dendritic cells with antitumor activity to be used in immunotherapeutic regimens. 
The main focus of this thesis is on the development of procedures that allow extensive 
numerical expansion of UCB HSCs and progenitors ex vivo without a concomitant loss 
of the ability for long-term engraftment. 
Expansion in vivo occurs after conditioning and SCT in the BM of man, while it 
occurs in the yolk-sac, aorta-gonad-mesonephros (AGM) region and fetal liver during 
the embryonic development, showing that these regions can produce, maintain and/or 
amplify HSCs and progenitors in vivo. The mechanism(s) involved herein has(have) 
not been elucidated, but in part proposed as a complex interplay between hematopoietic 
cells and cytokines elaborated either locally by stromal cells or peripherally with 
stimulatory (interleukins (!Ls), stem cell factor (SCF), fetal liver tyrosine kinase 3 
ligand (Flt3-L) and thrombopoietin (Tpo)) or inhibitory (transforming growth factor-j3 
(TGF-j3), macrophage inflammatory protein- Ia (MIP-la)) effects on the one hand and/ 
or the microenvironment through adhesion to matrix molecules or stromal cells on the 
other hand. Ex vivo culture systems have been based on mimicking the in vivo situation 
either by exogenous addition of cytokines and/or by the use of stromal cell layers. A 
major step toward extensive ex vivo amplification of hnman HSCs and progenitors has 
been reported after the introduction of the early acting cytokines fetal liver tyrosine 
kinase 3 ligand Flt3-L and Tpo [1-3]. Ample studies have demonstrated the supportive 
capacity of stromal cells on the HSC maintenance and ability to generate progenitors 
in co-cultures [ 4-9]. Despite intensive research, ex vivo expansion of HSCs with long-
term repopulating (LTR) ability is still elusive because the studies either looked only 
at progenitor generation or was not able to obtain expansion of LTR-HSCs. Therefore, 
we aimed to expand LTR-HSCs from UCB in the experimental work presented in this 
thesis. The main topics herein include (I) the analysis of optimal conditions in order to 
numerically expand the HSCs, where in particular the effect of combination of cytokines 
either in the absence or presence of a EM-derived stromal layer has been evaluated; (2) 
the analysis of the HSC supportive capacity of several newly developed stromal clones 
derived from AGM region, where the first definitive adult HSCs appear and expand; 
and (3) studies aimed to identify factor(s) that are involved in stromal support of HSC 
expansiOn. 
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1.2 The hematopoietic system 
Hematopoiesis 
The production of mature blood cells, or hematopoiesis, is a multistep process and takes 
place in the BM. They have a limited life-span and have to be replenished on a daily 
basis so that a life-long production of billions of new blood cells is guaranteed. The 
replenishment takes place by transitory cells known as progenitors, which proliferate 
and differentiate under appropriate stimuli. These developmentally restricted progeny 
originate from a rare pool of BM cells, the hematopoietic stem cells (HSCs) [10]. The 
HSCs have been considered to be a quiescent population with only few clones contributing 
to hematopoiesis during adult life at any moment in time [11, 12]. HSCs are particularly 
confined to the BM [10], however, they are also present in other tissues such as spleen 
and PB. HSCs are characterized by their ability (a) to self-renew; (b) to generate all 
myeloid and lymphoid lineages, and thus to be pluripotent; (c) to long-term repopulate 
a myeloablated recipient; and (d) to display extensive proliferative potential [13, 14]. 
Their progeny are progressively Jess immature and less capable of proliferation and 
differentiation into more than one cell type. The decision of a HSC either to self-renew 
or differentiate, and the commitment to a specific lineage by a multipotent progenitor is 
believed to be a complex process under the control of stochastic and deterministic events 
[15-19]. The HSC compartment is heterogeneous in various aspects. From physical 
sorting of hematopoietic cells it has become apparent that the human HSC compartment, 
in analogy to the situation in the mouse, represents a hierarchy of primitive cells on the 
basis of increasing tum-over rate, increasing chemo- and radiosensitivity, decreasing 
ability to generate new HSCs, decreasing proliferative potential and pluripotentiality 
[20-27]. As a result, in a transplant setting this heterogeneity may be reflected in the 
different time periods that different HSC clones contribute to the reconstitution of a 
conditioned recipient. Murine transplantation studies have revealed a subdivision of 
HSCs in roughly two compartments, existing of cells with short-term repopulating ability 
that are transient and those with long-term repopulating ability which are responsible for 
sustained multilineage hematopoiesis both in vitro and in vivo [28-30]. 
Human hematopoietic stem and progenitor cell purification 
The main problem in hematopoietic cell development studies is the isolation and 
identification of the pluripotent HSC. Many attempts to purify hematopoietic cells have 
used a combination of approaches based on physical and biological properties such as 
immunophenotype of the target cells. Density gradient separation is commonly used 
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as a pre-enrichment step in HSC purification [31]. As most primitive hematopoietic 
cells reside in the G0 phase of the cell-cycle (having low metabolic activity and low 
levels of nucleic acids), the pharmacological cell-cycle specific agents can be used to 
enrich these cells. For this, the DNA stain Hoechst 33342 can be used to isolate G,fG1 
cells, and the RNA stain Pyronin Y can be used to isolate G0 cells specifically [32]. 
Rhodamine!23 has also been used in enrichment strategies [33]. This stain passively 
diffuses into all viable cells, binds to mitochondria and can be efficiently removed by a 
multidrug resistance pump. Because this pump is more active in long-term repopulating 
hematopoietic cells, and resting cells have fewer mitochondria, HSCs are enriched 
in the Rhodaminel23 1'w cell population. Additionally, treatment with 5-fiuorouracil 
or 4-hydroperoxy-cyclophophamide results in elimination of proliferating cells and 
spared non-cycling stem cells [34]. This treatment might, however, be associated 
with potentially irreversible damage to primitive HSCs, which could lead to delayed 
engraftrnent. Another enrichment procedure uses the immunological characteristics of 
different hematopoietic cell populations. Initially, murine HSCs have been successfully 
characterized and phenotyped utilizing fiuorescently labeled monoclonal antibodies 
to cell surface antigens that are present on different hematopoietic cell subsets [35]. 
These stained cells can subsequently be isolated using fluorescent activated cell sorting 
(FACS). The major advance in human HSC purification has been the identification of 
CD34 (a transmembrane glycoprotein as a marker of a heterogeneous cell population 
that is functionally characterized by its in vitro capability of generating colonies derived 
from early and late progenitors and by its in vivo ability to reconstitute the myelo-
lymphopoietic system of an irradiated recipient [36-38]. The CD34 antigen is expressed 
on 1-4% of normal BM, 0.01-0.1% ofPB and 0.1-0.4% ofUCB cells [39]. In contrast, 
recent studies have demonstrated the presence of other candidate human HSCs within 
the CD34· population that do not express lineage markers (Lin·) showing the ability of 
these cells to engraft both primary and secondary recipients [40-44]. The Lin·CD34· 
cells were found with a frequency of0.03%, 0.08% and 0.45% in normal BM, MPB and 
UCB, respectively [43]. Another glycoprotein antigen is AC133, which is selectively 
expressed on CD34+ HSCs and progenitors derived from fetal liver, BM and PB [45-47]. 
Studies have shown that CD34+AC133+ cells derived from UCB were highly enriched 
in long-term culture initiating cells (LTC-ICs), non-obese diabetic/severe combined 
immunodeficiency (NOD/SCID) mice repopulating cells (SRCs) and dendritic cell 
precursors [ 46, 48], providing evidence for the long-term repopulating potential of 
ACJ33+ cells. In summary, HSCs are rare and morphologically not readily distinguishable 
from other cell types within the hematopoietic compartment, contain multiple subsets, 
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and therefore present the investigators and clinicians with an identity problem. The most 
common approach for partial purification is the use of cell surface markers, especially 
the CD34 antigen. These isolated cells are heterogeneous and include cells that are long-
term self-renewing stem cells, short-term progenitors and mature hematopoietic cells. 
To compare the in vitro and in vivo characteristics of different stem cell sources such as 
BM, PB and UCB, one should be aware of the differences in cell-cycle status, engrafting 
capability and cytokine response, which might potentially represent different subsets of 
pluripotent HSCs. 
Human hematopoietic stem and progenitor cell transplantation 
HSC transplantation is increasingly used for the treatment of a variety of hematological 
and non-hematological diseases of neoplastic and non-neoplastic origin [ 49]. The HSCs 
used in human clinical settings are derived from several sources. The classic source 
ofHSC is the BM, which has been used for more than fifty years [50, 51]. Other cells 
that are present in the BM include stromal and stromal progenitor cells, mature and 
maturing hematopoietic cells. Although the main source of hematopoietic cells for 
transplantation was the BM, limitations of this life saving procedure due to the frequent 
lack of an appropriate donor have led to search for alternative sources. As it was known 
for decades that a small number of HSCs with in vivo repopulating ability circulated in 
the PB [52, 53]. Additional studies revealed that administration of cytokines such as 
G-CSF, and/or chemotherapy to the donor dramatically increased the number of these 
cells in the systemic circulation, from which they can be collected by leukapheresis and 
successfully used in transplantations. The probable underlying drive of this mobilization 
process is a threatening depletion of HSC reserve due to infection, blood loss or the use 
of chemotherapy (so called stress hematopoiesis). After the first report of cytokine-MPB 
stem cell transplantation in 1989 [54], donor cells from PB were preferred to use in 
clinical transplantations. Several studies described a faster post-transplant recovery and 
higher survival rates after MPB transplantations as compared to BM [55-57]. However, 
MPB transplants were likely to cause more chronic graft-versus-host disease related 
problems in allogeneic settings due to the fact that these transplants contained more T-
lymphocytes than EM-derived ones, which has been shown to play an important role in 
transplant rejection [58]. To overcome these problems, the transplants were additionally 
depleted for donorT-lymphocytes [59, 60] and/or administered with immunosuppressive 
drugs [ 61]. These latter procedures have also been performed in allogeneic BM 
transplantations to minimize the transplant rejection [60, 62]. The presence of HSCs 
in UCB and placental blood [63, 64] facilitated the potential use of these cells also for 
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HSC transplantation. These tissues support the developing fetus during pregnancy, are 
delivered along with the baby and usually discarded. Since the first successful UCB 
transplant in a child with Fanconi anemia [65], the collection and therapeutic interest in 
these cells has grown quickly [66-68]. Extensive banks of cryopreserved and HLA-typed 
UCB HSCs have been established in many institutions [69-71]. The clinical advantages 
of UCB transplants can be summarized as widespread availability, easy access, low 
risk of transmitting infections and possibly reduced graft-versus-host disease related 
problems [72-75]. The ability to form more colonies in culture, a higher cell-cycle 
rate and the presence of longer telomeres in UCB HSCs contributed to a distinctive 
proliferative advantage as compared to adult-derived transplants [76-82]. However, 
reconstitution of hematopoiesis after intensive chemotherapy and subsequent grafting of 
UCB cells in children, and even more in adults appeared to be slower as compared to the 
use of BM or MPB transplants, resulting in increased risk for infections and bleedings 
in patients. This limited potential for rapid hematological recovery after transplantation 
with UCB cells is probably due to a limited number of HSCs transplanted per kg body 
weight [83-85]. Therefore, a substantial amount of research, which has been conducted 
on UCB, includes the search for ways to expand the numbers of HSCs and compare the 
biological properties of UCB and adult transplants. An important alternative source of 
HSCs in research, but not in clinical use, is the blood producing tissues of embryonic and 
fetal animals [86-90]. The earliest hematopoietic activity, beginning at about day 7 of a 
mouse embryo (E7), is indicated by the appearance of blood islands in the yolk-sac. It 
has been suggested that the yolk-sac hematopoietic cells are transient [91]. Recent data 
strongly suggest that definitive adult HSCs derive from the intra-embryonic splanchno-
pleura, the so called aorta-gonad-mesonephros (AGM) region, rather than the extra-
embryonic yolk-sac [92-94]. In the murine AGM region, hematopoietic cells which 
are capable of reconstituting definitive adult hematopoiesis, first appear autonomously 
at day 10.5 of gestation, expand in number rapidly in the following two to three days 
and migrate to the liver in subsequent couple of days. Here they continue to divide and 
migrate, spreading to the spleen, thymus, and near the time of birth to the BM. Ongoing 
efforts are devoted to identify and characterize the human embryonic and fetal HSCs 
[87, 88]. Recently, HSCs have been found in circulating blood of aborted human fetuses, 
and these circulating cells had different proliferative and differentiative abilities than 
cells from fetal liver, fetal BM and UCB [89, 90, 95]. 
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Regulation of hematopoiesis 
The complex process of hematopoiesis is regulated both positively and negatively by 
the BM microenvironment and/or cytokines, which pose their effects in synergistic, 
recruiting, or antagonistic ways. The fate of HSCs herein can be briefly hypothesized 
as (1) loss by differentiation; (2) maintenance or (3) expansion by self-renewal; (4) 
expansion by induction; or (5) expansion by dedifferentiation (figure 1). Steady-state 
hematopoiesis is believed to be a balance between these positive and negative stimuli, 
in which cytokines, cytokine receptors, direct cell-cell contact as well as indirect 
interactions mediated by matrix components constitute a complex network of growth 
modulators, regulating hematopoiesis within the marrow microenvironment [96-99]. In 
general, an important additional role of stochastic events in regulation of the HSC fate 
is also accepted. The heterogeneous stromal environment, itself a connective tissue, is 
composed of macrophages, endothelial cells, fibroblasts, adipocytes and smooth muscle 
cells. Fibroblasts, adipocytes and smooth muscle cells derive from a pluripotent cell 
located in the marrow [100, 101]. In conclusion, the hematopoietic microenvironment is 
defined largely by function as a complex of cells and factors critical for the maintenance 
and regulation of stem cells and their progeny in vivo. Initially, primary LTCs of marrow 
stroma have been used to approximate the microenvironment in vitro. A large amount 
of work has resulted in the identification of many gene products with in particular 
recombinant cytokines. Cytokines, membrane-bound and soluble glycoproteins, are 
produced by a variety of cells, such as stromal cells, mature blood cells (macrophages, 
T- and B-lymphocytes) and endothelial cells. Some common features of cytokines 
are their activity at picomolar concentrations, the wide range of activities that each 
displays (pleiotropy) and the similarity in activities that different cytokines share 
(redundancy). They are roughly subdivided into early and late acting groups according 
to the position of the target cells in the hierarchy of hematopoietic compartment [102]. 
Early acting cytokines tend to impact on proliferating multipotent HSCs, while late 
acting cytokines act on terminal differentiation of hematopoietic cells. Individual 
cytokines can preferentially act in one compartment, such as Flt3-L and SCF on early 
HSCs, and colony stimulating factors (CSFs) and erythropoietin (Epo) on more mature, 
lineage-committed progenitors, but they can also act on both compartments such as Tpo. 
Multi potent HSCs have been demonstrated to require activation by multiple cytokines 
for their proliferation and maintenance [I 03]. Cytokines mediate their biological 
activities by binding to specific receptors on the surface of the target cells which are 
coupled to intracellular signaling pathways [104]. 
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Figure L Scheme of the mechanisms involved in the regulation of HSC compartment. The decision of a 
HSC either to self-renew or differentiate is believed to be a complex process under the control of stochastic and 
deterministic events. As a result of these events the fate ofHSC can be loss. maintenance or expansion. 
During steady-state hematopoiesis most stem cells are thought to be quiescent. This 
quiescence has been interpreted as an absence of sufficient positive stimulating signals 
andJor the presence of inhibitory signals. Considerable effort has been directed towards 
identifYing signals that can inhibit hematopoiesis, and some have been identified. TGF-
j), MIP-1 a, interferon (INF) and tumor necrosis factor (TNF) have been shown to inhibit 
hematopoiesis in in vitro assays, and in some cases when administered to mice they 
inhibited the cycling activity of progenitors in vivo [I 05-1 09]. 
To study the activities of individual cells within the heterogeneous hematopoietic 
microenvironment stromal cell lines have been established from yolk-sac and embryonic, 
fetal and adult hematopoietic tissues. Stromal cells from the latter two tissues were able 
to maintain HSCs [110-112]. Stromal cell lines from yolk-sac have been demonstrated 
to expand yolk-sac and adult BM hematopoietic progenitors [110, 111]. The embryonic 
AGM region, which generates the first definitive HSCs, has additionally been shown 
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to be an attractive alternative microenvironment to evaluate the HSC growth. To date, 
only two hematopoietic supportive embryonic stromal cell lines, day ll embryo (Ell)-
derived DAS l 04-4 and E l 0.5-derived S3, have been reported to maintain HSCs in vitro 
[112, 113]. Furthermore, Remy-Martin and colleagues demonstrated that most stromal 
cell lines express markers that are generally found on smooth muscle cells as they start 
to differentiate from mesenchymal populations [!!4]. Recently, it has been shown that a 
population ofBM-derived mesenchymal cells can give rise to bone and cartilage, tendon, 
smooth and striated muscles, and stromal cells that support hematopoietic differentiation 
(reviewed in [115-117]). These newly identified non-hematopoietic stem cells have been 
referred to as mesenchymal stem cells. 
1.3 Human hematopoietic stem and progenitor cell assays 
A variety of experimental techniques, i.e. semisolid, suspension and stroma-based 
cultures investigating biological properties and the use of transplantation approaches, 
allowed a description of the heterogeneous and hierarchical developmental stages 
of pluripotent hematopoietic cells and their progeny. All these assays measure HSC 
activity from different perspectives and may therefore detect similar or overlapping 
(sub)populations (figure 2). From a practical point of view, hematopoietic cells that 
can generate active hematopoiesis for weeks in vitro or months in vivo are being 
considered to be LTR cells. This is a clinically adapted and useful criterion because it 
characterizes those cells which are important for sustained hematopoietic recovery after 
transplantation. As several of these assays have been used in this thesis to quantify the 
HSC and progenitor content in uncultured and cultured UCB CD34+ cell populations, a 
brief summary of commonly used in vitro and in vivo assays for human hematopoietic 
cells will be discussed in the following section. 
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Stem cells 
SCID xenograft 
models 
Progenitors 
F eta! sheep xenograft model 
CD.34+ 
or ACl33• 
CD34· 
Figure 2. Scheme of the surrogate hematopoietic stem and progenitor cell assays with their corresponding 
hematopoietic compartments. The endpoints used in this thesis to analyze the stem and progenitor cell properties 
are indicated in gray. 
1.3.1 Immunophenotypic analysis 
To define the surface marker profile ofHSCs, monoclonal antibodies against cell surface 
antigens were developed [118]. Based on the availability of such antibodies most of the 
mature and immature hematopoietic cell subsets can now be defined by their phenotype. 
For instance, cells expressing CD34 on their surface are hematopoietic cells with 
colony forming activity and long-term repopulating ability. The current acceptance of 
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experimental and clinical strategies for the enrichment of human HSCs and progenitors 
relies on the positive selection of cells expressing the CD34 antigen [119]. Additional 
enrichment strategies make use of the presence or absence of other cell surface markers 
on immature HSCs and progenitors and include: Thy-1• [120], CD381owi- [121, 122], 
CD45RA- [123], HLA-DR'ow/- [124], c-kit'owi- [125, 126], AC133• [46, 47], KDR1+ 
[127] and CXCR4+ [131,132]. These markers enable further characterization of the 
heterogeneous CD34 population into functionally distinct subsets. Moreover, recent 
studies define a new subset of cells characterized within the Lin·CD34· population 
that can reconstitute hematopoiesis in xenogeneic transplantation systems [40-44]. Ex 
vivo manipulation of this new HSC subset has shown the generation of CD34. cells, 
CPCs and SRCs, indicating that the CD34- subset contain precursors of CD34+ cells 
[128]. Additional studies reveal that the CD34 expression is reversible and related 
to the activation state of HSCs, as assayed in a mouse transplantation model [129]. 
These findings have resulted in growing controversy on the status of CD34 expression 
as a marker for HSCs and increased the necessity of functional characterization of 
transplantable hematopoietic cells. Whether this new candidate HSC population with 
the CD34- phenotype will find a place in clinical approaches requires the ultimate 
functional human HSC test, including genemarking and the transplantation of the long-
term (several years) multilineage reconstituting HSCs in patients. 
1.3.2 Semisolid colony forming cell (CFC) assays 
CFU-C assays 
The colony forming progenitors are hierarchically organized_ Progenitor cells that 
are restricted in their lineage potential and have limited self-renewal capability can 
be detected in colony forming unit in culture (CPU-C) assays using semisolid media 
[130-132]. These media allow the clonal progeny of a single progenitor cell to stay 
concentrated. Upon culturing for 14 days, committed and multipotentia1 progenitors 
can be distinguished as colonies that contain one or more myeloid and/or erythroid 
lineages. Using specific detection methods and exploiting the differences in size, color 
and morphological characteristics of progenitor subsets, committed progenitors, such as 
CPU-granulocyte, macrophage (CPU-GM) and burst forming unit-erythroid (BPU-E), as 
well as pluripotent progenitors, such as CPU-granulocyte, erythrocyte, megakaryocyte, 
macrophage (CPU-GEMM), can be assayed simultaneously in the same culture_ 
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1.3.3 Stroma-supported long-term culture (LTC) assays 
The hematopoietic microenviromnent is a site of residence of quiescent stem cells and 
provides more than structural support for hematopoietic cells during proliferation and 
differentiation. Observations led to the theory that the microenvironment in which 
HSCs reside influences the commitment process, termed the hematopoietic inductive 
microenvironment. After the introduction of a culture system by Dexter and colleagues 
[133], in which the hematopoietic microenvironment is initiated in tissue culture flasks 
by establishment of a confluent stromal layer, the use of stromal layers has been adapted 
for quantitative and qualitative analysis of primitive HSCs. The commonly used stroma-
dependent assay systems are briefly summarized below. 
CAFC assay 
The cobblestone area forming cell (CAFC) assay is a miniaturized stroma-dependent 
long-term BM culture in which hematopoietic cells are assayed. As an endpoint in the 
assay macroscopic, phase-dark clones formed beneath stromal layer, so called cobblestone 
areas, [134-136] are used as the readout (rather than replating in a progenitor cell assay 
as done in the LTC-IC assay). Initially, murine hematopoietic cells were overlaid on 
irradiated stromal layers in 96-well plates in a range of concentrations, and frequencies 
of cobblestone area-forming cells (CAFCs) were calculated by Poisson statistics. In 
these studies, the time-dependent cobblestone area formation reflected the renewal and 
primitiveness ofCAFCs. The frequency of murine precursors forming cobblestone areas 
on day-28 after culture has been shown to be a measure for marrow repopulating ability 
and on day-35 for LTR ability, whereas day-! 0 CAFC frequency closely corresponded 
witb day-12 CFU-S numbers [24, 29, 137]. In the following years this method has been 
adapted and used to analyze human HSC subsets. The late appearing human CAFCs 
have been shown to have overlapping characteristics to previously reported human LTC-
ICs [138]. The frequency of more primitive progenitors, which are functionally closer 
to the pluripotent HSC in the hierarchical step, has been determined by prolonging the 
culture time of these two assay systems [138-140]. These so called extended LTC-ICs 
and CAFCs were exclusively found in tbe CD34+CD38- fraction of human BM cells, 
whereas standard LTC-ICs and CAFCs were heterogeneous for the expression ofCD38 
within the CD34+ subset. 
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LTC-IC assay 
The LTC-IC assay is a quantitative assay for primitive HSCs based on their capacity to 
generate clonogenic cells in long-term stromal co-cultures for at least five weeks [141-
144]. Clonogenic cell output appeared to be linearly related to the input cell number 
over a wide range of cell concentrations. Using this limiting dilution analysis technique 
the frequency of LTC-ICs in normal human marrow has been established as I per 2 x 
104 MNCs and in a CD34+ purified subpopulation as I per 50-100 cells [141]. Although 
LTC-ICs are among the best available in vitro assay approximating the number ofHSCs 
in humans, they represent a heterogeneous population in terms of proliferative capacity 
and sensitivity to different cytokines. A subpopulation of these cells has been shown 
to share phenotypic and functional properties with long-term in vivo repopulating cells 
[145]. 
LTC-CFC assay 
The long-term culture colony forming cell (LTC-CFC) assay is routinely performed 
in 25T-flasks or large vessels. In this assay the ability of the transplant to generate 
committed progenitors for a period of several weeks to months can be determined. 
The number of progenitors produced at a certain time point in the LTC-CFC assay is 
accepted as a measure for the quality of the transplant [146-149]. The absolute number 
of these cells can be assayed by replating the hematopoietic cells from the adherent 
and non-adherent compartments of these stromal co-cultures into the CFU-C assay. 
Additionally, extension of the culture (referred to as extended LTC) made it possible to 
detect the ability of more primitive progenitors that are probably closer to long-term in 
vivo repopulating hematopoietic cells in the HSC hierarchy [139]. 
1.3.4 Human xenograft models 
The only functional measure of a long-term renewable HSC is the capacity to engraft 
myeloablated recipients and sustain long-term multilineage hematopoiesis in vivo. In 
order to strengthen the functional characterization of human HSCs, investigators have 
directed attention towards development of animal models for hematopoiesis. The most 
frequently used in vivo models for the evaluation of human HSC activities will be 
described briefly in this section. 
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SCID xenograft models 
Recent advances in mammalian genetics have provided a number of immunodeficient 
murine models for engraftment and quantitation of human HSCs. In initial experiments, 
mice triply homozygous for beige, nu, and X-linked immunodeficiency loci, the so-called 
bnx-mice, were used [150-152]. Other immunodeficient models include mice deficient 
in recombination activating gene-1 (Ragl) and Rag2 genes and mice homozygous for 
the Prkdc"" (scid) locus [153-155]. The first successful engraftment of human cells into 
homozygous scid mice was reported in 1988 [156, 157]. In this model, human fetal liver 
or fetal BM, either with or without human fetal thymus tissue, was transplanted under 
the renal capsule of unirradiated scid mice (referred to as SCID-hu mice). Intravenous 
injection of irradiated scid mice with human BM, UCB, or G-CSF cytokine-MPB 
mononuclear cells resulted in the engraftment of a human hematopoietic system in 
the murine recipient [158-162]. Two major limitations of this SCID-hu model are the 
low engraftment levels and the need of human cytokines and/or microenvironment for 
proliferation and differentiation of transplanted HSCs. The use of NOD/SCID mice, 
which are characterized by extremely low NK cell activity, and defective myeloid 
development [163, 164], partly overcomes these problems by providing a niche for 
engraftment and little graft rejection. The cells responsible for the engraftment of the 
BM ofNOD/SCID mice in both myeloid and lymphoid lineages have been termed "scid-
repopulating cells" (SRCs) [38, 165-167]. These cells have been postulated to be more 
primitive than any of the HSC populations that have been identified using the currently 
available in vitro methods [158, 159, 168]. The cell surface phenotype of SRC was 
found to be CD34+CD38· [38, 122]. However, CD34·CD38· or CD34+CD38+ cells were 
also reported to have limited engraftment capacities in transplanted NOD/SCID mice 
[ 43, 169]. Subsequent measurements revealed the frequencies of SRC in UCB, BM, and 
MPB as 1 in 9.3 x 105, l in 3 x 106 and l in 6 x 106 mononuclear cells, respectively, 
as determined by limiting dilution experiments [ 167]. However, Van Hennik et a/ 
indicated that their frequencies might be much higher, as only very limited numbers 
of transplanted human HSCs (0.9%-4% depending on the source) home to the murine 
BM [170]. Recently, an alternative mouse model, the NOD/SCID 132-microglobulin-
deficient (132 m'"11 ) mouse, has been reported [171-173]. As few as 8 x 104 human cord 
blood mononuclear cells transplanted into NOD/SCID/B2m'"11 mice gave multineage 
differentiation in the murine BM, revealing a more than !!-fold higher SRC frequency 
than in NOD/SCID mice. However, the SRCs producing human hematopoietic progeny 
in these mice exhibited only short-term repopulating ability and contained cells also 
expressing the CD38 antigen [174]. While SRCs in the NOD/SCID model are exclusively 
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CD38-, these results indicate that human repopulating cells in NOD/SCID/B2m""11 mice 
represent less primitive progenitors. 
Fetal sheep xenograft model 
Among the xenograft models to study the engraftment ability of human HSCs in vivo, 
the human/sheep xenograft model has several additional unique and advantageous 
aspects [175-178]. One advantage is the immunologic immaturity and developing spaces 
in fetal BM, which allows for donor engraftment in normal recipients without marrow 
conditioning. Transplanted human hematopoietic cells have been shown to colonize the 
BM, to remain there for several years contributing to multilineage differentiation, to 
respond to human cytokines, and to retain their ability to engraft secondary recipients. 
The large size of the recipient permits repeated evaluation of human cell activity in the 
same chimeric sheep over prolonged periods of time. All these features make this assay 
perhaps the most promising biological in vivo system for human HSCs. However, the 
high frequency of unsuccessful transplantations and abortions and the expensive costs 
limit the widespread use of this model. 
1.3 Experimental/clinical history of ex vivo expanded human hematopoietic stem and 
progenitor cells 
Experimental studies 
Effect of cytokines. To date, most research on ex vivo expansion has explored different 
combinations of cytokines, culture medium ingredients and the role of stromal support. 
In the early 1990s our group started to evaluate the numerical expansion of murine 
HSCs and progenitors derived from the BM. In these initial studies many permutations 
of cytokines and their concentration have been analyzed [135, 179-182]. Although the 
combination of several cytokines (for example IL3 + ILll/ILl2 + SCF) revealed a high 
increase in the numbers of progenitors and short-term repopulating murine HSCs (300 
to 1000-fold the input in 5-7 days of culture), a moderate increase or even decrease was 
observed with LTR-HSCs (0.1 to 3-fold the input) . In the following years, Breems et 
a! attempted to expand human HSCs and progenitors derived from normal BM, MPB 
or UCB under the same conditions and within the same experiment. It was found that 
the frequency as well as the quality of HSCs and progenitors in primary samples of 
individual MPBs [136, !49] and UCBs (unpublished data) was extremely variable 
as compared to the BM samples. In these studies a moderate numerical expansion of 
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various HSC and progenitor subsets was observed. However, this was at the expense 
of their quality in functional assays [5]. The cytokine-supplemented cultures required 
stroma for optimal maintenance of graft quality [6]. Ample other studies, in which LTC-
ICs or in vivo repopulating ability were used as endpoints, have reported that human 
HSCs could quantitatively be maintained or slightly increased (<5-fold the input values) 
in culture [183-187]. In addition, the culture time was found to be detrimental for the 
HSC survival. Primitive HSCs were reportedly lost after a culture period of 5-7 days, 
while the number of progenitors and CD34+ cells increased several hundred times as 
compared to the uncultured cells [188, 189]. All together, until the end of the 1990s the 
expansion of committed progenitors has been reported frequently, while the ability to 
expand more primitive HSCs has met with little success. 
Based on our previous results and the results of others, IL3, IL6, ILl!, G-CSF, SCF, 
Flt3-L and Tpo were selected as the candidate cytokines for use in HSC expansion 
studies. GM-CSF and Epo have also been used by many others but resulted only in 
extensive production of erythrocytes and granulocytes/monocytes with no significant 
effect on HSC and progenitor expansion. The most promising expansion results were 
obtained from the introduction ofFlt3-L and Tpo. The receptors of both of these ligands 
are expressed on early and committed progenitors. Analysis of the effect of different 
cytokine combinations on stroma-free cultures of CD34.CD38· BM cells indicated that 
Flt3-L, SCF and IL3 gave the highest expansion of the input LTC-ICs [190, 191]. In 
another study the addition ofFlt3-L, in conjunction with IL3, IL6 and SCF, in suspension 
culture during in vitro transductions maintained the ability of human CD34+ cells to 
sustain long-term hematopoiesis in vivo [192]. Tpo has also been reported to increase the 
multilineage growth of CD34+CD38· bone marrow cells under stroma-free conditions 
when added to the cytokine combination Flt3-L and SCF [193]. Others demonstrated 
that maximal expansion of progenitors by Flt3-L +ILl! required longer incubation than 
with SCF + IL 11 indicating involvement of different kinetics in enhanced production 
of progenitors [194]. The evaluation of all these cytokines resulted in the conclusion 
that Flt3-L and Tpo were able to give a moderate increase of CD34+CD38· derived 
LTC-ICs. Other reports emphasize an important role for the multifunctional cytokine 
IL6 in the regulation of hematopoiesis. This pleiotropic molecule has been shown to 
act synergistically with IL3 and SCF to enhance the proliferation of human progenitors. 
Because the intracellular portion of its receptor (IL6R) is very short, an associated 130-
kDa (gp 130) molecule that lacks IL6 binding activity appears to be required for the 
signal transduction. Moreover, gp 130-deficient mouse embryos show greatly reduced 
numbers of progenitors, thereby underlining the importance of this signal transduction 
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pathway in the regulation of hematopoiesis. Gpl30 is ubiquitously expressed on blood 
progenitors, whereas the expression of IL6R seems to be limited to approximately 30-
50% ofCD34+ UCB and 80% ofCD34+ PB cells [195, 196]. These results support and 
extend the studies of several investigators [197-199] who tested a complex ofthe soluble 
IL6R and IL6 (IL6/siL6R) in combination with SCF or Flt3-L in three-week stroma-free 
cultures and methylcellulose clonal assays, and demonstrated an increased expansion 
of multipotential and committed progenitors from UCB or EM-derived CD34+ cells. 
In addition, Zandstra et al reported a higher LTC-IC expansion in one-week serum-
free cultures of CD34+CD38· UCB cells stimulated by Flt3-L, in combination with the 
IL6/siL6R complex, when compared to the combinations of Flt3-L plus Tpo or Flt3-L, 
SCF, IL6, IL3 plus G-CSF [200]. Among the various early acting cytokine combinations 
tested for their ability to sustain long-term hematopoiesis in stroma-free cultures using 
CD34+ UCB cells, Flt3-L and Tpo were found to be necessary and sufficient to maintain 
early HSCs for several months [1, 2]. In these studies the number of LTC-!Cs were 
reported to be 2 x 105-fold increased and the CFU-GM were 2 x 106-fold increased after 
5 to 6 months of stroma-free cultures, respectively. These authors demonstrated that IL3 
induced the production of committed progenitors and was unable to sustain maintenance 
of HSCs. Recently, these authors also demonstrated that the SRCs were markedly 
expanded using Flt3-L, Tpo, SCF and IL6 in combination under the same conditions 
after ten weeks of culture [3]. Also, the addition of IL6/s!L6R complex instead of!L6 to 
the cytokine combination Flt3-L, Tpo and SCF has been shown to expand the SRCs in a 
7-day stroma-free cultures [201]. 
Another area where cytokines are involved is that of homing and migration of HSCs 
and progenitors. An important feature of intravenously infused HSCs and progenitors 
is the ability to migrate to sites that can sustain hematopoiesis, in order to guarantee 
a life-long regulated preservation and outgrowth of hematopoietic cells responding to 
the body's demand. This homing process can be considered to be multifactorial, similar 
to what has been found for trans-endothelial migration of leukocytes [202, 203]. The 
receptors involved in the regulation of homing of HSCs to the BM belongs to the so 
called G-protein-coupled seven transmembrane spanning receptor superfamily [204, 
205]. The ligands for these receptors have been referred to as chemoattractant cytokines, 
or chemokines [206]. Progress in understanding the specific interactions ofhematopoietic 
cells with chemokines has emerged from in vitro transwell migration studies [207-212]. 
The chemokine stromal cell-derived factor SDF-1 has been shown to strongly attract the 
CD34+ cells [207, 210, 211, 213-215]. It has also been shown to be a chemoattractant 
for monocytes and lymphocytes. In addition, this chemokine was found to be critical 
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for bone marrow engraftment. It binds to its receptor CXCR4, which is expressed on 
many cell types including CD34.CD38- cells, and. attracts CD34+CXCR4• HSCs and 
progenitors. Its important role in homing is illustrated by the absence of hematopoiesis 
in the bone marrow of mice that lack SDF-1 or do not express CXCR4 [216-218]. 
CXCR4 expression on human CD34+ cells can be enhanced by SCF and IL6 [172]. 
This enhanced expression has been suggested to potentiate migration towards SDF-1 
and engrafment in primary and secondary transplanted NOD/SCID mice. The CXCR4 
antagonist 12G5 (Pharmingen) or MBA171 (R & D Systems) completely abrogate HSC 
engraftment in this modeL Finally, the analysis of different HSC sources revealed that 
UCB have a significantly higher migratory potential than did BM or PB [21 OJ. All 
together, the process of homing can also be of importance in ex vivo expansion studies, 
as it may change the expression of appropriate molecules on HSCs and progenitors, 
which in tum affects the homing of these cells in vitro or in vivo. 
Effect of stroma in the presence or absence of cytokines. There is extensive data 
on the supportive capacity of stromal cells on the maintenance of primitive stem cells 
and their ability to generate progenitors in LTCs. However, the requirement for a 
stromal microenvironment in ex vivo amplification of HSCs and progenitors remains 
controversiaL In the absence of exogenous cytokines, stromal support derived from 
adult animals fails to significantly expand in vitro and in vivo repopulating cells [135, 
160, 188, 219]. In the presence of exogenous cytokines, lineage negative CD34.Thy-
l + human BM cells expanded on a porcine microvascular endothelial cell layer were 
consistently capable of competitive marrow repopulation with multilineage progeny 
present eight weeks post-engraftment, while grafts composed of cells expanded in 
stroma-free cultures did not lead to multilineage repopulation in vivo [7]. We have 
previously reported that exogenous cytokines, in conjunction with stroma-conditioned 
medium (harvested without the use of cytokines), enhanced the expansion of primitive 
HSCs from CD34+ selected MPB in short-term stroma-free cultures, while stroma 
and cytokines were also required for optimal maintenance and graft quality [5, 6]. In 
particular, the inclusion of Tpo in Dexter-type cultures has been shown to dramatically 
increase the longevity of hematopoietic activity and maintenance of in vivo repopulating 
ability of stem cells, indicating the importance of this cytokine in stroma-supported 
cultures [220, 221]. In the presence of the cytokines Flt3-L, Tpo, SCF, IL6 and GM-CSF, 
endothelial-based culture of UCB CD34.CD38- cells has been reported to give a higher 
CAFC expansion (11-fold increase) as compared to a 4-fold increase under stroma-free 
conditions after three weeks of culturing [222]. Both myeloid and lymphoid progenitors 
from UCB and MPB could be expanded in the presence of the murine fetal liver cell 
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line AFT024 under two to five-week stroma-contact and stroma-non-contact culture 
conditions supplemented with at least Flt3-L and Tpo [223]. A study of Xu eta!. showed 
that the stromal cells without exogenous addition of cytokines can also maintain in vivo 
repopulating ability ofCD34+CD38· UCB cells during a four-week culture period [112]. 
It should be noted that these cells were supported by a different stromal layer derived 
from the murine embryonic AGM region as compared to other studies. All these data 
together suggest that both stromal cells and exogenous cytokines, including at least Tpo, 
are required for maintenance and/or expansion ofHSCs in ex vivo cultures. There is still 
insufficient data on which factors contribute to this support under stromal conditions. 
However, the combination of stromal support and cytokines may potentially lead to 
dramatic improvement of the longevity of repopulating characteristics of HSCs and 
progenitors in cultures exceeding a time period of about two weeks as is the case when 
Tpo is used in stroma-supported BM cultures. 
Clinical studies 
Preclinical studies in normal baboons have demonstrated the potential clinical benefit 
of ex vivo expanded cells [224]. Baboons that were transplanted with expanded CD34+ 
MPB cells and given G-CSF and Tpo, showed a significantly shorter duration of 
neutropenia. On the basis of experimental findings and the development of automated 
closed-system for cell growth [225, 226], human clinical trials began. Initially, ex vivo 
expanded cells derived from BM were infused in combination with conventional cells 
[227]. After infusion of these cells no toxicity was observed demonstrating the feasibility 
of the expansion procedures and the clinical safety of the approach. Most importantly, 
a potential benefit was observed as measured by shortening of hospital stays, time to 
platelet recovery and days of febrile neutropenia when "' 60% of a standard cell dose 
of 1 x 105 CFU-GM/kg were infused. Additionally, a successful engraftment with only 
expanded BM HSCs was achieved in patients after high dose chemotherapy [228, 229]. 
The expanded cells used for infusion were obtained using a stroma-based continuous 
perfusion method with addition of the cytokines GM-CSF/IL3 fusion protein, Flt3-L 
and Epo or Tpo. These studies verify the importance of the combination stromal cells 
and cytokines in order to ex vivo expand transplantable HSCs and extend our previous 
data [ 6] where we show the requirement of stromal support for optimal maintenance of 
the graft quality. Several other groups reported decreased time to neutrophil recovery 
with ex vivo expanded PB cells. These authors cultured either C34+ cells or mononuclear 
fraction under similar conditions in teflon bags containing Defined Media (Amgen) 
supplemented with SCF, G-CSF and Tpo at 100 ng/ml for ten days [230-232]. Another 
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application of expanded hematopoietic cells, particularly more mature cells, has been 
explored as a means to accelerate the rate of recovery after myeloablative therapy. 
Along this line, Paquette et a! demonstrated that ex vivo expanded PB progenitors 
could ameliorate post-transplantation neutropenia, thrombocytopenia and anemia 
[232]. Also the successful clinical transplantation of ex vivo expanded UCB HSCs and 
progenitors has been described. In these studies transplantations have been performed 
with uncultured and ex vivo cultured cells together [233-236]. Therefore, the precise 
role of cultured UCB cells in post-transplant recovery could not be analyzed. To better 
evaluate the engraftment dynamics of cultured UCB cells in human, Fernandez et a! 
used a model of simultaneously transplanting cells from two different donors to the same 
patient [237]. Preliminary results of patients that have received one uncultured UCB 
unit and one cultured UCB CD34+ cells derived from a secondary UCB unit showed 
no significant contribution of cultured cells to early engraftment. Interestingly, also no 
prohibitive unfavorable immunological problems have been observed. Most of these 
human trials indicate the potential clinical use and benefit of expanded cells in post-
transplant rate of the neutrophil recovery, while the effect of expansion on long-term 
engraftment ability remains unanswered. These studies show no additional effect on 
platelet recovery after infusion of expanded cells independent of their source. Possible 
explanations therefore may be that the culture conditions do not support progenitors that 
differentiate into platelets and/or that expanded cells need cytokines such as Tpo for 
platelet development. 
Although ex vivo expanded HSCs have been and are being used in clinical settings, it 
is still unknown how many cultured HSCs are needed to successfully and rapidly engraft 
a recipient. It is also unknown what the loss is in graft quality during cultures. Clinical 
analysis has emphasized that the factor in predicting a positive outcome for transplant is 
the number ofUCB nucleated cells infused, and should be >3 x 107/kg body weight [70]. 
Others confirmed that reliable engraftment occurs after UCB transplantation with 3 to 
4 x 106/kg CD34+ cells [238]. The median body weight in these studies ranged between 
17-19 kg. In the experiments carried out in our laboratory we observed a mean absolute 
number of 2.2 x 104 CFU-GM and 4.1 x 103 CAFCwookG per 105 uncultured UCB CD34+ 
cells. The SRC frequency in UCB has been calculated as I in 1.5 x 1 0' uncultured CD34+ 
cells [239]. According to these data we made an estimation of the expansion factor 
for CFU-GM, CAFCw"'' and SRC being around 4-fold the input values for an adult 
recipient of 70 kg. Another application of expanded HSCs is to reduce the recovery time 
of neutrophils and platelets after myeloablative therapy. The recovery time after SCT is 
three to four weeks depending on the stem cell source being used [68, 70, 75, 83, 84]. 
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Several in vitro studies determined the doubling time of human HSCs and progenitors 
derived from UCB or MPB as being one to three days depending on the cytokines used 
in culture [240-242]. Assuming a one day doubling time, we estimated the required 
expansion factor ofHSCs and progenitors range between 1.3 x 102 and 3 x 104 fold the 
input value if a reduction of one and two weeks, respectively, for neutrophil and platelet 
recovery would be needed. Therefore, we aimed to obtain these increases for HSCs and 
progenitors with maintenance of the individual stem cell quality in the grafts. 
1.4 Outline of the thesis 
The goal of this thesis research is to establish ex vivo expansion conditions for HSCs 
derived from UCB. To realize the expansion of HSCs, CD34+ or ACJ33+ UCB cells 
were cultured in the absence or presence of various cocktails of early acting cytokines 
including Flt3-L, Tpo, SCF or IL6 under stroma-free or stroma-supported conditions. 
The HSC and progenitor expansion was assessed using in vitro and in vivo long-term 
repopulating cells. 
First, the experiments were designed to test whether HSC expansion would alter the 
in vivo long-term engraftment potential of CD34+ UCB cells in the presence of EM-
derived stromal cells during two weeks. Also the cytokines required for expansion of 
HSCs and progenitors in either the presence or absence of stroma have been evaluated. 
The experiments described in chapter 3 are closely linked to the work described in 
the previous chapter. They were designed to investigate whether HSC expansion could 
be improved when cultured for more than two weeks, and whether the presence of EM-
derived stromal cells, and combinations of specific cytokines could affect the HSC and 
progenitor maintenance or expansion. 
In chapter 4 the effect of a new fusion protein ofiL6 and the soluble IL6R, H-IL6, has 
been evaluated on the long-term ex vivo expansion ofHCSs derived from AC133+ UCB 
cells. To do this, we used stroma-free and stroma-supported LTCs and compared several 
cytokine combinations in the presence or absence of this chimeric protein, or IL6, and 
estimated the HSC and progenitor output by multiparameter FACS analysis and CAFC 
assays. 
Following these experiments, nineteen newly established murine embryonic stromal 
clones have been investigated for their ability to sustain human HSCs and progenitors 
in extended LTCs of CD34+ UCB cells in the absence or presence of the cytokines Flt3-
L and Tpo for periods as long as twelve weeks. A significant proportion of HSC and 
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progenitor subsets was found in the non-adherent compartment of these co-cultures. 
With an interest to elucidate the factors that determine the proportion of adherent and 
non-adherent compartments, we evaluated in chapter 6 the chemoattractive activity of 
different stromal cells and the effect of exogenously added cytokines herein. 
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Umbillical cord blood hematopoietic stem and progenitor cells 
Abstract 
In view of the limited potential for rapid hematological recovery after transplantation of 
umbilical cord blood cells (UCB) in adults we have attempted to expand CD34+ selected 
hematopoietic stem cells (HSCs) and progenitors in two-week cultures of whole graft 
pools in the presence or absence of serum and stromal layers, and with various cytokine 
combinations including a) Flt3-L + Tpo, b) Flt3-L + Tpo plus SCF and/or IL6, or c) 
SCF + IL6. Both in the input material and cultured grafts we determined the number of 
colony-forming cells (CFC), cobblestone area forming cells (CAFC), the NOD/SCID 
repopulating ability (SRA), and CD34+CD38· subset by phenotyping. The highest fold-
increase obtained for the number of nucleated cells (nc), CD34+, CD34+CD38· cell 
numbers and CFC content was, respectively, 102 ± 76, 24 ± 19, 190 ± 202 and 53 ± 
37 for stroma-free and 315 ± 110,25 ± 3, 346 ± 410 and 53± 43 for stroma-supported 
cultures. CAFCw"'' was maximally 11-fold expanded both under stroma-free and 
stroma-supported conditions. The FBMD-1 stromal cells supported a modest expansion 
ofCD34+CD38· cells (27 ± 18-fold) and nc (6 ± 4-fold), while a loss ofCFC and CAFC 
subsets was observed. The stromal cells synergized with Flt3-L + Tpo to give the highest 
expansion of hematopoietic progenitors. Stromal support could be fully replaced by 
complementing the Flt3-L + Tpo stimulated cultures with SCF + IL6. Flt3-L + Tpo were 
required and sufficient to give a I 0- to 20-fold expansion of the ability of CD34+ UCB 
cells in two-week cultures to engraft the BM of NOD/SCID mice. Stromal support, or 
complementation of the medium with SCF + IL6, did not significantly improve the in 
vivo engraftment potential. If the SRA and CAFCw"'' assays are accepted as tentative 
estimates of in vivo engrafting stem cells in humans, our findings may assist in the 
preparation of UCB grafts to meet the requirements for improved repopulation in the 
clinical setting. 
Introduction 
The discovery that umbilical cord blood (UCB) HSCs could be used as an alternative 
source to rescue myeloablated pediatric patients broadened the bone marrow (BM) 
transplantation treatment modality. However, reconstitution of hematopoiesis after 
intensive chemotherapy and grafting of UCB cells in children and even more in adults 
is slower compared to the use of BM or mobilized peripheral blood grafts [I]. This 
prolonged period of aplasia results in increased risk for infections and bleedings in 
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patients. The limited potential for rapid hematological recovery after transplantation of 
UCB cells is probably due to a limited number of nucleated cells and HSCs transplanted 
per kg BW, and may therefore be abrogated by ex vivo generation of the required 
numbers of stem and progenitor cells. Expansion studies might also increase our current 
know ledge on the regulation of hematopoiesis, contribute to new treatment strategies of 
hematological diseases and aid in manipulating stem cells as vehicles for gene therapy. 
Although ample studies on the culture of CD34+ UCB cells have been published in 
the last years, and expansion of committed progenitors has been reported, the ability to 
expand more primitive HSCs has met with little success [2]. The most promising results 
have been obtained after the introduction of Flt3-L, the ligand of the class III tyrosine 
kinase receptor Flt3, and Tpo, the ligand of c-mpl receptor, both receptors are expressed 
on early and committed hematopoietic progenitors. Analysis of the effect of 16 cytokines 
on stroma-free cultures of CD34+CD38· bone marrow cells indicated that Flt3-L, SCF 
and IL3 gave the highest (30-fold) expansion of the input long-term culture-initiating 
cells (LTC-I C) [3]. In an other study addition ofF!t3-L maintained the ability of human 
CD34+ cells to sustain long-term hematopoiesis [4]. Tpo has also been reported to 
increase the multilineage growth of CD34+CD38· bone marrow cells under stroma-free 
conditions when added to the cytokine combination Flt3-L and SCF [5]. The presence 
of additional cytokines e.g. IL3, IL6 and Epo did not significantly enhance the colony 
formation above that observed with Flt3-L, Tpo and SCF. Others demonstrated that 
maximal expansion of progenitors by Flt3-L + ILl! required a longer incubation than 
with SCF + ILl! indicating involvement of different kinetics in enhanced production 
of progenitors [6]. A major step toward extensive ex vivo amplification of early human 
progenitors has been reported by Piacibello et al. These authors demonstrated that IL3 
induced production of committed progenitors and was unable to sustain maintenance of 
hematopoietic stem cells. Among the various early acting cytokine combinations tested 
for their ability to sustain long-term hematopoiesis in stroma-free cultures using CD34+ 
UCB cells, Flt3-L and Tpo were found to be necessary and sufficient to maintain early 
progenitors for several months [7 -9]. 
Until recently, investigators have included CD34+ cells, or subsets, and LTC-IC 
or cobblestone area forming cell (CAFC) in vitro assays to measure the HSC activity 
after expansion studies, but few have evaluated the genetically immunodeficient mice 
repopulating ability of these expanded HSCs [10-12]. In HSC expansion studies, 
investigators also emphasized the role played by microenvironment, with stromal 
cells as essential components. Multiple mechanisms have been proposed to explain the 
regulatory effect of stromal cells on HSC functions such as survival of quiescent cells, 
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increased proliferation and differentiation, or, decreased cell proliferation mediated by 
contact with stromal elements [2, 13, 14]. However, there is incomplete evidence as to 
whether expansion ofNOD/SCID repopulating cells (SRC) is increased in the presence 
of a EM-derived stromal layer. In the present study we examined if HSC expansion in 
the presence of a EM-derived stromal cells, in synergy with potent cytokines during two 
weeks, will alter the in vivo long-term engraftment potential of CD34+ UCB cells and 
which cytokines are required in the presence or absence of stroma. Both in vitro (CAFC) 
and in vivo (SRC) HSC assays that have been reported to correlate with (multilineage) 
engraftment potential have been used simultaneously in each experiment, to evaluate the 
changes of cultured cells from different perspectives. We demonstrate that stroma is not 
required for NOD/SCID repopulating ability in two-week cultures by a combination of 
cytokines when Flt3-L and Tpo are included. 
Materials and methods 
Human umbilical cord blood cells. Human UCB samples were collected from umbilical 
cord vein after full-term delivery by the nursing staff of the Department of Obstetrics 
and Gynecology at the Sint Franciscus Gasthuis (Rotterdam, The Netherlands). Informed 
consent for taking samples for clinical study was obtained. UCB was collected in sterile 
flasks containing 1 0 ml citrate-glucose as anticoagulant, stored at room temperature and 
processed within 24 hours of collection. 
Isolation of CDJ4+ cells. Low-density cells were isolated using Ficoll Hypaque 
density centrifugation (1.077g/cm2 , Lymphoprep, Nycomed Pharma, Oslo, Norway). 
After centrifugation at 600 g for 15 minutes, the mononuclear cell (MNC) band at the 
interface was removed, washed twice with Hanks Balanced Salt Solution (HBSS, Gibco, 
Breda, The Netherlands) and resuspended in Iscove's modified Dulbecco's medium 
(IMDM, Gibco, Breda, The Netherlands). The MNCs were stored in liquid nitrogen 
until use. After thawing and before the CD34+ hematopoietic progenitor cells were 
isolated we pooled 5 to 20 different UCB samples. The CD34+ cells were harvested from 
the mononuclear cells using Variomacs Immunomagnetic Separation System (Miltenyi 
Biotec, Bergisch Gladbach, Germany). The CD34+ cells were labeled indirectly using 
a hapten-conjugated primary monoconal antibody and an anti-hapten antibody coupled 
to MACS microbeads. The magnetically labelled cells were enriched by passing them 
twice through a Variomacs positive selection column to reach a final purity of> 90% 
CD34+ cells. A nuclear cell count was performed and the progenitor and stem cell 
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numbers in the CD34+ selected UCB cells were assayed by CFC, CAFC and NOD/SCID 
repopulating cell assays. In addition, the immunophenotypic characteristics of the cells 
were assessed and part of the CD34+ cells were cultured for two weeks. 
Hematopoietic growth factors. The following cytokines were used: recombinant 
human stem cell factor (SCF) and FLT3-ligand (Flt3-L), both gifts from Amgen 
(Thousand Oaks, CA, USA); recombinant human interleukin 6 (IL6), recombinant human 
granulocyte-macrophage colony stimulating factor (GM-CSF), recombinant human 
granulocyte colony stimulating factor (G-CSF), murine stem cell factor (SCF), all gifts 
from Genetics Institute (Cambridge, MA, USA); recombinant human thrombopoietin 
(Tpo, a gift from Genentech, South San Francisco, CA, USA), recombinant human 
erythropoietin (Epo, Boehringer, Mannheim, Germany) and IL3 (Gist Brocades, Delft, 
The Netherlands). 
Ex vivo expansion cultures. Various culture conditions were used in I 0 consecutive 
experiments. In the first two experiments 5.0 xl04 CD34+ UCB cells were cultured 
in tissue culture 6-well plates (Costar, Badhoevedorp, The Netherlands) in an I ml 
IMDM-cocktail containing 10% fetal calf serum (FCS, Summit, Fort Collins, CO), I% 
bovine serum albumin (BSA, Sigma, Zwijndrecht, The Netherlands) supplemented with 
penicillin (I 00 U/ml, Gibco ), streptomycin (0.1 mg/ml, Gibco ), ~-mercapto-ethanol (I o· 
4 M, Merck, Darmstadt, Germany), bovine insulin (4 mg/ml, Gibco), cholesterol (15 f,IM, 
Sigma),linolic acid (15 f,IM Merck) iron-saturated human transferrin (0.62 g/1, Intergen, 
Uithoom, The Netherlands), nucleic acids (cytidine, adenosine, uridine, guanosine, 
2' -deoxycytidine, 2 '-deoxyadenosine, thymidine, 2 '-deoxyguanosine (all at JO·' g/ml, 
Sigma)) and the cytokines Flt3-L (50 ng/ml), Tpo (10 ng/ml), SCF (100 ng/ml), IL6 
(100 ng/ml). The cells were cultured with the following combination ofcytokines: Flt3-
L + Tpo, Flt3-L + Tpo + SCF, Flt3-L + Tpo + IL6, Flt3-L + Tpo + SCF + IL6 or SCF 
+ IL6. Cultures were set up using six to eight replicates of each cytokine combination. 
Additionally, 5.0 xl04 CD34+ cells were deposited in tissue culture 25T-fiasks in 4 ml 
IMDM-cocktail containing 20% FCS with these same cytokine combinations. Cells were 
also cultures in the absence of cytokines. In the following part of the study, 6.45 xi 05 
or 7.0 xl05 CD34+ cells were cultured in tissue culture 175T-fiasks (Falcon, Etten-Leur, 
The Netherlands) with the cytokine combination Flt3-L + Tpo + IL6 in 10 ml IMDM-
cocktail without BSA containing 5, 10 or 20% FCS. Finally, 3.5 xl04or 4.0 xl04 CD34+ 
cells were deposited in tissue culture 25T-fiasks in 4 ml IMDM-cocktail without BSA 
containing 20% FCS supplemented with the following cytokines: Flt3-L + Tpo, Flt3-L 
+ Tpo + SCF, Flt3-L + Tpo + SCF, Flt3-L + Tpo + SCF + IL6. The effect of the murine 
FBMD-1 stromal layer on the in vitro and in vivo repopulating ability was assessed 
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for the cytokines Flt3-L + Tpo, Flt3-L + Tpo + IL6, Flt3-L + Tpo + SCF + IL6, and 
SCF + IL6. Insulin was not added in the stromal groups because it potently stimulated 
adipogenesis in FBMD-1 cells. 
In the second part of the study, 3.5 xl05 and 7.75 xl05 CD34+ UCB cells were 
cultured in tissue culture 1 75T-flasks using 10 or 18 ml Cellgro• stem cell growth 
medium (SCGM, Boehringer Ingelheim, Heidelberg, Germany) with or without 10% 
FCS supplemented with the cytokine combinations Flt3-L + Tpo, Flt3-L + Tpo + SCF 
+ IL6, Flt3-L + Tpo + IL6 or SCF + IL6. In the last set of experiments, 4.0 x 104 CD34+ 
cells were deposited in tissue culture 25T-flasks in 4 ml SCGM containing 20% FCS 
supplemented with the following cytokines: Flt3-L + Tpo, Flt3-L + Tpo + SCF, Flt3-L 
+ Tpo + IL6 or Flt3-L + Tpo + SCF + IL6. The effect of the murine FBMD-1 stromal 
layer on the in vitro and in vivo repopulating ability was assessed for the cytokines Flt3-
L + Tpo, Flt3-L + Tpo + IL6, Flt3-L + Tpo + SCF + IL6 and SCF + IL6. Cells were also 
deposited on a stromal layer without any cytokine supplements. SCGM without insulin 
was used in stromal groups to prevent adipocyte formation. In all experimental sets Flt3-
L and Tpo were added twice a week to the expansion cultures. 
The cultures were maintained at 37°C and 10% C02 in a humidified atmosphere and 
terminated at week 2 by collecting the supernate after scraping each well or flask with 
a cell scraper to include all the adherent cells. The stromal groups were first trypsinized 
with trypsin-EDTA (Life Technologies, Breda, The Netherlands). The content of the 
various dishes or flasks belonging to a single group were pooled, centrifugated at 250 g 
for 10 minutes and resuspended in IMDM. Suitable aliquots of the output suspensions 
were assayed in CFC, CAFC and SRC assays for determination of progenitor and stem 
cell numbers. In addition, the immunophenotypic characteristics of the cultured cells 
were analyzed. 
Clonogenic assay. Granulocyte-macrophage colony forming unit (CFU-GM) and 
burst forming unit- erythroid (BFU-E) progenitor cells were assayed using a semisolid 
culture medium (1.2% methylcellulose), containing IMDM supplemented with 30% 
FCS, 13-mercapto-ethanol (5 x 10·' M), penicillin (100 U/ml), streptomycin (0.1 mg/ml), 
hu-Epo (I U/ml), hu-IL3 (20 ng/ml), hu-GM-CSF (5 ng/ml), hu-G-CSF (50 ng/ml) and 
mu-SCF (1 00 ng/ml). Duplicate cultures were plated in 35 mm tissue culture dishes 
(Falcon) and incubated at 3rC and 10% C02 in a humidified atmosphere for 14 days. 
Colonies containing 50 cells or more were scored at day 14 using an inverted light 
microscope. 
Cobblestone area forming cell assay. Confluent stromal layers of FBMD-1 cells in 
flat-bottom 96-well plates (Falcon) were overlaid with UCB cells in a limiting dilution 
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set up as described [15]. Briefly, twelve successive two-fold dilutions were used for 
each sample with 15 wells per dilution. The percentage of wells with at least one phase-
dark hematopoietic clone (cobblestone area) of at least five cells beneath the stromal 
layer was determined at week 2, 4, and 6. At initiation of the cultures 250 CD34+ UCB 
cells per well were plated in the first dilution, while after two weeks of cultures 200-
1000 CD34+ input equivalent cells per well were used in the first dilution. The CAFC 
frequencies were calculated using Poisson statistics. 
Immunophenotypic analysis. At least 5 .0 xI 04 fresh or cultured CD34+ cells or femoral 
bone marrow cells of the NOD/SCID mice were stained with anti human CD45/CD33, 
CD34/CD38, CD34/CDI9 (fluorescein isothiocyanate (FITC)- or phycoerythrin (PEl-
conjugated) labeled monoclonal antibodies (Immunotech, Mijdrecht, The Netherlands). 
To analyse the lineage commitment the femoral bone marrow cells were also stained 
with anti human CD15/CD33, CD41/CD33, glycopherin A (GlyA), CD20/CDI9, CD3/ 
CD4 and CD3/CD8. After incubation of the cells in phosphate-buffered saline (PBS, 
Life Technologies, Breda, The Netherlands) containing 0.5% BSA and 2% normal 
human serum for 30 minutes on ice, the cells were washed in PBS with 0.5% BSA and 
resuspended in 0.35 ml PBS. Just before the acquisition 7-aminoactinomycin (7-AAD, 
Molecular Probes, Leiden, The Netherlands) was added to each sample to determine 
the viability of the cells. FITC and PE-conjugated mouse isotype antibodies were used 
as control for each group. At least 1.0 xl 04 events were acquired using fluorescence-
activated cell sorting (FACS) analysis (Becton Dickinson). 
NOD/SCID repopulating cell (SRC) assay. Specific pathogen free (SPF) NOD/LtSz-
SCID/SCID (NOD/SCID) mice, six to fifteen weeks of age, were used as recipients of 
human cell grafts. The NOD/SCID mice were bred, maintained and used under SPF 
conditions in a laminar airflow unit, supplied with sterile food and acidified drinking 
water containing 100 mg/ml ciprofloxacine. All mice were sublethally irradiated with 
3.5 Gy from a 137Cs source (Gammacell, Atomic Energy of Canada, Ottawa, Canada) I to 
4 hours prior to intravenous transplantation. At day 0 of the experiments 5.0 xl04 or 1.0 
xl05 CD34+ cells and on week 2 of the cultures 5.0 xl03 and 5.0 xl04 input equivalent 
cells were transplanted. The number of mice used for each group varied from 3 to 4. 
Six weeks after transplantation mice were killed by C02 inhalation and bone marrow 
cells were harvested by flushing all cells from two isolated femurs per animal. After 
counting, the cells were analyzed by FACS to determine the human cell engraftrnent 
in each mouse. Between 1.0 xl04 and 1.0 xl05 events were acquired for analysis. If the 
percentage of CD4s+ cells was >0.1% the mice were considered positive, while all mice 
with a percentage > 1.5% were analyzed for expression of lineage-specific markers. 
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Statistical analysis. The values are reported as mean :!:: SD. The significance levels 
were determined by two-tailed Mann-Whitney test analysis. 
Results 
Characteristics of uncultured CDJ4+ cells. Highly purified CD34+ UCB cells were 
cultured in an attempt to expand the graft content of primitive stem cells using serum-
containing and serum-free conditions supplemented with two or more cytokines and 
in the presence or absence of a murine FBMD-1 stromal layer. After isolation of the 
MNC by low-density gradient from a pool of 5 to 20 UCB samples, immunomagnetic 
selection according to the CD34 antigen expression was performed. The purity of 
the selected cells, determined by FACS after staining with CD34-FITC conjugated 
monoclonal antibody, varied between 88% to 97%. The percentage of the cell fractions 
expressing the CD33+ (myeloid lineage), CD19+ (B-lymphocytes) and CD34+CD38· 
(primitive stem cells) from seven, eight and ten experiments were 21 :!:: 21%, 4 :!:: 2% 
and 3:!:: 2% respectively. The absolute number of clonogenic cells was 30,861 :!:: 12,862 
CFU-GM and 10,606:!:: 6,474 BFU-E per 105 input cells. The CAFCwook2 frequency as 
indicator of transiently repopulating stem cells ranged from 7,336 to 23,566, whereas 
the CAFCw"" as a measure of tentative long-term repopulating stem cells varied from 
2,381 to 8,308 per 105 input cells. To analyze the ability of uncultured CD34+ cells to 
give multilineage engraftment in the BM ofNOD/SCID mice 5.0 xI 04 or 1.0 xI 05 CD34+ 
UCB cells per mouse were injected i.v. into groups of sublethally irradiated mice. Six 
weeks after transplantation the mice were killed, BM cells harvested from both femurs 
and analyzed for the presence of different lineages of human hematopoietic cells using 
FACS. Fifty and hundred thousand CD34+ cells were able to engraft 100% of the mice. 
The percentage of CD45+ cells, as a marker for the presence of human hematopoietic 
cells in the murine BM, ranged from 5.3% to 19.5%. After two weeks of culture the 
numbers of nc, CFC, CAFC, immunophenotypic cell populations and the ability of the 
cultured cells to give multilineage engraftment in NOD/SCID mice were determined 
and compared with the corresponding input values. As the different medium conditions 
used in ten experiments did not significantly affect the output for the various parameters 
determined (data not shown), the results below represent pooled data for the groups with 
similar cytokine combination. 
Characteristics of cultured CD34+ cells. Stroma-free cultures. Stroma-free culture 
of CD34+ UCB cells in the presence of different combinations of cytokines resulted in 
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expansion ofnc, CD34+ and CD34+CD38- cells over the input values, while in absence of 
cytokines all cells died (figure !). The fold-increase of the CD34+ phenotype as measure 
of hematopoietic progenitor cells, and that of the CD34+CD38- phenotype as indicator 
for a quiescent and functionally primitive population of progenitor cells, varied from 
OA to 51 and 3.1 to 475, respectively. An increase of B-lymphoid and myeloid cells 
compared to the uncultured CD34+ UCB cells was also obtained (table I). The maximum 
recovery ofCFU-GM in stroma-free cultures was 42 ± 40 fold the input (figure 2), while 
the BFU-E were lost in all cytokine groups. In general, there was a higher fold increase 
of CD34+CD38· cells than of CD34+ cells. If this phenotype CD34+CD38- truly predicts 
the expansion of long term repopulating cells, then it would be likely to find similar 
dramatic expansion of the absolute number of CAFC subsets and SRC as well. However, 
the CAFCwook2md 6 were maximally 4 and 11-fold expanded, respectively, while in some 
Table L Expansion of B~lympboid and myeloid cell populations following two weeks of ex vivo culture of 
CD34- umbilical cord blood cells. 
Culture conditions 
(n= number of experiments) 
Stroma-free cultures 
No cytok:ines 
Flt3-L + Tpo; n=3 
Flt3-L + Tpo + SCF; n=l 
Flt3-L + Tpc + IL-6; n=6 
Flt3-L + Tpo + SCF + IL-6; n=3 
SCF + IL-6; n=3 
Stroma-supported cultures 
No cytokines; n=2 
Flt3-L + Tpo; n=3 
Flt3-L + Tpo + SCF 
Flt3-L + Tpo + IL-6; n=7 
Flt3-L + Tpo + SCF + IL-6; n=2 
SCF + IL-6; n=2 
Fold-increase of total number ofhematopoietic 
cells 
B-lymphoid Myeloid 
ND ND ND 
3.6 ± 5.0 3.6 ± 5.4 79±38 
10.5 7.9 304 
1.7±3.3 1.0 ± 1.4 117±195 
15.7 ± 25.2 8.3 ± ll.l 565 ±455 
5.1 ± 7.8 2.9 ± 3.9 102 ± 93 
0.2 ± 0.2 0.2 ± 0.3 23 ± 15 
3.4 ± 2.8 1.6 ± 1.5 442 ± 222 
ND ND ND 
2.9±2.7 4.1 ±4.5 3237 ±4997 
3.0 ± 1.2 2.9 ± 0.1 631 ± 146 
0.7 ± 0.8 1.0 ± 1.0 217 ± 65 
The data represent the mean fold-increase ± SD of 2-7 experiments performed, in which CD34+ UCB cells 
were cultured for two weeks under stroma-free and stroma-supported conditions with or without cytokines. 
Abbreviations: ND, not determined. 
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Figure 1. Fold-expansion of absolute number of nucleated cells. CD34' and CD34'CD38· cells following 
two weeks of culture of CD34+ UCB cells under stroma-free and stroma-supported conditions with or without 
cytokines. Data represent the mean (SD) of 2-11 experiments performed. Mann-Whitney test: * denotes 
significant difference (P< 0.05) betv.reen stroma-supported cultures with cytokines and stroma-supported culture 
without cytokines, #denotes significant difference (P< 0.05) between stroma-supported cultures and FT stroma-
free culture. Abbreviations: FT, Flt3-L + Tpo; FTS, Flt3-L + Tpo + SCF; FT6, Flt3-L + Tpo + IL6; FTS6, Flt3-L 
+ Tpo + SCF + IL6; S6, SCF + IL6. **.all cells died. 
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Figure 2. Fold-expansion of absolute number of colony forming unit-granulocyte-macrophage (CFU-GM) 
and cobble stone area forming cell (CAFC) subsets following two weeks of culture of CD34+ UCB cells under 
stroma-free and stroma-supported conditions with or without cytokines. Data represent the mean (SD) of 2-11 
experiments performed. Mann-Whitney test: *denotes significant difference (P< 0.05) between stroma-supported 
cultures with cytokines and stroma-supported culture without cytokines, # denotes significant difference (P< 
0.05) between stroma-supported cultures and FT stroma-free culture. Abbreviations: FT, Flt3-L + Tpo; FTS, Flt3-
L + Tpo + SCF: FT6, Flt3-L + Tpo + IL6; FTS6, Flt3-L + Tpo + SCF + IL6; S6, SCF + IL6. **.all cells died. 
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cytokine combinations (i.e. Flt3-L + Tpo and SCF + IL6) even less CAFCwoek2 '"' 6 than 
input were recovered (figure 2). The addition ofSCF +/- IL6 to the cytokine combination 
Flt3-L + Tpo promoted the early and late progenitor amplification in terms of CFU-GM 
and CAFC subsets, indicating a synergistic effect of these cytokines in combination 
with Flt3-L + Tpo. As can be seen from figure 2, the optimal cytokine combination for 
expansion of hematopoietic progenitors (CFU-GM, CAFC) under stroma-free conditions 
was Flt3-L + Tpo + SCF + IL6. 
Following two weeks of culture, a considerable expansion of the potential of CD34+ 
UCB cells to engraft the BM of sublethally irradiated NOD/SCID mice was also observed. 
The maximum levels of BM engraftment obtained for each group of mice infused with 
cultured cells is shown in figure 3. When cells had been cultured in the presence of 
Flt3-L + Tpo + SCF, upto 90% of the BM cells were of human origin, while culture with 
SCF + IL6 alone led to human chimerism levels below that of uncultured CD34+ UCB 
cells. In all other cytokine combination groups, higher levels of human chimerism were 
detected in mice injected with cultured cells than in mice infused with uncultured CD34+ 
UCB cells (figure 4). Addition of SCF+/- IL6 to the cytokine combination Flt3-L + Tpo 
elicited no significant effect on the estimated expansion of the SRA. The cultured cells 
also showed an increased ability to repopulate the mice with CD34+ and CD34+CD38· 
cells compared to the input cells. The highest absolute percentage of CD34+ cells (14% 
of all bone marrow cells) and CD34+CD38· (1.4% of all bone marrow cells) was found 
in mice infused with cells cultured in the presence of Flt3-L + Tpo + IL6 and Flt3-L + 
Tpo, respectively. 
Figure 5 shows the level of human engraftment at six weeks after transplantation of 
the NOD/SCID mice with 5.0 xl03 rather than 5.0 xl04 input equivalent cells. Even these 
limited cell numbers were similarly able to engraft 100% of the mice. The percentage of 
human engraftment ranged between 0.1% and 47%, with the highest value was observed 
for the cytokine combination Flt3-L + Tpo + IL6. Although the engraftment capacity of 
the cells cultured with either Flt3-L + Tpo or SCF + IL6 was lower as compared to other 
cytokine combinations, these 5.0 x1 03 input equivalent cells gave the same (using Flt3-L + 
Tpo and Flt3-L + Tpo + SCF +/- IL6 under stroma-free and stroma-supported conditions, 
respectively) or an even higher (using Flt3-L + Tpo + IL6) human engraftment than did 
1.0 xl 05 CD34+ uncultured cells. This strongly substantiates our contention that the ability 
of the cells to give engraftment in the bone marrow ofNOD/SCID mice can be expanded 
in a two-week culture system. Assuming a linear relation between the number of input 
equivalent cells transplanted and the level of chimerism found in the BM of NOD/SCID 
mice we have estimated the expansion of in vivo engraftment ability of cultured CD34+ 
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Figure 3. Flow cytometric analysis of femoral marrow cells from individual NOD/SCID mice six weeks 
after transplantation with two- week (a) stroma-free and (b) stroma-supported cultured CD34- UCB cells. The 
FACS profiles represent the highest human engraftment obtained within different culture conditions tested. The 
percentage of human chimerism expressing CD45 is given in the upper-right quadrant. The cells expressing the 
myeloid fraction (CD33) ranged between 3·20% of the femoral marrow. Mice were infused with either 5.0 xl04 
uncultured CD34+ cells, or 5.0 xl04 input equivalent cultured CD34+ cells. Abbreviations: FT, Flt3-L+ Tpo~ FTS, 
Flt3-L + Tpo + SCF; FT6. Flt3-L + Tpo + IL6; FTS6. Flt3-L+ Tpo + SCF + IL6; S6. SCF + IL6. 
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Figure 4. Engraftment ability of stroma-free and stroma-supported uncultured and two~week cultured CD34+ 
UCB cells in bone marrow ofNOD/SCID mice six weeks after transplantation. Mice were infused with either 
5.0 xl O' (n=I3) or 1.0 xi 05 (n=4) CD34' uncultured cells, or 5.0 xi 0' (n=4-15) input equivalent cultured CD34' 
cells. The values for each group represent the percentage ofhuman cells (CD45+) in the femoral marrow. Data are 
mean (SD) of3-20 NOD/SCID mice transplanted per experimental group. Abbreviations: ND, not determined; n, 
number of mice transplanted per group; FT, Flt3-L + Tpo; FTS. Flt3-L + Tpo + SCF; FT6, Flt3-L + Tpo + IL6; 
FTS6, Flt3-L + Tpo + SCF + IL6; S6, SCF + IL6. 
UCB cells, as we realized that the expansion in mice with high chimerism percentages 
could be underestimated. As shown in table 3, all cytokine combinations except for SCF + 
IL6 led to a more than an average of l 0-fold SRA expansion. 
In order to evaluate whether the expanded cells maintained their ability for 
multilineage engraftment in the NOD/SCID mice we studied the expression of lineage 
markers on the human cells present in the femoral marrow of the mice at six weeks 
post-transplant. We did not observe a significant difference between the ability of the 
cultured and uncultured cells to produce various progenitors (CD34+, CD34.CD38·, 
CD34+CD19•), B-lymphocytes (CDI9+, CD20•CDI9+, CDZO•), myeloid cells (CD33•), 
granulocytes (CD15+) and monocytes (CD3·CD4+) (table 2). Human T-lymphocytes 
(CD3•CD4+, CD3+CD8•) were never detected in the bone marrow of the recipients. 
Also, no significant differences were found in the percentage ofmegakaryocytes (CD33· 
CD4l+) formed by uncultured (3 ± 2%) and cultured cells (0.7 ± 0.6%) nor erythroid 
cells (GlyN) (8 ± 8 versus 8 ± 8%) in 5-8 experiments. 
Stroma-supported cultures. To investigate whether stromal support would improve 
the maintenance and/or expansion of primitive stem cells, we inoculated the CD34+ UCB 
cells on a murine stromal layer using the same liquid culture set up as used for stroma-
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Figure 5. Enhanced engraftment ability of two-week stroma-free and stroma-supported cultured CD34+ UCB 
cells in the bone marrow of NOD/SCID mice six weeks after transplantation. Mice were infused with either 
1.0 x105 (n=4) uncultured CD34' cells or with 5.0 xl03 (n=3-4) and 5.0 xlO' (n=3-4) input equivalent cultured 
CD34+ cells. The values for each group represent the mean (SD) percentage of human cells (CD4S+) in the 
femoral marrow. Mann-Whitney test: * denotes significant difference {P< 0.005) between transplantation of 5.0 
xl03 or 5.0 xl04 input equivalent cultured CD34+ cells. Abbreviations: ND, not determined; n, number of mice 
transplanted per group; FT. Flt3-L + Tpo; FTS. Flt3-L+ Tpo + SCF; FT6. Flt3-L + Tpo + IL6; FTS6, Flt3-L + Tpo 
+ SCF + IL6; S6, SCF + IL6; stroma-FT. stroma-supported culture in the presence ofFlt3-L + Tpo. 
free cultures except for insulin. Cultures were either supplemented with Flt3-L + Tpo, 
SCF + IL6 or Flt3-L + Tpo +I- SCF +I- IL6. Stroma-supported cultures without additional 
cytokines were included as a control. From figures l and 2 it is clear that stroma support 
without additional cytokines did not lead to an expansion of CFU-GM, CAFC subsets 
and CD34+ cells, however, it gave a 20 :t 17-fold increase of the CD34+CD38· subset. In 
the presence of Flt3-L + Tpo, stromal support synergyzed to give a significantly higher 
expansions of all parameters studied except of CD34+ cells as compared to stroma-
free culture (P< 0.05). Stromal support could be fully replaced by complementation 
of the Flt3-L + Tpo stimulated cultures with SCF + IL6. In the presence of FBMD-1 
stromal cells, other cytokine combinations could not significantly improve the total fold-
expansion. Also in the presence of Flt3-L + Tpo + SCF, or Flt3-L + Tpo + IL6, stroma-
support stimulated the average expansion ofnc, CD34+, CD34+CD38· cells, although not 
always significantly. In the presence of stroma, SCF + IL6 stimulated remarkably few 
total nc, CD34+ cells and CFU-GM, and did not prevent loss of CAFCwook2 '"' 6, while it 
also did not give an improved maintenance of all parameters as compared to non-stroma 
supported cultures. Stromal support alone was not sufficient to maintain the SRA of 
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Table 2. Multilineage engraftment ability CD34+ UCB cells in the bone marrow ofNOD/SCID mice before or after two~week culture period. 
Culture conditions %of human (CD45+) cells in the temoral marrow 
(n= number of mice ) 
CD34+ cm4'cms· CD34'CDI9+ CDI9+ CD20' CD20+CDI9' CD33+ CDI5' CD3"CD4+ 
Uncultured; n-17 I4 ± 8 2±2 7±6 59±22 20±9 IS± 8 29 ± I4 25 ± I3 2I ± I4 
Stroma~ free cultures 
No cytokines ND ND ND ND ND ND ND ND ND 
Flt3-L + Tpo; n~5 18 ± I2 5±6 3±4 51± 26 13 ± 4 8±3 2I ± I2 21 ± IO I3 ± 10 
Flt3-L + Tpo + SCF; n~4 7±3 I ±0.2 5±2 68±9 5± 1 5±1 12 ±4 8±3 4±1 
Flt3-L + Tpo + IL6; n~ 11 ± 3 I± 0.3 10± I 63 ± 10 8±4 8±4 I3±2 10 ± 5 4±1 
Flt3-L + Tpo + SCF + IL6; n~7 8±5 1±2 3±2 65 ± I6 7±3 6±2 I5±7 14± II 6±4 
SCF+IL6;n~ 10 ± 6 2±2 4±4 54± 15 9±3 6±1 I7± IO IS± 15 5±4 
Stroma-supported cultures 
No cytokincs; n=l 10 8 N 34 11 3 2 21 12 
F1t3-L + Tpo; tF!O 8±5 2±3 2±2 55±24 10±4 7±4 22 ± 15 IS ±9 12 ± I3 
Flt3-L + Tpo + SCF ND ND ND ND ND ND ND ND ND 
Flt3-L + Tpo + IL6; n~6 13±10 3±5 4±3 49±27 22 ± 17 13±6 13± 10 21 ± 14 24 ±II 
Flt3-L + Tpo + SCF + IL6; IF5 9±9 2±2 I± I 68 ± 19 18 ± IO 14 ± IO 15± 7 I9±9 12 ± 10 
SCF+ IL6;n~ 15 ± 7 2±2 4±2 53± 28 IS± 8 II ±9 44±22 37 ± 21 44±33 
Cells infused into NOD/SCID mice 'vere either uncultured, or propagated tOr two weeks in stroma-free or stronm-supported cultures. The inocula 'vere 
either 50,000 (n= 13) or I 00,000 (n=4) CD34+ cells/mouse for uncultured cells or 50,000 input equivalent cells/mouse for cultured cells. Values represent the 
mean(± SD) percentage of human cells (CD45+) in the femoral marrmv of 4-17 NOD/SCID mice transplanted per group. Abbreviations: N, not detectable; 
ND, not determined. 
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Table 3. Estimated fold-increase of the engraftment ability in NOD/SClD mice transplanted with cultured 
CD34' UCB cells. 
Culture conditions 
(n= number of mice) 
Stroma-free cultures 
Flt3-L + Tpo; n=o4 
Flt3-L + Tpo + SCF; n=o4 
Flt3-L + Tpo + IL6; n=o4 
Flt3-L + Tpo + SCF + IL6; n~3 
SCF + IL6; n~3 
Stroma-supported cultures 
Flt3-L + Tpo; n=o4 
Fold~ increase 
10 ± 8.5 
12.5 ± 6 
13.8 ± 5.8 
12.6 ± 5.5 
2.6 ± 2.1 
12.7 ± 2.8 
The fold-expansion ofthe engraftment ability, in the cell dose ranges as used, was calculated on the assumption 
that there is a linear relation between the number of SCID repopulating cells transplanted and the level of 
chimerism in the bone marrow ofNOD/SCID mice. The expansion data show the mean± SD calculated in one 
experiment, in which each mouse was transplanted with 100,000 CD34+ uncultured cells or with 50,000 input 
equivalent cells after two weeks of culture. 
CD34+ UCB cells in two-week cultures. Flt3-L + Tpo were required and sufficient to 
give a comparable high SRA expansion under stroma-supported cultures as compared 
to stroma-free cultures. Stromal support, or complementation of the medium with SCF 
+ IL6, did not significantly improve the NOD/SCID BM engraftment potential (figures 
4 and 5). 
Discussion 
Our data show a more than I O-f old expansion of CAFCw"'' and of the potential of 
CD34+ UCB cells to multilineage engraft the BM of sublethally irradiated NOD/SCID 
mice after two weeks of both stroma-free and stroma-supported culture in the presence 
of at least Flt3-L + Tpo. Among the cytokine combinations tested, stroma significantly 
improved the maintenance of CAFCw"'' with the cytokine combination Flt3-L + Tpo. 
This stromal support could be replaced by adding additional SCF + IL6 to the Flt3-
L + Tpo stimulated cultures. However, nor stromal support nor complementation of 
the medium with SCF + IL6 improved the in vivo engraftment potential of two-week 
cultured CD34+ UCB cells. 
The four cytokines used in the present study were chosen due to their key 
involvement in previous expansion studies as well as being early acting cytokines. 
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For example, while Tpo induces apoptosis with down regulation of CD44 in CD34+ 
UCB cells, Flt3-L does not [16]. In contrast, the continuous presence ofTpo in stromal 
cultures resulted in generation of both short- and long-term in vivo repopulating HSCs 
[17]. In the present study the results following two-week cultures have shown Flt3-L 
+ Tpo + SCF + IL6 under stroma-free conditions to represent an optimum cytokine 
combination for expansion of early and late progenitors. The addition of SCF +/- IL6 
to the combination Flt3-L + Tpo enhanced progenitor cell expansion in terms of CFU-
GM and CAFC subsets. These data indicate a synergistic effect of SCF +/- IL6 with 
Flt3-L and Tpo in our two-week stroma-free culture system, which is in contrast with 
previous data published by Piacibello eta!. indicating no difference in the extent of early 
progenitors to substantial addition of SCF +/- IL6. This may reflect differences in the 
sources of cytokines, the purification procedures of cell populations or the presence of 
uncharacterized factors in the sera. 
One of the essential issues remaining to be clarified was the assessment of in vivo 
repopulating ability of expanded cells. In our two-week culture system we obtained a 
considerable expansion of cells capable of multilineage outgrowth in the BM of NOD/ 
SCID mice. Luens et al. reported that human CD34+CD38- bone marrow cells after 6 
days stroma-free culture sustained, but not expanded, their in vivo repopulating ability in 
the qualitative SCID/hu bone assay [18]. A modest increase of competitive repopulating 
units was observed after 5-8 days stroma-free culture of CD34+CD38- UCB cells in 
the presence of cytokines F!t3-L, SCF, IL3, IL6 and G-CSF [19]. Similarly, Bhatia et 
al. reported that under serum-free conditions a 2- to 4-fold increase of SRC could be 
obtained after 4 days culture of CD34+CD38- UCB cells, while after 9 days of culture 
all SRC were lost [I OJ. All these data support the contention, that in contrast to CFU-
GM, SRC are difficult to expand, while they are rapidly lost in culture. In the present 
study, the expansion of the ability of CD34+ UCB cells to multilineage engraft the BM 
of sublethally irradiated NOD/SCID mice following two-week stroma-free cultures was 
observed in the presence of various cytokine permutations including Flt3-L + Tpo and 
SCF + IL6. Remarkably, addition of SCF +/- IL6 to the cytokine combination Flt3-
L + Tpo showed no significant effect on the estimated expansion of the engraftment 
ability. While preparing this manuscript Piacibello et al. showed that more than 70-fold 
SRC increase could be obtained after 9 to I 0 weeks culture of CD34+ UCB cells under 
stroma-free conditions in the presence of the cytokines Flt3-L, Tpo, SCF and IL6 [!I]. 
However, it is not clear from these studies whether SRC were expanded after two weeks 
of culture. The prolonged duration of the cultures would limit the usefulness of this 
expansion technique in a clinical setting. 
65 
Chapter 2 
There is ample evidence for the supportive role of stroma in maintenance of stem 
cells and progenitors [20-22]. Verfaillie eta!. demonstrated that the absolute number 
of stem cells (LTC-IC) and the colony forming cell production in long-term cultures 
was increased after propagation of hematopoietic stem cells derived from normal BM 
in stroma-noncontact cultures [14, 23]. 0-sulphated GAGs seemed to be responsible 
for this long-term stroma-supported maintenance of LTC-IC in culture [24]. Brandt 
et al. showed that three weeks stroma-free culture of CD34+Thy-1+ human BM 
cells with lineage-negative markers resulted in impairment of engraftment ability 
in NOD/SCID mice, which could be overcome by coculture with a layer of porcine 
microvascular endothelial cells [12]. Additionally, we have previously reported that 
stroma-conditioned medium enhanced the expansion of primitive hematopietic stem/ 
progenitor cells from CD34+ selected mobilized peripheral blood in short-term cultures, 
while stroma-support was also required for optimal maintenance and graft quality [25, 
26]. Chih eta!. have suggested LIF as the cytokine that is responsible for maintaining 
and expanding transplantable CD34+Thy1+ cells in stroma-supported cultures through 
an action on the stroma [27]. Our present results indicate that the addition of Flt3-L + 
Tpo to the stroma-supported cultures significantly improved the expansion results in 
terms of nc, CD34+, CD34+CD38· cells, CFU-GM, CAFC subsets and estimated SRA. 
Surprisingly, in contrast to the stroma-free cultures, the addition of SCF +/- IL6 to Flt3-
L + Tpo did not appear to substantially modify the extent of early progenitors, i.e. CAFC 
and estimated SRA. Although these data seem to contrast with several previous studies 
indicating that proliferation of hematopoietic stem cells in the presence of stroma is 
associated with loss of most in vivo repopulating ability [28, 29], it should be realised 
that Flt3-L and Tpo were not exogenously added to the cultures in the latter studies. 
Recently, a study by Xu et al. has shown that CD34+CD38· UCB cells after a four-week 
culture period could maintain their in vivo repopulating ability [30]. These cultures were 
supported by a stromal cell line derived from the aorta-gonad-mesonephros region of a 
10.5 days postcoitum mouse embryo, a location currently considered to generate the first 
definitive hematopoietic stem cells. In our study, the expansion of CAFC and estimated 
SRA in Flt3-L + Tpo stroma-supported cultures was as high as in stroma-free cultures 
in the presence of Flt3-L + Tpo + SCF + IL6. These observations suggest that SCF and 
IL6, which is elaborated by the FBMD-1 stroma, was sufficient to compensate for the 
exogenously added SCF and IL6. 
It may be likely, that the increased SRA of cultured CD34+ UCB cells is due to (a) an 
increase of the total SRC number, however, it is also possible that (b) quiescent SRC, 
or pre-SRC, are activated or recruited, respectively. Alternatively, it could be that (c) 
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cultured cells show an increased ability to home either to, or expand in the BM of NOD/ 
SCID mice, or that (d) there is a numerical or functional gain of facilitating cells that is 
possibly required for engraftment of the NOD/SCID BM by SRC. A study by Peled eta!. 
showed that the chemokine stromal cell-derived factor (SDF)-1 and its receptor CXCR4, 
which is expressed on some CD34+CD38· cells amongst others, may be important for 
engraftment of sublethally irradiated NOD/SCID mice [31]. The cytokines SCF and IL6 
induced CXCR4 up-regulation on CD34+ cells, which subsequently potentiated migration 
of these precursor cells and their engraftment in primary and secondary transplanted 
mice. In addition, antibodies to CXCR4 completely prevented the engraftment in vivo. 
According to these data, the use of at least SCF +/- IL6 in our culture system might have 
caused increased homing potential of the CD34+ UCB cells, which in tum contributed 
to the increased SRA. Recently, Yagi et a/. demonstrated that continuous presence of 
Tpo in mouse long-term bone marrow cultures resulted in generation of short and long-
term hematopoietic stem cells as detected by an in vivo competitive repopulation assay 
indicating that Tpo can mediate self-replication of HSCs ex vivo [17]. Our results on 
increased CAFC and SRA following two-week of culture suggest that the continuous 
presence of Tpo might also play an important role in ex vivo self-replication of human 
CD34+ cells. 
The simultaneous assessment of in vivo repopulating ability, phenotypic and 
functional characteristics of ex vivo manipulated cells enabled us to quantify the changes 
of cultured cells from different perspectives. It is interesting to note that in the presence 
ofF!t3-L + Tpo, expansion ofCAFC numbers (0.04 to 6 and 0.2 to II fold the input for 
weektype 2 and 6, respectively) paralleled the estimated expansion of SRA (table 3), in 
contrast to the much more extensive increases in the total number of CD34.CD38· cells 
(5 to 1149 fold the input). The CAFC, SRA and CD34•CD38· cells are known to identify 
closely related populations in uncultured UCB, BM and MPB samples. The much more 
rapid increase of CD34+CD38· cells compared to CAFC and estimated SRA indicates 
that these cell types may not detect the same cell populations after the culture period 
used. 
In conclusion, hematopoietic stem/progenitor cells can be expanded in short-term 
cultures and stroma does not seem to be required for this purpose. If assessment of SRA 
and CAFC subsets are measures of in vivo repopulating stem cells in humans these 
findings may contribute to a rapid preparation of UCB grafts to meet the requirements 
for improved repopulation in the clinical setting. 
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Abstract 
Current technology to numerically expand hematopoietic stem/progenitor cells (HSPC) 
ex vivo within one to two weeks is insufficient to warrant significant gain in reconstitution 
time following their transplantation. In order to more stringently test the parameters 
affecting HSPC expansion, we followed ex vivo cultures of CD34+ selected umbilical 
cord blood (UCB) HSPC for upto ten weeks and investigated the effects of stromal 
support and cytokine addition. The cytokine combinations included Flt3-L + Tpo, Flt3-
L + Tpo plus SCF and/or IL6, or SCF + IL6. To identify the HSPC in uncultured and 
cultured material we determined the number of colony-forming cells (CFC), cobblestone 
area forming cells (CAFC), the NOD/SCID repopulating ability (SRA), and CD34+ 
subsets by phenotyping. The highest fold-increase obtained for CD34+ and CD34•CD38· 
cell numbers was, respectively, 1,197 and 30,937 for stroma-free and 4,066 and 117,235 
for stroma-supported cultures. In general, CFC generation increased weekly in Flt3-L 
+ Tpo containing groups upto week 5 with a 28 to 195-fold expansion whereafter the 
weekly CFC output stabilized. Stroma support enhanced the expansion of CAFCw"k' 
maximally !!-fold to 89-fold expanded with Flt3-L + Tpo + IL6. Cultures stimulated 
with at least Flt3-L + Tpo gave an estimated 10 to 14-fold expansion of the ability of 
CD34+ UCB cells to multilineage engraft the BM of sublethally irradiated NOD/SCID 
mice at two weeks of stroma-free and stroma-supported cultures, while at week 5 and 
later the estimated SRA decreased to low or undetectable levels in all groups. Our 
results show that stroma and Flt3-L + Tpo but also inclusion of bovine serum albumin, 
greatly increase the long-term generation of HSPC as measured by in vitro assays and 
is indispensable for long-term expansion of CD34+CD38·CXCR4+ cells. However, the 
different surrogate methods to quantify the HSPC (CD34.CD38·, CFC, CAFCw"k' and 
SRA) show increasing incongruency with increasing culture time, while especially the 
phenotypic analysis and the CFC generation greatly overestimate the CAFC and SRA 
expansion in ten-week cultures. 
Introduction 
Ex vivo expansion of repopulating HSPC may aid in abrogation of neutropenia in 
cancer patients receiving myeloablative high dose chemotherapy. It may also open new 
opportunities for stem cell transplantation in cases where limited HSPC are available, 
such as in UCB grafts and leukapheresis samples from heavily pretreated patients. In 
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addition, expansion may contribute in developing culture conditions that permit efficient 
gene transfer into primitive HSPC without their concurrent differentiation-induced loss. 
Although expansion of total nucleated cells and progenitors has been documented, 
infusion of these cells has not resulted in any improvement of the time to recovery of 
neutrophils or platelets. Upto date, most research on ex vivo expansion has explored 
different combinations of cytokines or chemokines, culture medium ingredients, and 
recently the role of stromal support [1-7]. Flt3-ligand (Flt3-L), thrombopoietin (Tpo), 
stem cell factor (SCF) and interleukin-6 (IL6) are known to be early acting cytokines and 
have been reported to support primitive HSPC proliferation with maintenance of long-
term repopulating ability [8-11]. The important effects of these cytokines on early HSPC 
have led to the development of in vitro culture systems in order to expand these cells. 
Particularly, the long-term production of HSPC has been used as a stringent endpoint 
for HSPC maintenance or expansion [12-18]. Using a cytokine-supp!emented stroma-
free extended long-term culture (LTC) system Piacibello and colleagues have uniquely 
documented a dramatic expansion of primitive CD34+ UCB cells over periods as long 
as thirty weeks [19, 20]. Endpoints of primitivity in these studies included CD34+CD38· 
and long-term culture initiating cell (LTC-IC) subsets. Recently, these authors also 
demonstrated that the NOD/SCID repopulating cells were markedly expanded using 
Flt3-L, Tpo, SCF and IL6 under the same conditions after ten weeks of culture [21]. 
Additionally, we reported that the in vivo repopulating ability of CD34+ UCB cells 
could be expanded in two-week cultures containing at least Flt3-L and Tpo and that the 
stromal support was not required [22]. The requirement for a stromal microenvironment 
in ex vivo amplification of the HSPC remains controversial. Endothelial-based culture 
ofUCB CD34+CD38· cells has been reported to obtain higher CAFC expansion (11-fold 
the input) as compared to a 4-fold in the stroma-free system after three weeks of culture 
in the presence of the cytokines Flt3-L, Tpo, SCF, IL6 and GM-CSF [23]. A recent study 
by Lewis et al. showed that both myeloid and lymphoid progenitors from UCB and 
mobilized peripheral blood can be expanded in the presence of the murine fetal liver 
cell line AFT024 under two- to five-week stroma-contact and stroma-non-contact culture 
conditions supplemented with at least Flt3-L and Tpo [24]. Although in the absence of 
exogenous cytokines stroma-support fails to significantly expand in vitro and in vivo 
repopulating cells in stroma-supported cultures [12, 25-28], the inclusion ofTpo in such 
cultures dramatically increased the longevity ofhematopoietic activity and maintenance of 
repopulating ability of stem cells [29]. All of these data together suggest that both stromal 
cells and exogenous cytokines, including at least Tpo, are required for maintenance and/or 
expansion of HSPC in cultures exceeding a time period of about two weeks. 
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Although a shorter culture period is favourable in a clinical setting, the extend of 
HSPC expansion (3- to 15-fold increase of CAFC and SRA) obtained in one to two-
week cultures is not sufficient for a successful clinical application [22]. Therefore, in 
the present study we further examined whether HSPC expansion could be improved 
when cultured for more than two weeks, and whether the presence of EM-derived 
stromal cells, and combinations of specific cytokines affected the HSPC maintenance or 
expansion. As we have previously documented that certain BSA batches were inhibitory 
for murine HSPC expansion due their TGF~ 1 content, we have also compared the effect 
of BSA on human HSPC cultures in the present study. 
Materials and methods 
Human umbilical cord blood cells. Human UCB samples were collected from the 
umbilical cord vein after full-term delivery by the nursing staff of the Department 
of Obstetrics and Gynaecology at the Sint Franciscus Gasthuis (Rotterdam, The 
Netherlands). Informed consent for taking samples for clinical study was obtained. UCB 
was collected in sterile flasks containing I 0 ml citrate-glucose as anticoagulant, stored 
at room temperature and processed within 24 hours of collection. 
Isolation of CD34+ cells. Low-density cells were isolated using Ficoll Hypaque 
density centrifugation (1.077g/cm2, Lymphoprep, Nycomed Pharma, Oslo, Norway). 
After centrifugation at 600 g for 15 minutes, the mononuclear cell (MNC) band at the 
interface was removed, washed twice with Hanks Balanced Salt Solution (HBSS, Gibco, 
Breda, The Netherlands) and resuspended in Iscove's modified Dulbecco's medium 
(IMDM, Gibco, Breda, The Netherlands). The MNCs were stored in liquid nitrogen 
until use. After thawing and before the CD34+ hematopoietic progenitor cells were 
isolated we pooled 3 to 16 different UCB samples. The CD34+ cells were harvested from 
the mononuclear cells using Variomacs Immunomagnetic Separation System (Miltenyi 
Biotec, Bergisch Gladbach, Germany). The CD34+ cells were labeled indirectly using 
a hapten-conjugated primary monoconal antibody and an anti-hapten antibody coupled 
to MACS microbeads. The magnetically labelled cells were enriched by passing them 
twice through a Variomacs positive selection column to reach a final purity of> 90% 
CD34+ cells. A nuclear cell count was performed and the progenitor and stem cell 
numbers in the CD34+ selected UCB cells were assayed by CFC, CAFC and NOD/SCID 
repopulating cell assays. In addition, the immunophenotypic characteristics of the cells 
were assessed and part of the CD34 + cells were cultured for ten weeks. 
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Hemopoietic growth factors. The following cytokines were used: recombinant 
human stem cell factor (SCF) and FLT3-ligand (Flt3-L), both gifts from Amgen 
(Thousand Oaks, CA, USA), recombinant human interleukin 6 (IL6), recombinant 
human granulocyte-macrophage colony stimulating factor (GM-CSF), recombinant 
human granulocyte colony stimulating factor ( G-CSF) and recombinant murine stem 
cell factor (SCF), all gifts from Genetic Institute (Cambridge, MA, USA); recombinant 
human thrombopoietin (Tpo, a gift from Genentech, South San Francisco, CA, USA), 
recombinant human erythropoietin (Epo, Boehringer, Mannheim, Germany) and 
recombinant human IL3 (Gist Brocades, Delft, The Netherlands). 
Extended long-term expansion cultures. Various culture conditions were used in 
5 consecutive experiments. In the first experiment 5.0 xl04 CD34+ UCB cells were 
cultured in 6-well tissue culture plates (Costar, Badhoevedorp, The Netherlands) in an 
1 ml IMDM-cocktail containing 10% fetal calf serum (FCS, Summit, Fort Collins, CO), 
1% bovine serum albumin (BSA, Sigma, Zwijndrecht, The Netherlands) supplemented 
with penicillin (100 U/ml, Gibco), streptomycin (0.1 mglml, Gibco), ~-mercapto-ethanol 
(10-4M, Merck, Darmstadt, Germany), bovine insulin (4 mg/ml, Gibco), cholesterol (15 
f!M, Sigma), linolic acid (15 f!M Merck) iron-saturated human transferrin (0.62 g/1, 
Intergen, Uithoorn, The Netherlands), cytidine (10·3 glml, Sigma), adenosine (10'3 g/ml, 
Sigma), uridine (10·3 glml, Sigma), guanosine (10'3 g/ml, Sigma), 2'-deoxycytidine (!O· 
3 g/rnl, Sigma), 2'-deoxyadenosine (10'3 g/ml, Sigma), thymidine (10'3 g/ml, Sigma), 
2'-deoxyguanosine (10'3 glml, Sigma) and the cytokines Flt3-L (50 ng/ml), Tpo (10 
ng/ml), SCF (100 ng/ml), IL6 (100 ng/ml). The cells were cultured with the following 
combination of cytokines: Flt3-L + Tpo, Flt3-L + Tpo + SCF, Flt3-L + Tpo + IL6, Flt3-
L + Tpo + SCF + IL6, or SCF + IL6. Cultures were set up using six to eight replicates 
of each cytokine combination. In the subsequent two studies 5.0 x104 CD34+ cells were 
cultured in tissue culture 25T-flasks (Falcon, Etten-Leur, The Netherlands) in 4 ml 
IMDM-cocktail containing 20% FCS with the same cytokine combinations. The effect 
of the murine FBMD-1 stromal layer on the in vitro repopulating ability was assessed for 
the same cytokine combinations. Insulin was not added in the stromal groups because 
it potently stimulated adipogenesis in FBMD-1 cells. Finally, in the last two studies 3.5 
x104 and 4.0 xl04 CD34+ cells were deposited on FBMD-1 stromal layer in tissue culture 
25T-flasks in 4 ml IMDM-cocktail without BSA containing 20% FCS supplemented with 
the following cytokines: Flt3-L + Tpo, Flt3-L + Tpo + SCF, Flt3-L + Tpo + IL6 and Flt3-
L + Tpo + SCF + IL6. The cytokines Flt3-L and Tpo were added twice a week during 
the culture period. 
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The cultures were maintained with splitting of the cultured cells every one to two 
weeks starting from the second week of culture. When stroma-supported cultures had 
to be splitted, the adherent and non-adherent compartments of all corresponding dishes 
or flasks were pooled, and cells were reinoculated into culture on a newly preformed 
stroma. If at splitting a part of the cells were removed for analysis (on week 2 and 5), 
this was compensated in the calculations for total support. The cells were incubated at 
37°C and 10% C02 in a humidified atmosphere and harvested at different time points by 
collecting the supernate of each well or flask, whereafter all groups were trypsinized with 
trypsin-EDTA (Life Technologies, Breda, The Netherlands) to include all the adherent 
cells. The content of the various wells or flasks belonging to a single group were pooled, 
centrifugated at 250 g for 10 minutes and resuspended in IMDM. Suitable aliquots of 
the output suspensions were assayed in CFC, CAFC and SRC assays for determination 
of progenitor and stem cell numbers. The immunophenotypic characteristics of the 
cultured cells were also assessed. Remaining cell numbers of the output suspensions 
were cultured further for analysis at later time points. 
Clonogenic assay. Granulocyte-macrophage colony forming unit (CFU-GM) and 
burst forming unit- erythroid (BFU-E) progenitor cells were assayed using a semisolid 
culture medium (1.2% methylcellulose), containing IMDM supplemented with 10% 
FCS, 13-mercapto-ethanol (5 x 10·5 M), penicillin (100 U/ml), streptomycin (0.1 mg/ml), 
human(hu)-Epo (I U/ml), hu-IL3 (20 ng/ml), hu-GM-CSF (5 ng/ml), hu-G-CSF (50 ng/ 
ml) and murine-SCF (100 ng/ml). Duplicate cultures were plated in 35 mm tissue culture 
dishes (Falcon) and incubated at 37°C and 10% C02 in a humidified atmosphere for 14 
days. Colonies containing 50 cells or more were scored at day 14 using an inverted light 
microscope. 
Cobblestone area forming cell assay. Confluent stromal layers of FBMD-1 cells in 
fiat-bottom 96-well plates (Falcon) were overlaid with UCB cells in a limiting dilution 
set up as described [30]. Briefly, twelve successive two-fold dilutions were used for each 
sample with 15 wells per dilution. The percentage of wells with at least one phase-dark 
hematopoietic clone (cobblestone area) of at least five cells beneath the stromal layer 
was determined at week 2, and 6. At initiation of the cultures 250 CD34+ UCB cells 
per well were plated in the first dilution, while after cultures 200-1000 CD34+ input 
equivalent cells per well were used in the first dilution. The CAFC frequencies were 
calculated using Poisson statistics. 
Immunophenotypic analysis. At least 5.0 xi 04 fresh or cultured CD34+ cells or femoral 
bone marrow cells of the NOD/SCID mice were stained with anti human CD45/CD33, 
CD34/CD38 or CD34/CD19 (fluorescein isothiocyanate (FITC)- or phycoerythrin (PE)-
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conjugated) labeled monoclonal antibodies (Immunotech, Mijdrecht, The Netherlands). 
The cultured cells were also analyzed with anti human CD34, CD38 and CXCR4 
(Becton Dickinson, Woerden, The Netherlands) using allophycocyanin (APC), FITC 
and PE-conjugated monoclonal antibodies, respectively. Human cells from the femoral 
bone marrow of the NOD/SCID mice were also stained with anti human CD15/CD33, 
CD20/CD19, CD3/CD4 and CD3/CD8 to analyse the multilineage differentiation. After 
incubation of the cells in phosphate-buffered saline (PBS, Life Technologies, Breda, 
The Netherlands) containing 0.5% BSA and 2% normal human serum for 30 minutes 
on ice, the cells were washed in PBS with 0.5% BSA and resuspended in 0.35 ml PBS. 
Just before the acquisition 7-aminoactinomycin (7-AAD, Molecular Probes, Leiden, 
The Netherlands) was added to each sample to determine the viability of the cells. APC, 
FITC and PE-conjugated mouse isotype antibodies were used as control for each group. 
At least 1.0 xl04 events were acquired using fluorescence-activated cell sorting (FACS) 
analysis (Becton Dickinson). 
NODISCID repopulating cell (SRC) assay. The NOD/LtSz-SCID/SCID (NOD/SCID) 
mice, 8 to 13 weeks of age, were used as recipients of human cell grafts. The NOD/ 
SCID mice were bred, maintained and used under specific pathogen free conditions in a 
laminar airflow unit, supplied with sterile food and acidified drinking water containing 
100 mg/ml ciprofloxacine. All mice were sublethally irradiated with 3.5 Gy from a 137Cs 
source (Gammacell, Atomic Energy of Canada, Ottawa, Canada) 1 to 4 hours prior to 
intravenous transplantation. At initiation of the experiment the mice were transplanted 
with 1.0 xl05 CD34+ uncultured cells and at week 2 of cultures with 5.0 xl04 input 
equivalent cells. At week 5 of culture each mouse was infused with 391, 195, 391, 195, 
195 or 195 input equivalent cells for the groups Flt3-L + Tpo, Flt3-L + Tpo + SCF, Flt3-
L + Tpo + IL6, Flt3-L + Tpo + SCF + IL6, SCF + IL6 or stroma-supported Flt3-L + Tpo, 
respectively, and at week 10 of culture with 73, 37, 73, 37, 37 or 37 input equivalent 
cells for the same groups, respectively. The number of mice used for each group varied 
from three to four. Six weeks after transplantation mice were killed by C02 inhalation 
and bone marrow cells were harvested by flushing all cells from two isolated femurs per 
animal. After counting, the cells were analyzed by FACS to determine the human cell 
engraftment in each mouse. Between 1.0 xl04 and 1.0 x!O' events were acquired for 
analysis. If the percentage ofCD45+ cells was> 0.1% the mice were considered positive, 
while all mice with a percentage> 5% were analyzed for expression oflineage-specific 
markers. 
Statistical analysis. The values are reported as mean :!: I SD. The significance levels 
were determined by two-tailed Mann-Whitney test analysis. 
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Results 
Uncultured CD34+ UCB cells. The purity of the immunomagnetic selected cells, 
determined by FACS after staining with CD34-FITC conjugated monoclonal antibody, 
varied between 92% to 96%. The percentage of the primitive stem cells with the 
CD34+CD38- and CD34+CD38-CXCR4+ phenotypes, which are assumed to contain all 
BM repopulating ability, was 3"' I% (as percentage of total nc in five experiments) and 
4% (as percentage of total CD34+ cells determined in one experiment), respectively. 
The mean number ofclonogenic cells was 29,688 "'9,781 CFU-GM and 10,500;, 4,093 
BFU-E per 105 input cells. The CAFCwook2oodJrequencies as a measure of transiently and 
tentative long-term repopulating stem cells, respectively, ranged from 6,230 to 23,566 
and 3,988 to 9,997 per 105 input cells, respectively. To analyze the ability of uncultured 
CD34+ cells to give multilineage engraftment in the BM ofNOD/SCID mice, 1.0 x!O' 
CD34+ UCB cells per mouse were injected i.v. into groups of sublethally irradiated mice. 
Six weeks after transplantation the mice were killed, BM cells harvested from both 
femurs and analyzed for the presence of different lineages of human hematopoietic cells 
using FACS. Hundred thousand CD34+ cells were able to multilineage engraft 100% 
of the mice. The percentage of CD45+ cells, as a marker for the presence of human 
hematopoietic cells in the murine BM, ranged from I% to 19%. 
Cultured CD34+ UCB cells. Stroma-free extended LTC. To assess the ability of 
serum-containing stroma-free cultures to support the growth of primitive hematopoietic 
progenitors including CD34+ subsets, CFC, CAFC and NOD/SCID repopulating ability 
(SRA), their content was determined in each sample before and during ten-week cultures 
in the presence or absence of cytokines. First we evaluated the influence of medium 
conditions for expansion of CD34+ cells. The addition ofBSA gave a significant increase 
of the absolute number ofnc, CD34+ subsets and CFU-GM (P< 0.05). While the absence 
of BSA resulted in loss of early progenitors, the presence of BSA was able to give 
maintenance or moderate expansion of these cells during the culture period (table I). For 
this reason, data below represent the results obtained under BSA-containing conditions. 
Stroma-free culture of CD34+ UCB cells in the presence of different combinations of 
cytokines resulted in a dramatic expansion of nc and CD34+ subsets (figure I). The fold-
increase of the CD34+ phenotype as a measure of HSPC, and that of the CD34+CD38-
phenotype as an indicator of quiescent and functionally primitive population of HSPC, 
varied from 14 to 1197 and 54 to 30,937, respectively, at week 10 of the cytokine-
supplemented cultures. In general, there was a rapid increase in the fold-expansion of 
these parameters during the first few weeks of culture whereafter the rate of increase 
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Table 1. Expansion of various parameters during culture with Flt3-L + Tpo + IL6 under ditTerent medium conditions. 
Cultures in the Cultures in the presence(+) or absence(-) of stroma 
presence ( +) or 
absence (-) of BSA 2-\veek cultured 5-week cultured 10-week culh.trcd 
+ + + 
Nucleated cells 
9±6 30± 18 43 ±43 1042 ± 108 191* 12178± 1222 
+ 96± 14 113* 186 ± 70 2150* 504* 19200* 
CD34+ cells 
3±3 6±4 4±4 67 ± 23 6* 385 ± 327 
+ 54± 8 37* 7±3 292* 16* 4066* 
CD34+CD38- cells 
0 69±60 7±7 701 ± 304 21 * 15956 ± 14981 
+ 54±4 285* 14± I 3329* 24 68039* 
CFU-GM 
I± I 15 ± 7 9±9 245 ± 241 4* 162 ± 149 
+ 13 ± 3 117±83 39± 13 233 ± 212 17* 403 ±233 
CAFCwcek 6 
0 3±2 0 4±2 0* 8± 10 
+ 5± I 9± II 2±1 3±4 2* 72±24 
UCB cells \Vere either uncultured, or propagated for two, five and ten weeks in the presence of absence of stroma and/or BSA. Values represent the mean 
fold-increase(± I SD) of2-3 groups detennined in four independent experiments (data from 10% and 20% serum containing cultures were pooled for each 
group). Abbreviations: *measured in I experiment. 
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Figure 1. Fold-expansion of absolute number of nucleated cells, CD34 ... and CD34 ... CD3S· cells following ten 
weeks culture ofCD34+ UCB cells under stroma-free and stroma-supported conditions with or without cytokines. 
Data represent the mean of 1-2 experiments performed. Mann-Whitney test: **denotes significant difference (P< 
0.005 for CD34' cells, P< 0.05 forCD34'CD38· or CD34'CD38-CXCR4' cells) between stroma-free and stroma-
supported cultures in the presence of at least Flt3-L + Tpo. 
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Figure 2. Fold-expansion of absolute number of colony forming unit-granulocyte-macrophage (CFU-GM) 
and cobble stone area forming cell (CAFC) subsets following ten weeks of culture of CD34+ UCB cells 
under stroma-free and stroma-supported conditions with or without cytokines. Data represent the mean of 1-2 
experiments performed. Mann-'Whitney test: **denotes significant difference (P< 0.05 for CFU-GM, P< 0.005 
for CAFCweeJCorJ between stroma-free and stroma-supported cultures in the presence of at least Flt3-L + Tpo. 
became slower. Interestingly, the CD34+CD3S·CXCR4+ cells as an estimation of the 
NOD/SCID marrow repopulating fraction of HSPC [31] showed a rapid increase until 
week 2 of stroma-free cultures, a plateau between week 2 and 5 and a very rapid decline 
to undetectable levels at week I 0. The CFU-GM (figure 2) showed a continuous increase 
during the first five week of stroma-free culture whereafter their levels remained more 
or less constant, while the BFU-E were undetectable in all cytokine groups at all time 
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points analyzed. Among the different in vitro parameters determined in extended LTC, 
the CAFC subsets showed the lowest levels and fastest disappearance in all cytokine 
groups under stroma-free conditions except in the Flt3-L + Tpo + IL6 group, where there 
was a continuous increase during stroma-free culture reaching almost 10-fold expansion 
at week 10. Interleukin 6 +/- SCF synergized with Flt3-L + Tpo to promote the early and 
late progenitor amplification in terms of CAFC subsets and CFU-GM. The addition of 
SCF to the cytokine combination Flt3-L + Tpo in stroma-free cultures resulted in loss of 
CFU-GM and CAFC subsets at week 10 of culture which was abrogated by the addition 
ofiL6. 
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Figure 3. The percentage of human chimerism of uncultured CD34+ UCB cells and stroma-free and stroma-
supported cultured CD34+ UCB cells in bone marrow ofNOD/SCID mice six weeks after transplantation. Mice 
were infused with either 1.0 xlO CD34+ uncultured cells or with 5.0 xl04• 195 to 391 and 37 to 93 1 input 
equivalent cultured CD34+ cells at week 2, 5 and 10 of culture, respectively. The values for each group represent 
the percentage ofhuman cells (CD45•) in the femoral marrow. Data are mean(± I SD) of3-4 NOD/SCID mice 
transplanted per experimental group. Mann-Whitney test: **denotes significant difference (P< 0.05) between 
SCF + IL6 and at least Flt3-L + Tpo containing groups. 
In order to evaluate whether the expanded cells maintained their ability for 
multilineage engraftment in the NOD/SCID mice we studied the SRA of the cytokine-
supplemented stroma-free cultured cells. In agreement with our previous observations, 
a considerable expansion of the ability of CD34+ UCB cells to engraft the BM of 
sublethally irradiated NOD/SCID mice was observed after two weeks of culture (figure 
3). The percentage of human chimerism was 49 ± 42, 62 ± 29,68 ± 29, 62 ± 27, 13 ± 10 
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Table 2. Multilineage engraftment ability of CD34" UCB cells in the bone marrow ofNOD/SCID mice. 
Lin(!::J.ge markers us% of human cells in the femoral marrow 
Cell populations Uncultured Stroma-free Stro=-supported 
Flt3-L + Tpo Flt3-L + Tpo + SCF F!t3-L + Tpo + IL6 Flt3-L + Tpo + SCF + IL6 SCF+IL6 Flt3-L +Tpo 
(n"'3) (n=2) (n"'4) (n~) (n<4) (n"'2) (n=4) 
CD34+ 2±0 13±7 7±3 11 ±3 5±2 9±6 4±4 
CD34 .. CD38" I± I 0.1 ±0.06 0.6 ± 0.2 0.6± 0.3 0.4±0.1 0.6 ± 0.6 0.3 ± 0.2 
CD34 .. CDH' 3±2 7±3 5±2 10± 1 3±1 7±4 3±2 
CDI9"' 64±34 73± 12 68±9 63 ± !0 73 ±IS 62± 16 65±22 
CD20+ 12±6 10±3 5 ±I 8±4 6±2 6±0.1 7±3 
CD33"' 27± 16 11 ±6 12±4 13±2 10±3 16±4 12±7 
CDIS"' 20±7 13±7 8±3 10±5 7±4 9±1 10± 7 
CD3'CD4"' 8±3 3±2 3±1 4±1 3 ± 1 5±3 3±1 
CD3+CD4+ N N N N N N N 
cD3"'Cos+ N N N N N N N 
Cells infused into NOD/SCID mice were either uncultured, or prOpagated under stroma-free or stroma-supported 
conditions. The inocula were either 100,000 CD34 .. cells/mouse for uncultured cells or 37 to 50,000 input 
equivalent cells/mouse for cultured cells. Values represent the mean(± 1 SD) percentage of human cells (CD45 .. ) 
in the femoral marrow of 23 NOD/SCID mice with more than 5% human chimerism. Abbreviations: N, not 
detectable; n, number of mice per group. 
for Flt3-L + Tpo, Flt3-L + Tpo + SCF, Flt3-L + Tpo + IL6. Flt3-L + Tpo + SCF + IL6 and 
SCF + IL6, respectively, at week 2 of culture. The percentage of human chimerism in the 
BM of mice infused with cultured cells ranged between I %and 90% with no significant 
difference between the cytokine combinations when at least Flt3-L + Tpo was included. 
In all Flt3-L + Tpo containing groups, higher levels of human chimerism on average 
were detected in mice infused with cultured cells equivalent to 5.0 xl04 input cells than 
in mice infused with 1.0 xl05 uncultured CD34+ UCB cells. The cultures with SCF + IL6 
alone led to human chimerism levels as high as that of uncultured CD34+ UCB cells and 
ranged between I% and 20%. Addition of SCF +I- IL6 to the cytokine combination Flt3-
L + Tpo did not significantly affect the expansion of the SRA after two weeks of culture. 
The expression of lineage markers on human cells present in the femoral marrow of 
the mice at six weeks post-transplant showed no significant difference between the 
cultured and uncultured cells (table 2). Although we were able to expand the ability 
of UCB CD34+ cells to multilineage engraft the BM of NOD/SCID mice in two-week 
cultures, hardly or no detectable levels of human engraftment were observed in the mice 
transplanted when the CD34+ UCB cells had been cultured for five weeks or longer. 
Stroma-supported extended LTC. To investigate whether stroma would improve the 
support of primitive HSPC, the CD34+ UCB cells were cultured on the murine EM-
derived stromal cell line FBMD-1 using the same cytokine combinations and liquid 
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culture conditions as used for stroma-free cultures except for insulin. Insulin was omitted 
from these cultures as it induced extensive adipogenesis and consequently affected the 
rigidity of the stromal layers. Under suboptimal culture conditions, e.g. using medium 
lacking BSA, stroma was required to increase the absolute number of CFC, CAFC and 
CD34+CD38· cells as compared to stroma-free culture (table 1). The nc, CD34+ subsets 
and CFU-GM expansions were significantly improved with the addition of BSA into 
the medium both under stroma-free and stroma-supported conditions (P< 0.05), as were 
the CAFCwook6· We have therefore included BSA, except otherwise specified, into the 
medium to improve the growth of the inoculated CD34+ cells in the remainder of the 
experiments. The stroma support without additional cytokines gave a maximum of 26, 
161 and 74-fold increase of the CFU-GM, CD34+ and CD34+CD38· subsets respectively 
during the culture period often weeks, however, it did not lead to an expansion ofCAFC 
subsets (figures I and 2). At weeks two and five of culture no statistically significant 
difference in HSPC parameters was observed between stroma-free and stroma-supported 
cultures in the presence of at least Flt3-L + Tpo. Interestingly, stroma support with or 
without cytokine addition improved the support ofnc, CD34+, CD34+CD38· and CAFC 
subsets with at least one-log increase as compared to the corresponding stroma-free 
parameters at week I 0 of culture, with the exception of the cytokine combination SCF 
+ IL6 which showed similar (nc, CD34+) or decreased (CD34.CD38·, CFU-GM and 
CAFC subsets) levels of the HSPC parameters (figures I and 2). More interestingly 
was the observation that the CD34+CD38·CXCR4+ cells, which have been shown to 
represent the BM repopulating progenitors in uncultured grafts [31], required both 
stromal support and cytokines to expand for a time period of more than five weeks 
(figure I). The stroma support gave a similar increase of CFU-GM as the corresponding 
stroma-free groups under Flt3-L + Tpo containing conditions (figure 2). In contrast to 
the stroma-free cultures, stroma support induced a continuous increase ofCAFC subsets 
during the culture period when at least Flt3-L + Tpo was included, reaching a maximum 
of 89-fold (mean 72-fold) expansion with Flt3-L + Tpo + IL6 at week 10 of culture 
(figure 2). Additionally, the inclusion of SCF to the cytokine combination Flt3-L + Tpo 
under stroma-supported conditions showed a trend of diminished generation of CFU-
GM and CAFC subsets as compared to the Flt3-L + Tpo group at week 10 of the culture 
(CFU-GM, 141 versus 977-fold; CAFCwook'' 10 versus 54-fold). This effect of SCF was 
abrogated by the addition of IL6. In conclusion, in Flt3-L + Tpo containing cultures 
stroma support dramatically increased the expansion of HSPC as assessed by CAFC and 
CD34+CD38·CXCR4+ cells. We previously reported that Flt3-L + Tpo were required and 
sufficient to give a comparable high SRA expansion in two-week cultures. We therefore 
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Figure 4. Comparative expansion of in vitro and in vivo HSPC parameters during ten weeks stroma-free 
and stroma-supported culture of CD34+ UCB cells. Data represent the mean of 2 independent experiments for 
CD34 .. CD38· and CAFCweek6 and the mean of 4 mice at each time point analyzed within one experiment for 
estimated SRA. The calculation ofSRA expansion has been performed as previously published [22]. 
evaluated only the stroma-supported Flt3-L + Tpo group using the NOD/SCID assay in this 
study (figure 3). The percentage of human chimerism was 62 ± 26% when 5.0 xl04 input 
equivalent cells were inoculated from Flt3-L + Tpo supplemented stroma-supported two-
week culture, which was as high as under stroma-free conditions in the presence of at least 
Flt3-L + Tpo. A similar pattern ofmultilineage SRA expansion as compared to stroma-free 
cultures was observed with an increase at two weeks, whereafter hardly or no detectable 
levels of human engraftment with Flt3-L + Tpo propagated cells was observed. 
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Table 3. Lineage restriction within CD34" subset before and after stroma-supported culture ofCD34" UCB cells. 
Culture conditions Lineage restricted cells as% ofCD34~ subset 
co:t CD19" CD33"'" CD14+ CD15" CD41" CD71+ GlyA+ 
Uncultured 1 ± 1 1 ± 1 94±5 N 3±0 5±3 12* N 
2~wcck cultured 
Flt3~L +Tpo 9±9 1±1 92 ± 1 N 13±0 3±2 4±0 N 
Flt3~L + Tpo + SCF 6±6 N 92± 1 1±1 9±2 2±1 3±0 N 
Flt3-L + Tpo + IL6 10± 10 N 94±0 4±2 15±0 N 4±1 N 
Flt3-L + Tpo + SCF + IL6 8±8 N 95 ±0 3±2 17±4 N 3±1 N 
5-wcck cultured 
Flt3-L+Tpo N N 81 ± 19 N 2±1 N 1±1 N 
Flt3-L + Tpo + SCF N N 74±25 1 ± 1 5±1 N N N 
Flt3-L + Tpo + ll.6 N N 74±26 1±1 11 ±6 N N N 
Flt3-L + Tpo + SCF + IL6 N N 78±22 4±4 9±2 N N N 
I 0-wcck cultured 
Flt3-L +Tpo N N 83± 16 2±1 4±1 N 1 ± 1 N 
Flt3-L + Tpo + SCF N N 60± 10 N 4±2 N N N 
Flt3-L + Tpo + IL6 N N 43 ± 1 1 ± 1 3±0 N N N 
Flt3-L + Tpo + SCF + IL6 N N 76±23 2±2 6±3 N 1 ± 1 N 
UCB cells were either uncultured, or propagated for two, five and ten weeks under stroma-supported conditions 
with cytokines. Values represent the mean(± 1 SD) percentage oflineage restricted markers of two independent 
experiments within the CD34+ window. Abbreviations: N. not detectable;* measured in 1 experiment. 
Comparative expansion of various parameters after extended LTC. In the present 
study, the presence ofHSPC in uncultured and cultured CD34+ UCB cells was evaluated 
by different surrogate methods. Although the CD34+CD38· phenotype in uncultured 
material defines an immature population of progenitors and contains most long-term 
in vivo repopulating cells, the expansion of CD34+CD38· cells was not related to the 
CFC, CAFC and SRA present in the inoculum of cultured cells, both in stroma-free and 
stroma-supported conditions (figure 4). There was also no direct correlation between the 
number of CFC present in the inoculum of cultured cells and repopulation of sublethally 
irradiated recipients or CAFCw"''" This is not surprising, as it is known that CFC define 
a relatively mature population of progenitors lacking long-term repopulating ability. 
Also the CAFCw"''' which is considered to include long-term in vitro repopulating 
stem cell subsets, was not indicative for the in vivo repopulating ability. The expansion 
of CAFCw"'' estimated in the present study was maximally 17-fold at week 2 and 89-
fold at week I 0 of cultures. However, the estimated SRA expansion, as calculated 
previously [22], was approximately 14-fold at week 2, whereafter SRA was lost. In 
summary, our data show increasing incongruency with increasing culture time between 
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Table 4. The CD34" subpopulations before and after stroma-supported culture of CD34" UCB cells. 
Culture conditions CD34~ subsets 
CD3S'cclls Lin ~ems· cells Lin+cms· cells 
as% of nucleated cells as% of CD34+ cells as% ofCD34+Cms· cells 
Culture time in weeks 
0 2 5 10 0 2 5 10 0 2 5 10 
Flt3~L + Tpo 4±0 3± I 4±0 8±3 
C02 <0.1 2±2 < 0.1 < 0.1 <0.1 II± 15 <0.1 <0.1 
CD33 <0.1 21 ±5 33 ±8 54± 17 <0.1 93± I 86±20 89± 15 
Flt3-L + Tpo + SCF 4±0 3± I 1±1 6±4 
CD2 <0.1 I ±I <0.1 <0.1 <0.1 4±5 < 0.1 <O.l 
CD IS <0.1 < 0.1 1 ±I I± I <0.1 <0.1 1±2 I ±2 
CD41 <0.1 < O.l <0.1 <0.1 <0.1 3±5 <0.1 < 0.1 
CD33 <0.1 27±0 20± 18 52±2 <0.1 93 ±5 74±34 89 ± 16 
Flt3-L + Tpo + IL6 4±0 3±2 1±1 3±0 
CD2 < 0.1 4±4 <0.1 <0.1 <0.1 15±22 <0.1 <0.1 
CDI4 <0.1 1±1 <0.1 <0.1 <0.1 5±6 <0.1 < 0.1 
CD33 <0.1 20±4 15 ± 6 29± 13 <0.1 98 ±3 78±31 77±33 
Flt3-L + Tpo + SCF + IL6 4±0 I ±0 I ±0 2±2 
C02 <0.1 1 ±I < 0.1 <0.1 <0.1 II± 16 <0.1 <0.1 
CD!4 < 0.1 <0.1 2±2 <0.1 <0.1 <0.1 29±40 <0.1 
CD15 <0.1 <0.1 1±0 1±1 <0.1 <0.1 15±2 3±4 
CD33 < 0.1 15 ± 0 11±2 27±3 <0.1 97±4 85 ±22 84±"" 
UCB cells were either uncultured, or propagated for five. five and ten weeks under stroma-supported conditions 
with cytokines. Values represent the mean(± 1 SD) percentage of two independent experiments. The CD34+CD38· 
cells were considered lineage-positive (Lin+) if they additionally expressed at least one of the following markers 
CD2, CD14. CD15, CD19. CD33, CD41, CD71 orGlyA. If any of these markers was detected on less than 0.1% 
of the cells at any time point in any one group, these data were excluded from this table. 
the different surrogate methods used to quantitate stem and progenitor cells. Especially 
the flowcytometry and CFC generation greatly overestimated the in vivo repopulating 
ability and CAFC content of these cells at the time points analyzed. 
The expression ofCD38 antigen after extended LTC. The in congruency of the dramatic 
expansion of CD34+CD38· cells and the limited increase in SRA and CAFC numbers 
during ex vivo propagation made us question whether the generated CD34+CD38· cells 
arose from the input CD34+CD38· cells or by loss of CD38 antigen expression on more 
lineage-restricted cell populations. Therefore. we assessed immunophenotypically 
the expression of lineage markers within the CD34+CD38· cell population during the 
ten-week culture period and determined the corresponding progenitor content of UCB 
CD34+ cells under BSA-lacking stroma-supported conditions in the presence of at least 
Flt3-L + Tpo. The UCB CD34+ cells maintained in vitro their ability to differentiate into 
myeloid cells (CD33+), monocytes (CD14+) and granulocytes (CD15+) for ten weeks 
(table 3). The CD34+ cells co-expressing CD2 (T· lymphocytes, natural killer cells), 
CDI9 (B-lymphocytes), CD41 (megakaryocytes) and CD71 (transferrin receptor) were 
lost with increasing culture time and erythroid cells (GiyA+) were never detected at the 
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time points analyzed. The CD34+CD38· cells were considered lineage positive (Lin+) if 
they additionally expressed at least one of the following markers CD2, CD14, CD15, 
CD33, CD4l, CD7l or GlyA. Before culture the CD34.CD38· cells did not express any 
of the above mentioned lineage markers. However, during culture the majority of the 
CD34+CD38· cells co-expressed the lineage marker CD33. At two, four and ten weeks of 
culture the CD34.CD38· cells expressing CD33 antigen ranged between 15 to 27%,2 to 
40% and 17 to 72 %, respectively (table 4). No significant difference in expression of the 
detected markers was observed between the different cytokine combinations used. These 
observations clearly indicate that many CD34+CD38· cells were in fact lineage marker 
expressing cells that failed to express the CD3 8 epitope. 
Discussion 
In the present study we have evaluated the ability of a murine EM-derived stromal cell 
line to increase maintenance and/or undifferentiated expansion of UCB CD34+ cells 
in extended cultures. We show that both stromal support and the inclusion of BSA 
dramatically improved the expansion ofCAFC subsets in cultures exceeding a time period 
of two weeks and that important differences exists between the used stem and progenitor 
cell assays. Especially, the enumeration of CD34+ subsets and CFC generation greatly 
overestimated the expansion of CAFC or SRA at the time points analyzed, confirming 
that the different surrogate methods to quantitate HSPC are unlikely to detect identical 
populations after culture. 
There is extensive data on the supportive capacity of stromal cells on the maintenance 
of primitive stem cells and their ability to generate progenitor cells in long-term cultures 
[32]. The plethora of cytokines that have become available in the last decennium has 
offered an attractive alternative for the use of stroma in ex vivo expansion of stem cells 
for clinical applications. However, the combination of stroma support and cytokines has 
been insufficiently explored, but potentially may lead to dramatic improvement of the 
longevity of repopulating characteristics ofHSPC as is the case when Tpo is induced in 
stroma-supported BM cultures [29]. In the absence of exogenous cytokines, proliferation 
of HSPC in the presence of EM-derived stroma is associated with loss of most in vivo 
repopulating ability of hematopoietic progenitors [25, 33, 34]. Brandt et al. showed that 
three weeks stroma-free culture of CD34+Thy-1 +human BM cells with lineage-negative 
markers resulted in impairment of engraftment ability in NOD/SCID mice, which could 
be overcome by coculture with a layer of porcine microvascular endothelial cells [28]. 
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We and others have previously reported that stroma-conditioned medium enhanced the 
expansion of primitive HSPC from CD34+ selected mobilized peripheral blood in short-
term cultures, while stroma-support was also required for optimal maintenance and graft 
quality [12, 35, 36]. In addition, Xu et al. have shown that CD34.CD38- UCB cells 
could maintain their in vivo repopulating ability during a four-week culture period [37] 
when supported by an embryonic stromal cell line derived from the murine aorta-gonad-
mesonephros region, a location currently considered to generate the first definitive 
HSPC. There is still insufficient data on which factors contribute to maintenance and/or 
expansion under stromal conditions. 0-sulphated GAGs have been shown to aid the 
long-term maintenance of LTC-IC under stroma noncontact conditions (38], while LIF 
have been suggested to be responsible for maintaining and expanding transplantable 
CD34.Thy1 +cells in stroma-supported cultures through an action on the stroma [39]. It 
is likely, that additionally cell adhesion molecules and extracellular matrix molecules 
contribute to the specific contextual interaction between stem cells and the stromal 
environment, and that chemotactic factors as SDF-1 and specific lipids help to guide 
and maintain HSPC in their niches [ 40-44]. The present study indicate that stroma and 
cytokines are required to obtain expansion of CAFC when cultured for more than two 
weeks. Also the CD34+CD38-CXCR4+ cells representing the NOD/SCID repopulating 
cells [31] required both stromal support and cytokines to expand over a time period 
of five weeks. Our data contrast with the previous data published by Piacibello and 
colleagues indicating no stromal requirement in expansion of LTC-IC for more than 
six months and of SRC for ten weeks. In initial studies these authors used FCS in 
stroma-free long-term cultures for evaluation of optimal conditions which resulted in 
massive and prolonged expansion of in vitro hematopoietic progenitors (CFC) and more 
primitive hematopoietic stem cells (LTC-IC) from UCB CD34+ cells [19, 20]. Secondly, 
they switched to pooled human serum as a substitute for FCS in order to make a step 
further toward a clinical application and assessed whether the combination of early 
acting cytokines with best results could maintain and amplify SRC (21]. The latter 
resulted in an increase of more than 70-fold the input SRC after a culture period of nine 
to ten weeks. So, the differences observed between these and our extended long-term 
data may partly be attributable to the culture conditions used with special reference to 
serum batches or the source of serum used. Also the sources of cytokines and the cell 
purification procedures may have contributed to the contradictory results. 
Previous attempts to expand stem cells in vitro have also emphasized the role of the 
early acting cytokines Flt3-L, Tpo, SCF and IL6 in regulation of HSPC growth and 
survival [8-11, 45-47]. Using combinations of these cytokines we observed synergistic 
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effect in support of early progenitors for extended periods of ten weeks if at least Flt3-
L + Tpo were included. While we observed that the use of cytokines alone expanded 
early progenitors, and the use of stroma alone decreased their numbers, the combination 
of stroma and cytokines greatly increased the maintenance and production of HSPC 
in our extended LTC. The effect of cytokines could be partly explained by a direct 
effect on HSPC, however, they are also likely to act indirectly by an effect on stroma. 
Human Flt3-L, Tpo and IL6 are known to exhibit cross-species activity on mouse cells. 
Unpublished observations in our lab indicate that the FBMD-1 cell line does not express 
murine c-kit (receptor for SCF) and FLT3 (receptor for Flt3-L), however, expresses the 
murine IL6-receptor-a and c-mpl (Tpo receptor), while human Tpo down modulates 
IL6-receptor-a expression on these cells. These data substantiate our contention that at 
least the cytokines Tpo and IL6 used in the present study might have reacted on both 
HSPC and stroma. 
Interestingly, in SCF + IL6 stimulated cultures, stroma decreased the expansion 
magnitude ofCD34+ and CD34.CD38· cells, CFU-GM and CAFC subsets as compared 
to the stroma-free conditions. A possible explanation for this observation is that the 
exogenous soluble ligand SCF may compete with the stroma membrane-bound SCF 
for c-kit receptors on HSPC, assuming that the interaction with the membrane-bound 
SCF results in the modification of the most effective signaling pathways in maintaining 
HSPC. The importance of membrane-bound SCF in hematopoiesis, fertility and skin 
pigmentation has been documented in studies on the anemic mouse traits W ;wv and 
Sl/Sl' [48, 49]. An· alternative explanation for this SCF effect on primitiveness of 
HSPC observed in the presence of stroma is that SCF induces differential expression of 
adhesion molecules on HSPC and/or stromal cells, which in tum could cause different 
stem cell subsets to contact different adherent cell compartments capable of differently 
affecting the HSPC self-renewal. 
In agreement with our previous observation [22], human cells were found in the 
BM ofNOD/SCID mice following transplantation with two-week cultured cells. These 
cells showed multilineage engraftment in vivo, and no significant difference between 
the cytokine combinations used was observed if at least Flt3-L + Tpo was included. 
The extended cultivation time and consequent dilution of input equivalent stem cells 
over time prohibited the use of a limiting dilution setup for calculating the numbers of 
SRC present in our samples. Instead, we have used the remaining cells to infuse limited 
numbers ofNOD/SCID recipients to arrive at meaningful repopulation percentages. For 
this reason we were not able to precisely determine the fold expansion ofSRC, but rather 
calculated an estimated increase in the ability of the infused cells to repopulate the BM 
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of the recipient mice with human hematopoietic cells as previously published [22]. The 
very high percentages of human cells (over 90 percent) in some groups having received 
cultivated cells indicates, that we might have reached the maximal human chimerism 
percentage in the NOD/SCID assay, which in turn suggests that our SRA calculations are 
conservative. While at week 2 the expansion of SRA was similar under both stroma-free 
and stroma-supported conditions, after five weeks of culture cells were hardly (Flt3-L + 
Tpo + IL6 group) or not at all able to give detectable levels of human engraftment in the 
mice. Possibly, this low SRA is due to a loss ofNOD/SCID repopulating cells (SRC), or 
due to their differentiation. It is not yet clear whether inclusion ofFCS has an inhibitory 
or beneficial effect on the maintenance or expansion of SRC [50, 51]. However, using 
I 0% or 20% FCS we recently obtained expansion of in vivo repopulating ability ofUCB 
CD34+ cells [22] and present study). It is very likely that the concentration or batch of 
FCS used may be responsible for different results. Alternatively, SRC in the current 
study may have been diluted out as limited numbers of input equivalent cells were 
infused at weeks 5 and 10 of the culture with 37 to 391 input equivalent cells infused 
per mouse, when compared with the two-week time point where we transplanted 5.0 
xl04 input equivalent cells per mouse. As a fourth alternative, it could be that more than 
two-week cultured cells show a decreased ability to home to and to expand in the BM of 
NOD/SCID mice. A study by Peled eta!. showed that the chemokine stromal cell-derived 
factor (SDF)-1 and its receptor CXCR4, which is expressed on some CD34+CD38· cells 
amongst others, may be important for engraftment of sublethally irradiated NOD/SCID 
mice, although there is evidence that CXCR4 is heterogeneously expressed on SRC [31, 
52]. The cytokines SCF and IL6 induced CXCR4 up-regulation on CD34+ cells, which 
subsequently potentiated migration of these precursor cells and their engraftment in 
primary and secondary transplanted mice. Thus, the use of at least SCF +/- IL6 in the 
present study might have caused increased homing potential of the CD34+ UCB cells in 
two-week cultures, which in turn contributed to the increased SRA. 
It is generally accepted that the CD34+CD38· phenotype in uncultured material 
defines an immature population of progenitors and includes many CAFCwook/LTC-IC 
and all long-term in vivo repopulating cells. However, in the present study the expansion 
of CD34+CD38·(CXCR4+) cells was not related to the CAFC and SRA after culture. 
These results are in agreement with previously published data indicating a differential 
maintenance ofLTC-IC and SRC during stromal or endothelial-based cultures in three-
week cultures of UCB or BM cells [23, 34]. Recently, also others reported a large 
expansion of CD34+CD38· cells (166-fold) during retroviral transduction period of 2 
to 6 days without an increase in SRC numbers indicating a dissociation between the 
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primitive CD34+CD38- phenotype and SRC function [51]- Overall, our data indicate 
that the different surrogate methods to quantitate HSPC show great incongruency 
with increasing culture time, in which especially phenotypic characterization and the 
CFC assay seem to greatly overestimate the in vivo and in vitro repopulating ability of 
cultured cells at the time points analyzed. One of the essential issues that we wished 
to clarifY was whether the dramatic CD34+CD38· expansion during culture arose from 
the input CD34+CD38- cells or by downregulation of CD38 antigen expression within 
a population of cultured CD34+CD38+ cells that no longer contained any long-term 
repopulating ability, both in vitro and in vivo. While preparing this manuscript, Von 
Lear eta/. demonstrated for the first time that during four days of stroma-free culture 
the CD34+CD38+ cells lost the CD38 antigen while remaining CD34+ resulting in an 
overestimation of the expansion of the CD34.CD38- population [53]- In our study we 
evaluated immunophenotypically the expression of lineage-restricted markers within 
the CD34+CD38- cell population under BSA-lacking stroma-supported conditions 
during ten weeks of culture. Remarkably, although before culture the CD34+CD38· cells 
were all Lin·, after culture the majority of the CD34+CD38- (> 70%) cells co-expressed 
lineage restricted markers. These observations clearly indicate that this phenotype is not 
a reliable indicator for HSPC assessment after culture. 
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Abstract 
We investigated the effect of a new fusion protein ofiL6 and the soluble IL6R, H-IL6, 
on the long-term ex vivo expansion of hematopoietic progenitors derived from AC133+ 
cord blood cells. H-IL6, which acts on both IL6Ra-positive and IL6Ra-negative cells, 
effectively synergized with Flt3-L and Tpo with or without SCF for the propagation of 
primitive progenitors. However, IL6 showed a greater synergistic effect with Flt3-L and 
Tpo than H-IL6 for long-term progenitor propagation. During the first six weeks of culture 
under stroma-free serum-containing conditions, IL6 induced a 1.96 ± 0.64-fold higher 
expansion of nucleated cells, a 2.28 ± 0.33-fold higher expansion of CD34+ cells and 
a 2.74 ± 0.28-fold higher expansion ofCD34+AC133+ cells than H-IL6 in combination 
with Flt3-L and Tpo. The propagation of CAFCw"'' was up to four-fold higher in the 
presence of IL6 than with H-IL6. While the expansion of CD34+ and CD34+AC133+ 
cells dropped after five-seven weeks in the stroma-free cultures with Flt3-L, Tpo and 
H-IL6, a sustained expansion for twelve weeks was obtained in the presence of Flt3-L, 
Tpo and IL6. Stroma-contact greatly enhanced the progenitor expansion induced by 
Flt3-L and Tpo or Flt3-L, Tpo and H-IL6 although the highest proliferation was again 
obtained in the presence of IL6. In contrast, the presence of SCF resulted in increased 
differentiation. Since the majority of primitive progenitors are pro-posed to be IL6Ra 
negative, tbe results suggest that the synergistic effect of IL6 is mediated by accessory 
cells, which have been more effectively stimulated by IL6 than by the fusion peptide, 
H-IL6, in this culture system. 
Introduction 
Over the past 5 years, umbilical cord blood (UCB) has become an important alternative 
source of hematopoietic stem cells for transplantation and gene transduction protocols 
[1], since it is highly enriched for hematopoietic progenitors compared to bone marrow 
(BM) and adult peripheral blood (PB) [2, 3]. However, due to the small volume and the 
high variability in stem cell numbers, a single UCB collection is often considered to be 
insufficient to secure marrow engraftment in adults, and so far, UCB transplantations 
have been limited to pediatric patients. Since UCB is available without donor risk, 
and has the advantage of reduced risks for graft-versus-host disease and infections 
[3], it would be of great benefit if UCB-derived long-term repopulating cells could be 
expanded in vitro. Such expansion studies might also improve our current understanding 
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of the regulation of hematopoiesis and open the way for new strategies in the treatment 
of hematological disorders and for the optimization of PB mobilization protocols. 
High proliferation rates accompanied by a rapid differentiation of primitive progenitor 
cells have been obtained with previous ex vivo expansion systems [4-6]. More recently, 
several groups have reported the qualitative and quantitative maintenance in vitro of 
engrafting stem cells [7-9], and there is now evidence for a slight, but net increase in 
SCID repopulating cells during ex vivo culture [10-12]. However, the culture conditions 
and growth factor combinations used to promote stem cell maintenance and proliferation 
differ substantially, although many of the cytokine cocktails include Flt3 ligand (Flt3-
L), KIT ligand (SCF) and IL3 [11, 13-18]. Recent studies indicate that the c-mplligand, 
Tpo, may also be a potent agent to support the survival and expansion of primitive 
hematopoietic progenitors [19-23). In fact, Piacibello eta!. [24, 25) have described the 
extensive amplification of primitive human UCB-derived progenitor cells, using the 
single growth factor combination ofFlt3-L and Tpo. 
Other reports emphasize an important role for the multi-functional cytokine IL6 in 
the regulation of hematopoiesis [11, 22, 26, 27]. This pleiotropic molecule has been 
shown to act synergistically with IL3 and SCF to enhance the proliferation of human 
hematopoietic progenitor cells [28, 29). The intracellular portion of the IL6Ra is very 
short and signal transduction requires an associated 130-kDa (gp 130) molecule that 
lacks IL6 binding activity [30). This transducer unit is also shared by receptors for 
ILl!, leukemia inhibitory factor (LIF), oncostatin M (OM), ciliary neurotrophic factor 
(CNTF), and cardiotrophin 1 (CT-1), and therefore explains the overlapping activities 
of these cytokines. Binding of IL6 or ILl! to their respective receptors leads to the 
homodimerization and activation of gp 130, while LIF, OM, CNTF, and CT-1 induce 
a gp130 heterodimerization [30]. Interestingly, gp130-deficient mouse embryos show 
greatly diminished numbers of hematopoietic progenitors, thereby underlining the 
importance of this signal transduction pathway in the regulation of hematopoiesis [31). 
Gp130 is ubiquitously expressed on blood progenitors, whereas the expression ofiL6Ra 
seems to be limited to approximately 30-50% ofCD34+ UCB and 80% ofCD34+ PB cells 
[32, 33]. These CD34+JL6Ra+ cells are predominantly myeloid precursors. In contrast, 
erythroid and megakaryocytic progenitors as well as long-term culture initiating cells 
(LTC-I C) have been found to be enriched in the CD34+JL6Ra· UCB fraction and to lack 
responsiveness to IL6 [32). However, a soluble form ofiL6Ra (s!L6R) has been shown 
to complex with IL6 and to act agonistically on gp13o+!L6Ra· cells [34). In vitro short-
term culture studies, using a combination of!L6 and siL6R, report a dramatic expansion 
of primitive hematopoietic cells as well as an erythropoietin (Epo )-independent 
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erythrocyte production, and a trilineage blood cell generation in the presence of SCF and 
IL3 [32, 35, 36]. Similar results have been obtained using a combination of IL6, siL6R 
and Flt3-L although the synergistic action was weaker than with SCF [37]. Recently, 
the complex of IL6 and siL6R has also been shown to stimulate megakaryopoiesis in 
the presence of SCF or IL3 and Tpo [38]. The importance of this IL6/siL6R complex 
is further demonstrated in IL6/siL6R double transgenic mice, which develop a marked 
extramedullary hematopoiesis in the spleen and liver. It has been hypothesized that the 
IL6/siL6R complex is able to expand primitive resident stem cells in these primary 
hematopoietic organs in vivo [34, 39, 40]. 
An important objective of the present study was to investigate the potential benefit 
of the new designer recombinant IL6 and siL6R fusion protein, H-IL6, for the ex vivo 
expansion of hematopoietic UCB progenitors. Using stroma-free and stroma-supported 
long-term cultures, we compared several cytokine combinations in the presence or 
absence of this chimeric protein or with IL6 and estimated the progenitor output by 
multiparameter FACS analyses and CAFC (cobblestone area forming cell) assays. Our 
results indicate that H-IL6 effectively synergizes with Flt3-L and Tpo with or without 
SCF for the expansion of CD34+ and CD34+AC133+ progenitors including primitive 
CAFCwook6" However, in this respect, the action of the H-IL6 fusion peptide was less 
potent than that of the full-length recombinant human IL6 under our culture conditions. 
Materials and methods 
Cells. UCB samples were obtained from the placenta of full-term deliveries at the St 
Franciscus Hospital, Rotterdam, The Netherlands, after informed consent of donors 
and with the permission of the local ethical committee. The cells were separated over 
a Ficoll-Hypaque density gradient (1.077 g/ml; Nycomed Pharma, Oslo, Norway) and 
mononuclear cells (MNC) were either processed directly or cryopreserved at -196°C 
in 10% (vol!vol) dimethylsulphoxide (DMSO), 20% fetal calf serum (FCS; Summit, 
Beunde Ronde), and 70% Hank's balanced salt solution (HBSS; Gibco-BRL, Breda, The 
Netherlands). 
Cell purification. Fresh or thawed UCB MNCs were purified for AC 133+ or CD34+ 
cells using the VarioMACS Immunomagnetic Separation System (Miltenyi Biotec, 
Bergisch-Gladbach, Germany) according to the manufacturer's protocol. The purity 
assessed by FACS analysis ranged between 75% (single-selected) and 99% (double-
selected). The recovered cells were either directly cultured or further purified for 
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CD34+CD38-, CD34+AC133+, CD34+AC133· and CD34-AC133+ cells by FACS sorting 
using standard protocols (see below). 
Antibodies. The following monoclonal antibodies (MoAbs) were used in this study: 
AC133-PE (cloneAC133; Miltenyi Biotec), CD34-APC, -PE, -FITC (clone 581), CD38-
PE, -FITC (clone T16), CDI4-PE (clone RM052), CD15-FITC (clone 80H5), CD19-PE 
(clone J4.119), CD20-FITC (clone B9E9), CD33-PE (clone D3HL60251), CD41-FITC 
(clone P2), CD45-PE, -FITC (clone J33), CD71-FITC (clone YDJL2.2), GlycA-PE 
(clone 11 E4B7 .6; all from Coulter Immunotech, Mijdrecht, TheN etherlands), CD90-PE 
(clone 5El0; PharMingen, San Diego, CA, USA), HLA-DR-PE, -FITC (clone L243), 
IgGI-FITC, -PE, -APC (all from Becton Dickinson, San Jose, CA, USA). 
FAGS analysis and FAGS sorting. FACS analyses and FACS sorting were performed 
on a FACS-Calibur flow cytometer (Becton Dickinson) equipped with an argon laser 
tuned to 488 nm and a helium neon laser tuned to 630 nm using Cellquest software 
(Becton Dickinson). Cell labeling was carried out either in 96-well round-bottom plates 
(non-sterile staining) or in sterile polystyrene tubes. Immunoglobulin binding sites were 
blocked with l 0% (vol/vol) human serum and the cells were labeled on ice with the 
respective antibodies for 25 min in HBSS containing 0.5% (wt/vol) BSA ± 0.1% (wt/vol) 
sodium azide. The stained cells were washed twice, resuspended in HBSS, and l mg/ 
ml 7-amino-actinomycin D (7-AAD; Molecular Probes, Leiden, The Netherlands) was 
added for viable cell selection prior to analysis and sorting. Non-specific background 
staining was determined using cells labeled with isotype-matched control antibody 
conjugates. Sorted cells were collected in 50 ml tubes pre-filled with 5 ml FCS and one 
sorted sample per sorting gate was re-analyzed to verifY cell purity (85-97%). 
Stroma-free cultures. Cells were cultured in Cell Gro SCGM (Cell Gro; Boehringer 
Ingelheim Bioproducts, Verviers, Belgium) supplemented with l 0% (vol/vol) FCS 
or l 0% (vol/vol) human AB serum. The medium was supplemented with 10'4 M j3-
mercaptoethanol ( j3-ME; Merck, Darmstadt, Germany), l 00 U/ml penicillin, 50 mg/ml 
streptomycin (Gibco-BRL), and various recombinant human growth factor combinations 
at final concentrations of l 00 ng/ml rhFlt3-L (Amgen, Thousand Oaks, CA, USA), l 0 
ng/ml huTpo (Genetech, San Francisco, CA, USA), l-20 ng/ml H-IL6 [41], 100 ng/ml 
rhiL6 (Genetics Institute, Cambridge, MA, USA), l 00 ng/ml huSCF (Amgen) and 50 
U/ml rhiLll (Genetics Institute). The cytokines were added weekly, except for Flt3-L 
and Tpo, which were added twice per week .. 5 x 104 AC133+ or CD34+ cells were plated 
in 6-well plates (Coming Costar, NY, USA) in duplicate or triplicate in l ml medium 
with the respective cytokine combinations to initiate the cultures. At weekly intervals, 
the cells were harvested by rinsing the wells twice with HBSS. All cells from each group 
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were pooled, demidepopulated by reducing the volume by 50% (or 33% at week 1 ), and 
replated in fresh medium. The remaining cells were analyzed for viability (using trypan 
blue), cell number immunophenotype, and for CAFC and CFC content. Cell samples 
were also cytocentrifuged at various time points and stained with MayGrunwald-Giemsa 
for morphological analysis. Single- cell cultures were performed in round-bottom 96-
well plates (Falcon, Becton Dickinson). Sorted CD34+CD38· cells were diluted to a 
concentration of 0.7 cells/100 ml in CellGro SCGM with 10% (vollvol) FCS. The 
cell suspension was mixed well, aliquoted, supplemented with the various cytokine 
combinations and seeded into microliter plates at a volume of 100 ml per well (60 wells 
per plate). Fresh medium and cytokines were added every 10 days. The number of cells 
in the single wells was scored weekly using an inverted microscope. Cluster and clones 
up to 100 cells were counted, larger clones were estimated according to their surface 
occupancy. All cultures were maintained in a humidified atmosphere of 10% C02 at 
37°C. 
Stroma-contact cultures. AC133+ cells were seeded in duplicate at a concentration 
of 5 x 104 cells per ml in 6-well plates previously coated with murine FBMD-1 
stromal cells. Every week the cells were harvested by collecting first the non-adherent 
fraction and then carefully trypsinizing the adherent cells. Both fractions were pooled 
and suspended in fresh CellGro SCGM medium without insulin (supplemented with 
penicillin/streptomycin and ~-ME). Half of the volume was replated on a new confluent 
FBMD-1 layer, and supplemented with the respective cytokines, while the other half 
was used for analyses. 
CAFC and CFC assays. CAFC assays were performed as follows: confluent 
stromal layers of the mouse FBMD-1 cell line in 96-well plates were overlaid with 
primary MACS-separated or ex vivo cultured cells in a limiting dilution assay. Twelve 
dilutions, two-fold apart, with 8-15 replicate wells were prepared in IMDM (Iscove's 
modified Dulbecco's medium; BioWhittaker, Boehringer Ingelheim, Verviers, 
Belgium) supplemented with 1% (vol/vol) Glutamax (GibcoBRL), 104 M ~-ME, 100 
U/ml penicillin, 50 mg/ml streptomycin, 10% FCS (Summit), 5% horse serum (Integro, 
Zaandam), 10·5 M hydrocortisone 21-hemisuc-cinate (Sigma), 10 ng/ml rhiL3 (Gist 
Brocades, Delft, The Netherlands) and 20 ng/ml rhG-CSF (Amgen). Half of the medium 
was replaced weekly with fresh medium supplemented with cytokines as described 
above. The cell input values ranged between 1.0 xl02 and 2.0 xl04 cells per well. The 
percentage of wells with at least one cobblestone area (minimum of five cells) beneath 
the stroma layer was determined after two, four and six weeks, and CAFC frequencies 
were calculated using Poisson statistics. The clonal cell cultures were plated in duplicate 
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in 35-mm petri dishes (Becton Dickinson) in I ml methylcellulose-based medium 
consisting of: !.2% methylcellulose (Methocel, Stade, Germany), 30% (vollvol) FCS, 
l O·' M j)-ME, l U/ml recombinant human (rh) Epo (Boehringer Mannheim, Mannheim, 
Germany), 10 ng/ml rhiL3 (Gist Brocades), 5 ng/ml rhGM-CSF (Genetics Institute), 
20 ng/ml rhG-CSF (Amgen), 100 ng/ml murine rSCF (Genetics Institute) in IMDM. 
AC 133+ and CD34+ cells were plated at a concentration of 50 cells per dish and cultured 
cells at a concentration of !.0 xl02 to 2.0 xl04 cells per dish. Granulocyte/macrophage 
colony-forming (CFU-G/M) pro-genitor numbers were scored after 14 days at 37°C and 
5% C02. 
Statistical analysis. Results were expressed as means (± SD) of data obtained 
from three or more experiments, unless otherwise specified. Significance levels were 
determined using the Student's !-test. 
Results 
The H-IL6 fusion protein increases the expansion of CDJ4+ and CDJ4+ACJJJ+ 
progenitors in the presence of Flt3-L and Tpo. The combination of F!t3-L and Tpo has 
recently been described as inducing an extensive amplification and 'self-renewal' of 
UCB-derived 'stem cells' under serum-containing conditions [24, 25]. We therefore 
analyzed various concentrations of the H-IL6 fusion protein for its ability to enhance 
progenitor output in liquid cultures supplemented with Flt3-L and Tpo in the presence of 
I 0% serum. As shown in figure l, the expansion of CD34+ progenitor cells over a four-
week period increased in a H-IL6 dose-dependent manner, reaching maximal values at 
3 ng/ml H-IL6, when assayed using FACS analyses. As a single agent H-IL6 failed to 
induce an expansion of CD34+ cells (data not shown). In order to evaluate the effect 
of the fusion protein in more detail, AC133+ and CD34+ UCB cells, separated using 
MiniMACS columns, were grown in Flt3-L and Tpo containing suspension cultures in 
the presence or absence of H-IL6 in a defined serum-free medium (CellGro SCGM) 
supplemented with FCS concentrations varying from 0% to 20%. The progenitor 
output over a period of five-six weeks was estimated using CFC and CAFC assays 
and FACS analyses. The proliferation of nucleated cells and CD34+ cells increased in 
a FCS concentration-dependent manner reaching plateau values at l 0% FCS. Figure 2 
shows the results of a representative experiment analyzing the expansion of nucleated 
cells, CD34+ cells and CD34+AC!33+ cells from AC133-separated or CD34-separated 
UCB cells during five-six weeks of culture in the presence of l 0% FCS and Flt3-L plus 
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Figure 1. Synergistic effect of increasing concentrations of H-IL6 on the expansion of CD34+ cells derived 
from AC!33-separated UCB cells in four-week cultures supplemented with Flt3-L (!00 ng/ml) and Tpo (!0 
ng/ml). 
Tpo with or without 3 ng/ml H-IL6. In three independent experiments, Flt3-L and Tpo 
induced an 86.04 ± 45.10-fold increase in nucleated cell numbers, a 10.58 ± 5.19-fold 
increase in CD34+ cells, and a 6.29 ± 2.29-fold increase in CD34+ ACJ33+ cells, all 
derived fromACI33-separated UCB cells. In the presence of the fusion protein, a 384.0 
± 170.54-fold expansion of nucleated cells, a 68.41 ± 35.91-fold expansion of CD34+ 
cells, and a 37.69 ± 25.65-fold expansion of CD34+ACJ33+ cells was obtained from 
AC133-separated UCB cells (i.e. a respective 4.5-fold, 6.5-fold and six-fold higher 
expansion than for Flt3-L plus Tpo alone, P< 0.01 in all cases). The expansion potential 
of the CD34-separated UCB cells, derived from the same donor pools, was lower than 
that oftheACI33-separated cells, and the addition ofH-IL6 to the combination ofFlt3-
L and Tpo enhanced the CD34+ and CD34+ACJ33+ output only three- and four-fold, 
respectively. Flt3-L and Tpo, in the presence or absence ofH-IL6, were not sufficient to 
increase total cell numbers for longer than two weeks at serum concentrations lower than 
5% (data not shown). Furthermore, no maintenance or expansion of primitive CAFCw"k' 
could be obtained using this medium without serum addition (data not shown). The 
growth-promoting effect of H-IL6 on progenitor cells is also illustrated in a typical 
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Figure 2. Expansion of nucleated cells (nc), CD34• cells and CD34.AC133• cells from AC133-separated 
(--)and CD34-separated (---)pooled UCB cells in the presence ofFlt3-L (100 ng/ml) and Tpo (10 ng/ml) 
with or without H-IL6 (3 ng/ml). 
FACS analysis in figure 3. While the percentage of CD34+AC133+ and CD34+AC133· 
cells rapidly decreased after one-week of culture if only Flt3-L and Tpo were present, a 
slower decrease was found in cultures supplemented with the H-IL6 fusion protein. In 
three independent experiments, the percentage of CD34+ cells after six weeks of culture 
was 7.2 ± 4.2-fold higher in the presence ofH-IL6 than in its absence (P= 0.001). 
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Figure 3. Flow cytometric analyses of AC133~separated UCB cells before and during ex vivo culture with 
Flt3-L and Tpo in the presence or absence ofH-IL6. Cells were stained with CD34-APC andACl33-PE. The 
quadrants were set according to negative control samples labeled with lgG 1-PerCP and IgG 1-PE. 
111 
Chapter 4 
Table 1. Ex vivo expansion of CFU-GM and CAFC in liquid cultures with Flt3-L and Tpo in the presence or 
absence ofH-IL6. 
Factors 
Flt3-L + Tpo 
Week 
wk3 
wk6 
Flt3-L + Tpo + H-IL6 wk3 
wk6 
Fold-expansion of progenitor cells compared with input numbers 
wk2CFU-GM 
14.70 ± 5.43 
3.10 ± 1.19 
36.90 ±4.78 
50.0 ± 7.01 
wk2CAFC 
4.33 ± 1.73 
1.62 ± 1.07 
!8.13 ± 4.49 
35.18 ± 7.53 
wk4CAFC 
3.59 ± 1.32 
0.18 ± 0.33 
4.50 ± 1.01 
7.28 ± 2.40 
wk6CAFC 
3.40 ± 1.28 
0.27 ± 0.37 
5.33 ± 1.07 
6.92 ± 2.61 
AC13Y UCB cells were grown in serum-containing cultures supplemented with Flt3-L and Tpo in the presence 
or absence of H-IL6. After three and six weeks of culture fractions of cells were plated in methyl cellulose for 
CFU assays and stroma-coated 96-well plates for CAFC assays. The colony assays were initiated with 400-1000 
cells per ml. the CAFC assays with 750-5000 cells in the first dilutions. and analyzed as described in Material and 
methods. Results are means ± SD of n=3 experiments. 
H-IL6 improves the CFU-GIM and CAFC expansion in the presence of Flt3-L and 
Tpo. The CAFC assay allows the frequency analysis of very primitive (CAFC week 5-
8) as well as more mature progenitor cells (CAFC within the first four weeks), while 
the CFC assay determines the frequency and lineage commitment of colony-forming 
cells [42]. As shown in table I, the combination ofFlt3-L and Tpo induced only a small 
expansion of CAFCw,,k6 (two- to four-fold) from AC133+ UCB cells during three weeks 
of ex vivo culture, but was not sufficient to maintain week 4 and CAFCwoekG over six weeks 
of culture. In contrast, the addition ofH-IL6 resulted in a 6.92 ± 2.61-fold expansion of 
CAFCweekG during six weeks of culture (P= 0.001). The highest increase was obtained for 
the more mature progenitor fractions, with the total expansion of CAFCwook2 being 8.1-
fold higher (P= 0.001) and the expansion of CFU-G/M being three- to four-fold higher 
in the presence ofH-IL6 (P= 0.001). 
Gp130-signaling and long-term expansion. To investigate the effect of H-IL6 in 
long-term cultures, AC!33+ UCB cells were grown under stroma-free, serum-containing 
or stroma-supported, serum-free conditions for up to twelve weeks in the presence or 
absence of the H-IL6 fusion protein or IL6 and various combinations ofFlt3-L, Tpo and 
SCF. A representative experiment with a single pool of ACI33-separ-ated UCB cells is 
shown in figure 4. 
Under stroma-free, serum-containing conditions, the two-factor combination Flt3-
L and SCF induced a !90 ± 32.5-fold expansion of nucleated cells, a 15.5 ± 3.5-fold 
expansion ofCD34+ cells, and a 5.5 ± 0.1-fold expansion ofCD34+AC133+ cells during 
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Figure 4. Expansion of nucleated (a), CD34' (b) and CD34'AC133' (c) UCB cells in ilie presence or absence 
of H-IL6 or IL6. AC133-separated cells were cultured with the indicated cytokine combinations under either 
stroma-free serum-containing conditions or on the FBMD-1 stromal cell line without serum. The cells were 
demidcpleted weekly andre-plated as described. 
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the first two to four weeks of culture before declining. The addition ofH-IL6 to Flt3-L 
and SCF increased the number of total nucleated cells a further two-fold (1.85 ± 0.92-
fold, P= 0.1; figure 4a). Interestingly, the highest propagation was obtained for CD34+ 
cells with the expansion of these being 4.7 ± 1.9-fold higher (P= 0.049; figure 4b), 
and the expansion of CD34+AC133+ cells being 4.0 ± 1.8-fold higher (P= 0.03; figure 
4c) in the presence of H-IL6 than with Flt3-L and SCF alone. These progenitors also 
persisted for a longer time in culture in the presence of H-IL6 than in its absence. The 
addition of Tpo to Flt3-L plus SCF induced similar levels of expansion of nucleated 
cells, CD34+ cells and CD34+ACJ33+ cells during the first two to four weeks of culture 
when compared to Flt3-L and SCF plus the H-IL6 fusion protein. Over twelve weeks 
of culture, the highest proliferation was obtained with a combination of all four factors. 
The number of nucleated cells increased up to 12705-fold, and the number of CD34+ 
and CD34+ACJ33+ cells up to 1477-fold and 1455-fold, respectively, over input values 
during twelve weeks of culture in Flt3-L, Tpo, SCF and H-IL6. 
The two-factor combination Flt3-L and Tpo induced a two-fold lower expansion of 
nucleated cells and CD34+ cells than Flt3-Lplus SCF under stroma-free conditions during 
the early phases of the culture. The addition of the H-IL6 fusion protein to Flt3-L and 
Tpo increased the number ofCD34+ACJ33+ cells to the same level as Flt3-L, SCF plus 
H-IL6 but resulted in a three-fold lower expansion ofCD34+ cells, which were negative 
for AC133 (data not shown). Interestingly, IL6 showed a greater synergistic effect with 
Flt3-L and Tpo for the long-term expansion of UCB progenitors than the H-IL6 fusion 
protein. In four different experiments, IL6 induced, during the first six weeks of culture, 
a 1.96 ± 0.64-fold higher expansion of nucleated cells (P= 0.039), a 2.28 ± 0.33-fold 
higher expansion ofCD34+ cells (P= 0.037) and a 2.74 ± 0.28-fold higher expansion of 
CD34+ ACJ33+ cells (P= 0.022) than the H-IL6 fusion protein in combination with Flt3-
L and Tpo. While the progenitor expansion dropped after five-seven weeks in the H-IL6 
supported cultures, a long-term expansion could be sustained in the presence ofFlt3-L, 
Tpo and IL6 resulting in an up to 10-fold higher propagation ofCD34+ cells over twelve 
weeks of culture. 
Co-culture with the murine FBMD-1 stromal cell line in the absence of serum 
greatly increased the progenitor output in cultures containing Flt3-L and Tpo. Although 
the addition of H-IL6 to Flt3-L and Tpo induced a further 10-fold increase in .CD34+ 
numbers, the synergistic effect of the fusion protein for the propagation of CD34+ and 
CD34+ACJ33+ cells was approximately four-fold lower than that of IL6 under the 
same conditions, while the increase in nucleated cells differed only by a factor of 2.5-
fold between IL6 and the H-IL6 fusion protein (n = 2). The benefit of the full-length 
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recombinant IL6 compared to the designer protein was also exemplified by the finding 
that IL6 was more potent in enhancing the expansion of CAFCwook6 in the presence of 
Flt3-L and Tpo. A preliminary but direct comparison showed an 18.5 ± 3.9-fold (mean± 
SD of Poisson analysis) increase in primitive CAFCwook6 after six weeks of culture with 
Flt3-L, Tpo and IL6 in the absence of stroma, while in the presence of Flt3-L, Tpo and 
Without stromal support 
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Figure 5. Lineage commitment of AC133-separated UCB cells after two weeks of culture in serum-containing 
medium supplemented with the indicated cytokine combinations. The cells were labeled with different lineage-
specific antibodies as described in Materials and methods, and analyzed on a FACS-Calibur flow cytometer. 
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H-IL6 CAFCw"'' were only 4.6 ± 1.8-fold higher than the input. Stroma-contact greatly 
increased the expansion ofCAFCw"'' in the presence ofFlt3-L and Tpo, and the addition 
of IL6, or to a lesser extent H-IL6, further enhanced the number of these primitive 
progenitors. The effect of stroma on the propagation of primitive progenitor cells is 
described in more detail in Ku~adas1 et al. (manuscript in preparation). 
Lineage commitment of ex vivo expanded cells in the presence of gp130 signaling. 
Flt3-L is known to stimulate the growth/differentiation of myelo/monocytic cells [18] 
while Tpo has been shown to regulate megakaryocyte and platelet development [20]. 
Accordingly, approximately 25% of the in vitro expanded cells expressed the monocytic 
marker CDI4, and up to 15% (9.6-14.8%) showed a CD33·CD41+ megakaryocytic 
phenotype after two weeks of culture in serum-containing medium supplemented with 
Flt3-L and Tpo (figure 5). The addition of H-IL6 increased the percentage of CD33· 
CD4]+ cells 2.5-fold (26-33% CD33·CD4]+ cells) reducing tbe fraction of myelo/ 
monocytic cells by about the same amount. IL6 also synergized with Flt3-L and Tpo for 
the differentiation/proliferation of megakaryocytic cells although to a lesser extent than 
the fusion protein (15-20% less CD33·CD41+ cells). 
The presence of SCF supported the differentiation to CDI4·CDI5+ granulocytic 
cells but decreased the megakaryocytic differentiation. No CD33-CD41 +cells could be 
detected when only Flt3-L and SCF (without Tpo) were present, and the addition of the 
fusion protein to this combination was also insufficient to increase the percentage of 
CD33·CD41+ megakaryocytic cells over 1%. Interestingly, no CD33·CD41+ cells were 
detected in the FBMD-1-contact cultures, even in the presence ofFlt3-L, Tpo and gpl30-
signaling. The addition of serum also failed to increase the number ofCD33+CD41 +cells 
in the presence of stroma (data not shown). In contrast, tbe percentage ofCDI4+CDI5+ 
monocytic cells was more than two-fold higher in tbe stroma-supported than in the 
stroma-free cultures. A small fraction ofCD71 +Q]ycA+ erythroid progenitors (0.9-2.1 %) 
could be detected after two weeks in the stroma-free cultures with Flt3-L and Tpo ± IL6 
or H-IL6. 0-0.5% erythroid cells were found in the other cultures (data not shown). 
Phenotype of long-term expanded cells in the presence or absence of stroma. 
The immunofluorescence analysis of long-term expanded cells showed considerable 
differences between tbe stroma-free and stroma-supported cultures. As shown in figure 6 
for tbe cytokine combination Flt3-L, Tpo and IL6, the percentage of CD34+CD381'w;. and 
CD34+CD90+ (hu Thy-! antigen) cells after twelve weeks of culture was more than five 
times higher in the presence of stroma than in its absence. The percentage ofCD34+ ACI33+ 
cells was similar under both types of culture conditions. However, tbe majority of ACI33+ 
cells were negative for CD34 under stroma-free conditions, while the expression of this 
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Figure 6. Phenotype of cells cultured fort\Velve weeks in the presence ofFlt3-L, Tpo and IL6 with or without 
stromal support. The cells were labeled with CD34-APC, CD38-FITC, and either AC133-PE or CD90-PE as well 
as 7-ADD to exclude dead cells. The cells were analyzed on a FACS-Calibur flow cytometer, and the quadrants 
were set according to control samples stained with isotype-matched control antibodies. 
antigen was, as on primary cells, restricted to the CD34+ fraction under stroma-supported 
conditions. Similar percentages (i.e. 5-7% CD34+CD381owi-, 1-1.5% CD34+CD90+, and 4.5-
10% CD34+AC133+ cells) were obtained in the stroma-supported cultures containing Flt3-
L, Tpo plus H-IL6 with or without serum after twelve weeks of culture. The proportion 
of CD34·ACJ33+ cells increased with time of culture under stroma-free conditions and 
showed a transition from CD341ow to CD34·AC13J+ cells. CD34·ACJ33+ cells could also 
be detected in the stroma-free cultures with Flt3-L, Tpo plus SCF but the frequency was 
higher in the presence ofH-IL6 or IL6. The majority of these cells co-expressed CD 15, and 
preliminary cell sorting results indicate that CD34·ACJ33+ cells are enriched in CAFCwoek2 
but do not comprise the more primitive CAFCw,,k6• 
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Figure 7. Proliferation of single CD34+CD38· UCB cells during four weeks of culture in the indicated cytokine 
combination with or without IL6. Sorted CD34+CD38· cells were plated by limiting dilution to 0.7 cells per well 
into 96-well plates. The number of cells per well was counted weekly or estimated (clones >100 cells) by surface 
occupancy, and fresh medium with cytokines was added every 10 days. 
Growth promoting effect ofgpl30-signaling on single CD34+CD38· cells. To further 
analyze the effect of gpl30-signaling on the proliferation of primitive progenitor cells, 
we FACS-sorted CD34+CD38· UCB cells and plated single cells in 96-well plates in 
the presence of various cytokine combinations. Figure 7 shows the number and size of 
individual clones after one to four weeks of culture. IL6 increased the number of clones 
(>5 cells) seven- and five-fold when added to Flt3-L plus SCF and Flt3-L plus Tpo, 
respectively. Notably, H-IL6 was less potent than IL6 in recruiting CD34+CD38· cells 
into cell cycle in synergism with Flt3-L and Tpo. The highest cloning frequency (52%) 
was found in the presence ofFlt3-L, Tpo plus SCF, which could not be further enhanced 
by IL6 (50%). However, the number of viable clones decreased after one week of culture 
in the presence of Flt3-L, Tpo and SCF, while a further recruitment of quiescent cells 
into cell cycle was observed with Flt3-L, Tpo and IL6. In addition, clones containing 
more than 5000 cells were found exclusively in the presence of IL6, and were most 
frequent in the wells supplemented with the four-factor combination. 
118 
Umbillical cord blood hematopoietic stem and progenitor cells 
Discussion 
In this study, we have examined the effect of a designer fusion protein of IL6 and the 
soluble IL6R, H-IL6, on the ex vivo expansion of cord blood progenitors. As a single 
agent, the fusion protein failed to induce the propagation of UCB-derived CD34+ cells 
and CAFC, but synergized effectively and in a dose-dependent fashion with Flt3-L and 
Tpo for the expansion of hematopoietic progenitor cells under both stroma-free and 
stroma-supported conditions. In addition, we have shown that IL6 is more potent than 
the fusion protein in supporting the long-term propagation of UCB CD34+AC133+ or 
CD34+ cells and CAFC in the presence ofFlt3-L and Tpo. 
Most data indicate that the proliferation of primitive hematopoietic progenitor cells 
requires co-stimulation by different regulatory factors [ 43]. Among the cytokines that 
are considered primary mediators in early hematopoiesis are Flt3-L and Tpo. Primitive 
CD34+CD38· rhodamine-123 1'w 4-hydroperoxycy-clophosphamide ( 4-HC)-resistant 
cells respond to Flt3-L [ 16], and several studies report a higher expansion of primitive 
progenitors in the presence of this cytokine [15, 44]. Tpo has also been shown to enhance 
the recruitment of early hematopoietic progenitors into cell cycle and to increase the 
clonal growth and the viability of single CD34+CD38· cells [19, 21-23]. Studies by 
Piacibello et al. [24] have described a 1000-fold amplification of CD34+ cells and a 
300-fold amplification of primitive LTC-IC after three to six weeks in serum-containing 
cultures supplemented with the single combination of Flt3-L and Tpo. Using AC133+ 
or CD34+ UCB cells, we were unable to reproduce such levels of expansion for CD34+, 
CD34+AC133+, CFC or CAFC subsets with Flt3-L and Tpo under serum-containing 
conditions in our culture system. This may reflect differences in the sources of cytokines 
or the presence ofuncharacterized factors in the sera. The addition ofH-IL6 increased the 
propagation ofCD34+ cells more than six-fold over Flt3-L and Tpo and further enhanced 
the proliferation of both CFC by three- to four-fold and primitive CAFCwook6 by two-fold 
during six weeks of culture. The fusion protein also acted synergistically with Flt3-L 
plus SCF and with Flt3-L, Tpo plus SCF for the expansion of CD34+ cells and CAFCwook6 
both under serum-containing stroma-free and serum-free stroma-supported conditions. 
These results support and extend the studies of Sui et al. [35] and Ebihara et al. [37], 
who tested a complex of the soluble IL6R and IL6 (IL6/siL6R) in combination with 
SCF or Flt3-L in three-week suspension cultures and methylcellulose clonal assays and 
demonstrated an increased expansion of multi potential and committed progenitors from 
UCB or BM-derived CD34+ cells. Kimura et al. [33] did not find a significant colony 
formation from FACS-sorted CD34+IL6R+ or CD34+IL6R· PB cells in the presence of 
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SCF and IL6/siL6R alone, but a high proliferation ofBFU-E and CFU-Mix colonies was 
induced in the IL6R-negative fraction when IL3 was added to this cytokine combination. 
Recently, Zandstra et al. [ 45] reported a higher LTC-IC expansion in one-week serum-
free cultures of CD34+CD38· UCB cells stimulated by Flt3-L in combination with the 
IL6/siL6R complex when compared to the combinations of Flt3-L plus Tpo or Flt3-L, 
SCF, IL6, IL3 plus G-CSF. Since the half-life of this IL6/siL6R complex is very short, 
high concentrations of the soluble IL6R were needed to obtain effective stimulation [34, 
35, 45]. In contrast, the H-IL6 fusion protein has proven to be fully active at 100- to 
1000-fold lower concentrations than the combination ofiL6 and IL6R [41], and in the 
present study 3 ng/ml H-IL6 were found to be sufficient to induce maximal expansion of 
CD34+ cells in the presence of Flt3-L and Tpo. 
Fischer eta!. [41] were the first to test the effect of the H-IL6 fusion protein on 
hematopoietic progenitors in short-term cultures. They found an increased expansion 
of CFU-GM when H-IL6 or the IL6/siL6R complex was added to the combination of 
SCF and IL3 in two-week cultures of CD34+ mobilized PB cells. Notably, under the 
same conditions, stimulation with IL6 in place of the IL6/siL6R complex resulted in a 
lower expansion of these committed progenitors. Sui et a!. [35, 36] also described an 
increased number of clonogenic progenitors generated from CD34+ UCB cells in the 
presence of SCF and IL6/siL6R compared to SCF and IL6. In their study, the IL6/siL6R 
complex stimulated in particular the expansion of erythroid and mixed colonies, while 
the number of CFU-GM was similar in the cultures supplemented with either IL6 or the 
IL6/siL6R complex. This is in line with the findings of Tajima et al. [32], who showed 
that erythroid progenitors and CFU-GEMM segregate with the CD34•gpl30•IL6Ra· 
fraction of FACS-sorted UCB cells, whereas the CFU-GM are concentrated in the 
CD34•gpl30+IL6Ra+ fraction. In addition, a six-fold higher LTC-IC frequency was 
found in the CD34•gp J30+IL6Ra· subset compared to the CD34•gp J30+ IL6Ra• fraction, 
leading to the conclusion, that 'stem cells' or at least LTC-IC are IL6Ra negative, and 
cannot be stimulated by IL6 alone. However, due to the low IL6Ra receptor expression, 
positive and negative fractions are not clearly distinguishable, and LTC-IC were not 
found to be restricted solely to the IL6R-negative fraction. McKinstry eta!. [ 46], using 
radio labeled IL6, also detected IL6Ra expression on 13% of primitive murine Rh low 
Lin·Scal •kit+ progenitors. Furthermore, murine 5FU-treated BM cells could be shown 
to proliferate in response to IL6, SCF and IL3 [47]. Evidence that IL6 complexed to 
the soluble IL6R, but not IL6 alone, may be able to stimulate early murine progenitors, 
comes from phenotypic analyses of mice single transgenic for either IL6 or siL6R or 
double transgenic for both IL6 and siL6R [34, 39, 40]. Interestingly, double transgenic 
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mice developed a marked extramedullary hematopoiesis in the spleen and to a lesser 
extent the liver while the bone marrow cellularity was not significantly changed. The 
liver showed distinct foci with predominantly granulopoietic cells, while large numbers 
of erythrocytes, granulocytes and megakaryocytes were found equally distributed in the 
spleen. In addition, the number of primitive Lin·ScaJ+kit+ cells in the liver of double 
transgenic mice was increased from about 0.03% to 0.3% leading to the hypothesis that 
persisting fetal progenitor cells in spleen and liver can be recruited into proliferation 
by IL6 in combination with the soluble IL6R. However, as mentioned above, high 
concentrations of IL6R seemed to be necessary to generate this effect, as Hirota et al. 
[ 48] did not find hematological abnormalities in their IL6 and s!L6R transgenic mice 
with lower shedding levels of the membrane-bound IL6R. 
Interestingly, although the H-IL6 fusion protein enhanced the expansion of ACI33-
separated hematopoietic progenitors with a variety of cytokine combinations in our 
culture system, IL6 synergized more potently than the fusion protein with Flt3-L and 
Tpo for the expansion of CD34+ and CD34+ AC 133+ cells as well as of CAFC. This 
became more pronounced after pro-longed ex vivo culture and may in part be due to 
the use of MACS-separated ACI33+ UCB cells in preference to CD34-separated cells, 
which have been found to possess a lower expansion potential in our culture system. 
In this respect, the ACI33 antigen is expressed on a subfraction of CD34+ cells, which 
comprises committed progenitors as well as LTC-IC and long-term repopulating cells. 
Our own unpublished data con-firm that approximately 90% of the CAFCwook6 and 
approximately 80% of the CFU-GM can be recovered in the CD34+ACI33+ fraction 
of sorted primary UCB cells. In contrast, CD34+ AC 133· cells have no long-term 
repopulating ability and are enriched for erythroid progenitors [49, 50]. Since erythroid 
progenitors have been shown to be IL6Ra negative [32], we would therefore expect that 
the separation of AC!33+ cells results in an enrichment ofiL6Ra+ cells and an enhanced 
response to IL6. Of further interest was the observation that the expansion of UCB-
derived CD34+ and CD34+ AC 1333• cells in serum-containing liquid cultures with Flt3-
L, Tpo and the H-IL6 fusion protein resembled more the expansion induced by ILl! than 
by IL6 under the same conditions (unpublished data). Since both ILl! and IL6 induce 
a homodimerization of gpl30, it can also be speculated that the activation of gpl30 by 
the H-IL6 fusion protein may differ from the stimulation induced by an interaction of 
IL6 with the IL6Ra chain. Recently, Rakemann et al. [51] have reported, that STAT3-
depen-dent gene transcription in HepG2 cells is about I 0-fold higher after stimulation 
with H-IL6 than after activation with IL6. However, with increasing amounts ofiL6Ra 
expression transgenic HepG2 cells became less sensitive to H-IL6 while the response to 
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IL6 increased. Upregulation ofiL6Ra expression during differentiation could therefore 
favor stimulation by IL6 compared with H-IL6 and indirectly mediate an as yet unknown 
growth promoting signal to more primitive progenitor cells. 
While it has not as yet been shown that the direct stimulation of primitive 
CD34+gp J30+IL6Ra· cells by the IL6/siL6R complex or the H-IL6 fusion protein results 
in an expansion of long-term repopulating cells, IL6 and ILll have been shown to 
synergize with other cytokines for the expansion of SCID repopulating cells (SRC). For 
instance, our recent studies indicate that IL6 in combination with Flt3-L and Tpo induces 
a 10- to 20-fold expansion of the ability ofUCB-derived SRC in serum-containing liquid 
cultures to repopulate the murine bone marrow (Ku~adas1, manuscript in preparation), 
and also causes a higher expansion ofCAFCwook6 than the combination ofFlt3-L, Tpo and 
SCF. In addition, a cytokine cocktail ofiL3, IL6, G-CSF, SCF and Flt3-L is reported to 
support a two-fold expansion ofNOD/SCID competitive repopulation units (CRU) from 
CD34+CD38· UCB cells in serum-free suspension cultures [11]. Bhatia et al. [12] have 
also described a two- to four-fold increase in SRC after short-term culture ofCD34+CD38· 
UCB cells with an IL6 containing cytokine cocktail, while murine hematopoietic stem 
cells with transplantable lympho-myeloid reconstituting ability could be expanded 
three-fold in serum-free medium containing ILl!, Flt3-L and SCF [10]. Notably, Peled 
et al. [52] recently reported an upregulation of CXCR4 expression on CD34+ cells by 
SCF and IL6. This receptor for the chemokine stromal cell-derived factor-! (SDF-1) has 
been found to be critical for human stem cell engraftment and repopulation of NODI 
SCID mice. Very recently, Piacibello et al. [53] reported that CD34+ UCB cells could be 
expanded for up to ten weeks in stroma-free cultures in the presence ofFlt3-L, Tpo, SCF 
and IL6 without losing their in vivo repopulating potential. 
In addition to the effects on primitive progenitor amplification, we observed that both 
IL6 and H-IL6 further enhanced the ex vivo expansion of megakaryocytic cells when 
combined with Flt3-L and Tpo. This observation is important in a clinical setting where it 
is necessary to shorten the period of chemotherapy-induced thrombocytopenia, which is 
prolonged after UCB transplantation when compared to BM transplantation [3]. Contact 
with the murine stromal line FBMD-1 reduced the percentage of CD33·CD41+ cells 
almost to background levels but, on the other hand, greatly enhanced the amplification of 
phenotypically and functionally primitive progenitor cells in the presence of Flt3-L and 
Tpo with or without H-IL6 or IL6. Again, the highest progenitor expansion was found 
in the presence ofiL6. Interestingly, the phenotype ofUCB progenitors expanded in co-
culture with FBMD-1 stromal cells (in the presence or absence of serum) corresponded 
to the phenotype of primary progenitors with the expression of the AC133 antigen 
122 
Umbillical cord blood hematopoietic stem and progenitor cells 
being restricted to the CD34hlgh subset. In contrast, a fraction of CD341'w1-AC133+ cells, 
which most likely represents more mature myeloid progenitors, appeared and increased 
during liquid culture in the absence of stroma. In conclusion, although the H-IL6 fusion 
protein supported the ex vivo expansion of different progenitor populations in synergy 
with various cytokine combinations, no advantage over IL6 could be observed in our 
culture system. Further studies are necessary to investigate whether this fusion protein 
can directly stimulate primitive marrow engrafting cells or if, like IL6, it acts indirectly 
via accessory cells. 
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Abstract 
The first definitive long-term repopulating hematopoietic stem cells (HSCs) emerge 
from and undergo rapid expansion in the embryonic aorta-gonad-mesonephros 
(AGM) region. To investigate the presumptive unique characteristics of the embryonic 
hematopoietic microenvironment and its surrounding tissues, we have generated stromal 
clones from subdissected day 10 and day 11 AGMs, embryonic livers (ELs) and gut 
mesentery. We here examine the ability of nineteen of these clones to sustain extended 
long-term cultures (LTCs) of human CD34+ umbilical cord blood (UCB) cells in vitro. 
The presence of in vitro repopulating cells was assessed by sustained production of 
progenitor cells (extended LTC-CFC) and cobblestone area forming cells (CAFC). The 
embryonic stromal clones differed greatly in their support for human HSCs. Out of eight 
clones tested in the absence of exogenous cytokines, only one (EL-derived) clone was 
able to provide maintenance of HSCs. Addition of either Tpo or Flt3-L + Tpo improved 
the long-term support of about 50% of the tested clones. Cultures on four out of nineteen 
clones, i.e. the EL-derived clone mentioned, two urogenital-ridge (UG)-derived clones 
and one gastrointestinal (GI)-derived clone, allowed a continuous expansion of primitive 
CAFC and CFU-GM with over several hundred-fold more CAFCwook6 produced in the 
twelfth week of culture. This expansion was considerably higher than that found with 
the FBMD-1 cell line, which is appreciated by many investigators for its support of 
human HSCs, under comparable conditions. This stromal cell panel derived from the 
embryonic regions may be a powerful tool in dissecting the factors mediating stromal 
support for maintenance and expansion of HSCs. 
Introduction 
A major clinical challenge in HSC transplantation is the establishment of culture 
systems that mediate extensive numerical expansion of HSCs in vitro with maintenance 
of HSC potential for proliferation and multilineage differentiation. Using well-defined 
early-acting cytokines, we and others have reported an increased ability of UCB cells 
for multilineage repopulation of NOD/SCID mice following ex vivo culture [1-4]. In 
addition, several stromal cell lines derived from adult, fetal or embryonic origin have been 
shown to support HSCs and/or progenitors, emphasizing the role of microenvironment 
m promoting the survival, proliferation and differentiation of hematopoietic cells 
in vitro [ 4-9]. However, the use of cytokines or stromal mono layers alone, or in 
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combination, has met with limited success in expanding long-term repopulating HSCs 
for clinical applications, or improving rapid engraftment and early recovery of platelet 
and neutrophil numbers. 
In the past few years, we have demonstrated that definitive murine HSCs and 
progenitors first emerge from the intra-embryonic region, which forms the aorta-, 
gonads-, and mesonephros (AGM) region [10]. These hematopoietic cells capable of 
reconstituting definitive adult hematopoiesis first appear at day I 0.5 after gestation 
(El0.5) and expand rapidly in the subsequent two to three days. Furthermore, from 
AGM explant cultures we learned that HSC activity is autonomously generated and 
amplified in the AGM [I 0]. In addition, we demonstrated that functional definitive HSCs 
developed particularly from the major arterial regions, i.e. the dorsal aorta, vitelline and 
umbilical vessels, indicating a close relationship between the developing hematopoietic 
and vascular systems [II]. The fetal liver, which is an important hematopoiesis-
supportive microenvironment, does not become a major site for HSC expansion until 
El2 [12-14]. 
In subsequent years, a few stromal cell lines from the E 11 AGM region have been 
reported to maintain HSCs with competitive repopulating activity in vitro [6, 9]. 
However, this support did not seem to be better than that of earlier established stromal 
cell lines from El4.5 fetal liver or adult bone marrow [7, 8]. As the factors responsible 
for the induction and expansion ofHSCs are still incompletely defined, we hypothesized 
that the EIO and Ell AGM region with surrounding tissues and the embryonic Ell liver 
(EL), display unique characteristics with regard to support of HSC activity and that 
the cloning of stromal cells from these regions would aid in identifying mechanisms 
involved in HSC expansion. 
We have generated more than hundred stromal clones from subdissected day I 0 or II 
AGMs, ELs and gut mesentery of murine embryos transgenic for a temperature-sensitive 
mutant of the SV40 large T antigen (SV40 Tag) gene or the LacZ marker gene [15]. In 
the study presented here, we investigated the ability of nineteen embryonic stromal 
clones to sustain extended Dexter-type LTCs of CD34+ umbilical cord blood (UCB) 
cells for periods as long as twelve weeks. Our previous experiments indicated that 
addition of the cytokines Flt3-L and Tpo results in superior maintenance of immature 
cobblestone area forming cells (CAFCw,,,,) [ 4, 16]. Moreover, UCB cells cultured in 
the presence of at least these cytokines maintained their ability to undergo multilineage 
differentiation in vitro along myeloid and lymphoid pathways [ 17, 18]. The production 
of CAFCwook6 or LTC-initiating cells(IC) in ex vivo expansion cultures has been shown 
to be indicative for the presence and quantity of in vivo repopulating HSC as measured 
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using the quantitative NOD/SCID xenotransplant model [3, 4, 19-21]. However, 
behaviour of the LTC-IC populations may only partly overlap with that of the HSC and 
show distinct characteristics under specific experimental conditions [16, 22]. Screening 
a large number of stromal cell lines using this in vivo model is not practicable. Thus, we 
have used the in vitro production of CFC and CAFCw"'' in extended LTC as a pseudo-
assay for repopulating HSC instead. Using this assay we were able to identify several 
embryonic stromal co-cultures (one EL-, two UG- and one GI-derived) that supported 
an expansion of CAFCw"'' largely exceeding that of the reference co-cultures under 
comparable conditions. All co-cultures required at least human Tpo for their prolonged 
expansion of human HSCs and progenitors. 
Material and methods 
Human umbilical cord blood cells. Human UCB samples were collected in sterile flasks 
containing 10 ml citrate-glucose as anticoagulant from umbilical cord vein after full-
term delivery by the nursing staff of the Department of Obstetrics and Gynecology at 
the Sint Franciscus Gasthuis (Rotterdam, The Netherlands). UCB was stored at room 
temperature and processed within 24 hours of collection. Low-density cells were isolated 
using Ficoll Hypaque density centrifugation (L077g/cm2, Lymphoprep, Nycomed 
Pharma, Oslo, Norway) by centrifugation at 600 g for 15 minutes. The mononuclear 
cell (MNC) band at the interface was removed, washed twice with Hanks Balanced Salt 
Solution (HBSS, Gibco, Breda, The Netherlands) and resuspended in Iscove's modified 
Dulbecco's medium (IMDM, Gibco, Breda, The Netherlands). The MNCs were stored 
in I 0% FCS, 20% DMSO in IMDM in liquid nitrogen until use. 
Isolation of CDJ4+ cells. In all experiments human UCB were positively selected 
for the expression of CD34 using either Variomacs or Automacs Immunomagnetic 
Separation System (Miltenyi Biotech, Bergisch Gladbach, Germany) according to 
the manufacturers instructions. After thawing and before the CD34+ hematopoietic 
progenitor cells were isolated we pooled 3 to 16 different UCB samples. The purity of 
the CD34 selected cells from UCB, as determined by FACS after staining with a CD34 
antibody, was 90% :t 3%, and the percentage of cells with a CD34+CD38· phenotype was 
8% ± 7%. The progenitor and stem cell numbers in the input and output suspensions 
were determined by CFC and CAFC assays. The absolute number of progenitors present 
in uncultured material was 1.8 :t 1.0 x104 and 2.7 :t 1.6 x103 per 105 CD34+ cells for 
CFU-GM and CAFCw"''' respectively. 
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Hematopoietic growth factors. The following cytokines were used: recombinant 
human Flt3-L, a gift from Amgen (Thousand Oaks, CA, USA); recombinant human 
granulocyte-macrophage colony stimulating factor ( GM -CSF), recombinant human 
granulocyte colony stimulating factor (G-CSF) and recombinant murine stem cell 
factor (SCF), all gifts from Genetic Institute (Cambridge, MA, USA); recombinant 
human Tpo, a gift from Genentech (South San Francisco, CA, USA), recombinant 
human erythropoietin (Epo, Boehringer, Mannheim, Germany) and recombinant human 
interleukin-3 (IL3) (Gist Brocades, Delft, The Netherlands). 
Stromal cells and clones. The FBMD-1 cells were cultured as previously described 
[23]. The embryonic stromal clones were generated from subdissected AGM regions, 
gut and stomach tissues and livers from EIO and Ell embryos of BL!b, Tag05 and 
Tag!! mice with BL!b transgenic for LacZ inserted into the first intron and Tag 05/11 
transgenic for temperature-sensitive mutant of the SV 40 large T antigen. Details about 
the establishment of these stromal clones have been described elsewhere [15]. The 
embryonic stromal clones were cultured in 25 cm2 flasks (Costar, Cambridge, MA, USA) 
with 5 ml IMDM containing 10% fetal calf serum (FCS, Summit, Fort Collins, CO) 
and 10% horse serum (HS, Gibco), supplemented with penicillin (100 U/ml, Gibco), 
streptomycin (0.1 mg/ml, Gibco), 10-mercapto-ethanol (104 M, Merck, Darmstadt, 
Germany). The stromal cells were grown to confiuency at 33 °C and I 0% C02 and 
irradiated with 40 Gy prior to co-cultures. 
Extended LTCs. Confluent 25 cm2 flasks of different stromal cells were overlaid with 
I or 2 xl03 CD34+ UCB cells. These cells were cultured in 5 ml LTC-medium (IMDM 
containing 20% FCS, further supplemented with penicillin (100 U/ml), streptomycin 
(0.1 mg/ml), 10-mercapto-etbanol (JO·' M, Merck), cholesterol (15 !-lM, Sigma), linolic 
acid (15 I-'M Merck), iron-saturated human transferrin (0.62 g/1, Intergen, Uithoom, The 
Netherlands), nucleic acids (cytidine, adenosine, uridine, guanosine, 2'-deoxycytidine, 
2'-deoxyadenosine, thymidine, 2'-deoxyguanosine (all at 10·3 g/ml, Sigma)). The 
cultures were either supplemented with Tpo (10 ng/ml) alone or a combination ofFlt3-
L (50 ng/ml) and Tpo (10 ng/ml). In some experiments cells were also deposited on 
stromal layers without any cytokine supplements. 
Depleted extended LTCs. Cultures were set up in quadruplicate and maintained at 33° 
C and I 0% C02 for twelve weeks with weekly half medium change and consequently 
depletion of half of the non-adherent cells. Every two weeks the CFC output in non-
adherent supernatant was determined without correcting for weekly demidepopulations. 
At weeks seven/eight or twelve the adherent layers were assayed for the CFC and 
CAFC numbers as welL Thus, the total CFC and CAFC production (in adherent plus 
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non-adherent cells) could be determined at these timepoints. In the subsequent two 
experiments four stromal clones and one control line were set up in six-fold in flask 
cultures and the adherent and non-adherent compartments were analyzed separately 
for their progenitor and stem cell contents at week 2, 4 and 6 of culture. To harvest 
the adherent layer, the non-adherent cells were first collected and the layer washed 
with PBS and subsequently incubated with trypsin-EDTA (Life Technologies, Breda, 
The Netherlands) at 37"C for 5-10 minutes. The digestion was stopped by adding 1 ml 
FCS. 
Non-depleted extended LTCs. In the last experiment, confluent layers of FBMD-1, 
UG26-1B6, EL08-lD2 and GI29-2B4 were irradiated with 40 Gy and seeded with 2 x104 
UCB CD34+ cells in LTC-medium additionally containing 1% bovine serum albumin 
(BSA, Sigma, Zwijndrecht, The Netherlands). In stead of weekly demidepopulating the 
non-adherent cells, these cultures were maintained by splitting the cultures every four 
weeks and seeding suitable aliquots of5 x103 and 1,25 x103 input equivalents cells (both 
adherent and non-adherent cell fractions harvested and pooled) on two newly established 
corresponding stromal layers at weeks 4 and 8, respectively. The remaining number of 
cultured cells was analyzed for their progenitor and stem cell numbers using the CFC 
and CAFC assays every fourth week. Every two weeks the non-adherent fraction of the 
flask cultures was removed, centrifuged to collect the non-adherent cells, which were 
returned to the cultures, and replaced with fresh medium. The cytokines Flt3-L (50 ng/ 
ml) and Tpo (1 0 ng/ml) were added twice weekly. The other culture conditions were the 
same as mentioned above. 
Clonony forming cell assay. Granulocyte-macrophage colony forming unit (CFU-
GM) and burst forming unit-erythroid (BFU-E) progenitor cells were assayed using a 
semisolid culture medium (1.2% methylcellulose), in IMDM supplemented with 30% 
FCS, 13-mercapto-ethanol (5 x 10·' M), penicillin (100 U/ml), streptomycin (0.1 mg/ml), 
hu-Epo (1 U/m1), hu-IL3 (20 ng/m1), hu-GM-CSF (5 ng/ml), hu-G-CSF (50 ng/ml) and 
mu-SCF (100 ng/ml). Duplicate cultures were plated in 35 mm tissue culture dishes 
(Falcon) and incubated at 37"C and 10% C02 in a humidified atmosphere. Colonies 
containing 50 cells or more were scored at day 14 using an inverted light microscope. 
Cobblestone area forming cell assay. Confluent stromal layers of FBMD-1 cells in 
flat-bottom 96-well plates (Falcon) were overlaid with UCB cells in a limiting dilution 
set up as described [24]. Briefly, twelve successive two-fold dilutions were used for each 
sample with 15 wells per dilution. The percentage of wells with at least one phase-dark 
hematopoietic clone (cobblestone area) of at least five cells beneath the stromal layer 
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Figure 1. Flowcytometric analysis of uncultured and cultured CD34+ UCB cells in a representative experiment. 
The FACS profiles represent the percentage of CD34+ UCB cells within the life-gate before and after ten weeks 
of ex vivo culture on EL08-1 D2 stromal cells under different conditions. The total CD34+ percentage is given in 
the comer of the right quadrant for each sample. Cells were stained with CD34-FITC or CD34-APC and CD38-
PE. The quadrants were set according to negative control samples labeled with IgGI-FITC or IgGl-APC and 
IgG!-PE. 
was determined at week 6 (CAFCwook6). The CAFC frequencies were calculated using 
Poisson statistics. 
Immunophenotypic analysis. At least 50,000 fresh or cultured CD34+ cells were 
stained with anti human CD45/CD34/CD38 (allophycocyanin (APC)-, fluorescein 
isothiocyanate (FITC)- or phycoerythrin (PE)-conjugated) labeled monoclonal 
antibodies (Immunotech, Mij drecht, The Netherlands). After incubation of the cells in 
phosphate-buffered saline (PBS, Life Technologies, Breda, The Netherlands) containing 
0.5% BSA and 2% normal human serum for 30 minutes on ice, the cells were washed 
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Figure 2. Functional screening approaches of the newly established embryonic stromal clones. 
in PBS with 0.5% BSA and resuspended in 0.35 ml PBS. Just before the acquisition 7-
aminoactinomycin (7-AAD, Molecular Probes, Leiden, The Netherlands) was added to 
each sample to determine the viability of the cells. APC, FITC and PE-conjugated mouse 
isotype antibodies were used as control for each group. At least 10,000 events were 
acquired using fluorescence-activated cell sorting (FACS) analysis (Becton Dickinson). 
The flow cytometric analysis of a representative experiment is given in figure 1. 
Statistical analysis. The values are reported as mean ± 1 SD. The significance levels 
were determined by two-tailed Mann-Whitney U-test analysis. 
Results 
The strategy for selecting functionally supportive embryonic stromal cell clones is 
shown in figure 2. In initial studies more than hundred stromal clones from different 
embryonic tissues and subregions of the AGM, i.e. aorta-mesenchyme (AM), UG, 
EL and GI, were established from E 10 and E 11 mouse embryos transgenic for the 
temperature sensitive tsA58 mutant of the SV 40 large T antigen gene or a control LacZ 
marker gene [15]. The stromal clones have been tested for their support of sustained 
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Figure 3. Extended generation of non-adherent CFU-GMs in three representative stromal co-cultures. Data 
represent one experiment with duplicate cultures. The cultures were maintained by weekly half medium change 
with removal of half of the non-adherent cells. The cells were assayed after pooling the corresponding cultures 
prior to CFC. The CFU-GM generation of the reference line FBMD-1 and two embryonic clones with distinct 
patterns are included for comparison. The CFU-GM and CAFCweek6 numbers present in uncultured material 
were 1.8 ± 1.0 xl04 and 2.7 ± 1.6 xl03 per 105 CD34+ UCB cells, respectively. Abbreviations: AM. aorta 
mesenchyme; UG, urogenital ridge; EL, embryonic liver; GI, gastrointestinal tract. 
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Figure 4. Non-adherent CFU-GM generation with stromal cells from embryonic subregions in extended co-
cultures. Data represent the mean non-adherent CFU-GM production in different stromal co-cultures, averaged 
per subdissected region. The number of stromal clones averaged per region were 4-8, 2-9, 1-2, 1-2 and 2-3 for 
UG, AM, EL, GI regions and FBMD-1, respectively. The cultures were maintained by weekly half medium 
change with removal of half of the non-adherent cells. Mann-\Vhitney U-test: P< 0.05 or P< 0.005 between 
cultures without and with supplementation of Tpo or Flt3-L + Tpo at all time points~ P< 0.05 between Tpo 
and Flt3-L + Tpo supplemented cultures on weeks 2 and 4. Because there was no significant difference in non-
adherent CFU-GM generation between the stromal cells with respect to their origin we pooled these groups 
for statistical analysis. Abbreviations: .AJ\1, aorta mesenchyme~ UG, urogenital ridge; EL embryonic liver; GI, 
gastrointestinal tract. 
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generation of murine CFC in LTC. Twenty-five clones supported the growth of murine 
CFC better than several reference stromal lines [25]. Seven of these clones were able 
to maintain transplantable murine HSCs in a short-term co-culture. Though prolonged 
culture decreased the maintenance ofHSCs on most stromal clones, the urogenital ridge-
derived clone, UG26-1B6, maintained in vivo repopulating murine HSCs for at least four 
weeks. For the evaluation of the functional support for human HSCs and progenitors 
nineteen best supportive embryonic stromal clones, including the seven which supported 
murine transplantable HSCs, were selected. 
Generation ofCFC and CD34+ subsets in extended long-term co-cultures with human 
CD3¢ UCB cells. Highly purified CD34+ cells from UCB were cultured on twenty-one 
different stromal layers, including the reference line FBMD-1, under serum-containing 
conditions for up to twelve weeks with medium containing either no cytokines, Tpo 
or Flt3-L + Tpo. We have previously shown that addition of these cytokines improves 
the maintenance of primitive CAFCw"k' on FBMDl stromal cells dramatically [4]. 
The stromal cells were grown to confluency and irradiated with 40 Gy prior to culture. 
In the first set of experiments we studied the ability of these stromal cells to sustain 
production of human progenitors in extended LTCs either in the absence or presence of 
cytokines. The extended LTCs were maintained by weekly half medium change resulting 
in removal of half of the non-adherent cells. The corresponding supernatants of the same 
cultures were pooled every two weeks and used to determine the CFU-GM production in 
the non-adherent compartment. 
The non-adherent CFU-GM kinetics of the reference cell line and two representative 
clones are presented in figure 3. We observed a gradual decline in non-adherent CFU-
GM production in the absence of cytokines with the majority of the stromal clones 
similar to the FBMD-1 reference line. In contrast, co-culture with the EL08-1D2 clone 
sustained human CFU-GM production under these conditions for more than eight 
weeks. Moreover, the same clone supported the generation of more CFC than observed 
for the reference cell line FBMD-1 when either Tpo alone or a combination of Flt3-L 
and Tpo was added. In figure 4 all stromal cell lines tested are plotted per embryonic 
region. Long-term non-adherent CFU-GM production was observed in cultures 
supported by stromal clones derived from all of the different embryonic regions. The 
limited number of clones did not allow statistical analyses of possible region-related 
differences in support. Cytokine supplementation dramatically improved the long-term 
non-adherent CFU-GM generation supported by stromal cell layers derived from all 
regions. This resulted in a 30-700 fold significant increase in CFU-GM retrieved from 
Tpo-supplemented cultures as compared to control cultures on week 12 (figure 4, P< 
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Figure 5. Extended long-term production of non-adherent CD34+ cells in three representative stromal co-
cultures. Data represent one experiment with duplicate cultures. The cultures were maintained by weekly 
half medium change with removal of half of the non-adherent cells. The cells were assayed after pooling the 
corresponding cultures prior to phenotyping. The production of cells by the reference line FB"MD-1 and two 
embryonic clones with distinct patterns are included for comparison. Abbreviations: AM, aorta mesenchyme; 
UG, urogenital ridge; EL. embryonic liver; GI, gastrointestinal tract. 
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0.05, Mann-Whitney U-test). The addition of Flt3-L to Tpo-complemented co-cultures 
showed no substantial improvement of the CFU-GM generation oer that seen with TPO 
alone, except for weeks 2 and 4. 
In addition to the functional screening, we also looked at the expression of CD34 
and the CD34+CD38· cells as an indicator of progenitors and stem cells within the non-
adherent compartment. The results of CD34 assessment after co-culture experiments 
with the reference cell line and two representative clones are shown in figure 5. The 
non-adherent compartment of different embryonic stromal co-cultures showed a large 
variability in the generation of CD34+ and CD34+CD38· cells. Several clones maintained 
or slightly increased their numbers in the presence of cytokines as compared to the 
reference line. In the presence ofFlt3-L + Tpo the CD34+CD38· cell production reached 
a maximum of 2330-fold the input with UG26-IB6 stromal cells at week 12 of co-
culture (data not shown). 
Stromal support for primitive stem and progenitor cells in human extended long-term 
co-cultures. To test whether the stromal clones supported the generation of primitive 
human progenitors, we determined the total (combined adherent and non-adherent 
cells) CFU-GM and CAFCw,,k6 fractions of co-cultures after 7/8 and twelve weeks in the 
presence ofTpo alone or a combination ofFlt3-L and Tpo. The embryonic stromal clones 
showed substantial variation in their ability to support primitive progenitors (table 1 ). 
Seven stromal co-cultures that maintained in vivo repopulating ability of murine HSCs 
are highlighted (bold typeface) in table I. Two of these clones, UG15-IB7 and UG26-
2D3, did not long-term support human HSCs indicating different requirements of human 
HSCs for in vitro maintenance, or the lack of cross-specificity of one or more factors 
involved in the cross-talk between murine stromal cells and human progenitors. The 
clones GI29-2B4, UG26-IB6, UG26-3D4 and EL08-ID2, which most optimally support 
murine progenitors, also gave the best support for human HSCs and progenitors. 
The distribution of stem and progenitor cells among adherent and non-adherent 
compartments in stromal co-cultures. The extended LTCs were maintained with half-
medium changes each week and removal of half of the non-adherent cells. We observed 
that with some stromal clones only few cells adhered and realized therefore that the 
weekly depletion of half of all non-adherent cells would lead to a different depletion 
of HSCs and progenitors on different stromal cells. Therefore, we determined the 
percentage of CFU-GM in both adherent and non-adherent fractions of several stromal 
co-cultures of CD34+ UCB cells in the presence of Tpo or a combination of Flt3-L 
and Tpo. Remarkably, the different stromal clones showed different non-adherent 
proportions ofCFU-GM at week 7/8 of the cultures for Tpo (range 7-95%) and Flt3-L + 
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Table 1. Functional characteristics of stromal clones in extended long~term co-cultures with CD34+ UCB cells. 
Stromal Total stem and progenitor cell subsets 
co-cultures (%of input) 
CFU-GM CAFCw""'' 
Tpo Flt3-L + Tpo Tpo Flt3-L + Tpo 
7/8 12 7/8 12 7/8 12 7/8 12 
FBMD-1 750 275 648 542 66 11 28 44 
AM06-1C4 7 Nd 77 Nd 0.04 Nd 0.04 Nd 
AM06-2C4 35 0 87 0 0.04 Nd 0.04 Nd 
AM20-1A4 395 Nd 245 Nd 6 Nd 0.04 Nd 
AM20-1B4 4 0 12 0 0.04 Nd O.D4 Nd 
AM30-2A4 290 80 82 53 0.04 Nd 3.4 0.7 
A.lV!30-3A3 158 175 96 106 23 1.7 4 0.5 
AM30-1C6 443 312 415 118 2 Nd 3.4 Nd 
AM30-3F4 292 133 383 204 40 3.1 4 5.2 
AlV!30-3F5 270 Nd 158 347 I Nd 2.3 2 
UG07-1C6 75 Nd 347 Nd 0.04 Nd 0.04 Nd 
UGI5-IB7 33 0 4 0 0 0 0.06 0 
UG26-lB4 258 133 500 238 0.04 0 0 
UG26-IB6 327 360 732 802 0.04 0.5 64 18 
UG26-2D3 31 2 Nd I 2 Nd 7 0 
UG26-3D4 254 167 Nd 519 74 13 151 23 
EL08-ID2 2538 12544 3163 3150 66 146 47 296 
EL23-1C2 168 4 145 Nd 2 0 0.04 0 
GI09-2E6 260 375 310 207 3 Nd 5 Nd 
GI29-2B4 506 336 650 620 94 878 112 3 
Data represent one experiment with duplicate cultures. Values are given as percentage of input numbers 
generated in total (adherent+ non-adherent) flask cultures at 7/8 or 12 weeks of co-cultures. The extended LTCs 
were maintained by weekly half medium change with removal of half of the non-adherent cells in the presence 
of cytokines. The cultured cells were assayed after pooling the corresponding cultures prior to CFC and CAFC 
assays. The CFU-GM and CAFCweek 6 numbers present in uncultured material were 1.8 ± 1.0 xl04 and 2.7 ± 
1.6 xl03 per 105 CD34+ UCB cells. Co-cultures with seven clones that maintained in vivo repopulating ability 
of murine HSC are highlighted (bold face). Abbreviations: AM, aorta-mesenchyme; UG, urogenital ridge; GI, 
gastrointestinal tract; EL, embryonic liver; N d, not detennined. 
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Table 2. The number of progenitors present in the non-adherent compartment of extended long-tenn stromal 
co-cultures in the presence of cytokines. 
Stromal Non-adherent 
co-cui tures CFU-GM proportion 
(%of total) 
Tpo Flt3-L +Tpo 
FBMD-1 50 41 
AM06-IC4 7 26 
AM06-2C4 24 19 
AM20-!A4 27 47 
AM20-IB4 9 71 
AM30-2A4 36 63 
AM30-3A3 44 93 
AM30-!C6 19 40 
AM30-3F4 66 39 
AM30-3F5 31 100 
UG07-IC6 24 ?' _,
UG15-IB7 95 20 
UG26-IB4 51 34 
UG26-IB6 32 32 
UG26-2D3 82 Nd 
UG26-3D4 40 Nd 
EL08-!D2 64 63 
EL23-IC2 47 63 
GI09-2E6 31 59 
Gl29-2B4 55 36 
Data represent one experiment with duplicate cultures. Values are given as percentage of total (adherent + 
non-adherent) numbers generated at 7/8 weeks of co-culture. The extended LTCs were maintained by weekly 
half medium change and thus removal of half of the non-adherent cells, in the presence ofFlt3-L +/- Tpo. The 
cultured cells were assayed after pooling the corresponding cultures prior to CFC assay. The adherent and non-
adherent fractions of the corresponding stromal co-cultures were analyzed separately. Abbreviations: AM, aorta-
mesenchyme~ UG. urogenital ridge; GL gastrointestinal tract EL. embryonic liver; Nd, not determined. 
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Table 3. Variable proportions of human UCB progenitor and stem cells are found in the non-adherent 
compartment of extended long-term stromal co-cultures. 
Stromal Non-adherent stem and progenitor cell subsets 
co-cultures (%of total) 
CFU-GM CAFCwcck6 
2 4 6 2 4 6 
FBMD-1 62±22 78± 14 84±9 78 ± 15 81 ± 14 74±6 
UG26-IB6 55± 10 90±4 88±6 69 ± 16 70±26 94±20 
EL08-ID2 50±2 76±2 73 ± 10 53 ±2 68 ±II 82±8 
GI29-2B4 56± 0.2 74± 0.4 72 ± 17 52±5 66±22 59± 13 
Data represent the mean of t\vo independent experiments (± 1 SD) with duplicate cultures. Values are given as 
percentage of total (adherent+ non-adherent) numbers generated at weeks 2, 4 or 6 in whole flask co-cultures. The 
extended LTCs were contained supplemental with Flt3-L + Tpo, and maintained by weekly half medium change 
with removal of half of the non-adherent cells. The cultured cells were assayed after pooling the corresponding 
cultures prior to CFC and CAFC assays. The adherent and non-adherent fractions of the corresponding stromal 
co-cultures were analyzed separately. Abbreviations: UG, urogenital ridge; GI, gastrointestinal tract; EL, 
embryonic liver. 
Table 4. The expansion of CFU-GM and CAFCwcek6 subsets after extended long-term stromal co-cultures 
without weekly depletion. 
Stromal Total stem and progenitor cell subsets 
co-cultures (fold the input) 
CFU-GM CAFCwcck6 
4 8 12 4 8 12 
FBMD-1 211 200 Nd 22 26 101 
UG26-!B6 49 122 Nd 29 ?' _, 825 
EL08-ID2 59 367 Nd 16 40 340 
GI29-2B4 144 244 Nd 9 34 163 
Data represent one experiment with duplicate to quadruple cultures. Values are given as fold of input numbers 
generated in total (adherent+ non-adherent) flask cultures at 4, 8 or 12 weeks of co-cultures. The extended LTCs 
were maintained in the presence ofFlt3-L + Tpo and splitted when necessary without weekly depletion of half of 
the non-adherent cells. The cultured cells were assayed after pooling the corresponding cultures prior to CFC and 
CAFC assays. The CFU-GM and CAFCweek 6 numbers present in uncultured material were 2.2 ± 0.6 x10
4 and 2.9 
± 1.5 x103 per 105 CD34+ UCB cells. Abbreviations: BM, bone marrow~ AM, aorta-mesenchyme; UG, urogenital 
ridge~ GI. gastrointestinal tract: EL, embryonic liver~ Nd, not detennined. 
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Tpo (range 8-100%) groups (table 2). The median non-adherent CFU-GM fraction was 
66% (range 37-91 %) and 60% (range 0-86%) at week 12 for the same groups (data not 
presented). We subsequently determined the stem cell and progenitor fractions in the 
adherent and non-adherent compartments with the best supportive stromal clones during 
the first six weeks of co-cultures in the presence of Flt3-L and Tpo. The percentage 
non-adherent CFU-GM fraction in these co-cultures ranged from 40-90% (table 3). 
All together, the majority (> 80%) of the stromal clones contained most (30-90%) of 
the human progenitors in the non-adherent fraction during the two-twelve weeks of 
culture. Surprisingly, also high CAFCw"k' numbers were contained in the non-adherent 
compartment of stromal co-cultures (table 3). This observation is at variance with those 
of other investigators, who found that most primitive progenitors are located in the 
adherent compartment of primary BM stromal co-cultures [26-30]. Our data indicate 
that the weekly half-medium change in our culture system may have strongly affected 
the CFC and CAFC numbers in the total cultures leading to an underestimation of the 
HSC and progenitor expansion. 
In order to assess the full potential of stromal co-cultures to expand human HSCs 
and progenitors, we measured the expansion factor of HSCs and progenitors under 
conditions where no weekly depletion of non-adherent cells was applied. For this 
purpose we performed extended LTCs of CD34+ UCB cells on the three best supporting 
stromal clones and the reference line FBMD-1 in the presence of the cytokine 
combination Flt3-L + Tpo, because the addition of these cytokines resulted in superior 
maintenance of CAFCwooko in our previous FBMD-1 co-culture studies [16]. These 
cultures were maintained by splitting the flask cultures at weeks 4 and 8 and seeding the 
harvested cells on newly established corresponding stromal layers. Indeed, under these 
conditions a dramatic expansion of both CFU-GM and CAFCw"k' were observed (table 
4). The AGM region derived stromal clone UG26-l B6 was superior in the expansion 
of CAFCweok6 as compared to other clones tested and contained 825-fold more CAFC 
per culture as had been inoculated at the start of the experiment. However, the superior 
support of this stromal clone became only apparent after more than eight weeks of in 
vitro propagation. During the whole culture time cobblestone areas and single phase 
dark cells were observed in high frequencies in the stromal layers. 
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Discussion 
During murine development HSC activity has been found in the AGM region, vitelline 
and umbilical arteries, yolk-sac and liver, suggesting that these sites provide a supportive 
microenvironment for maintenance and probably numerical expansion of these HSCs. 
However, the precise role of the microenvironment in these midgestational sites in 
maintenance and growth of human HSCs is largely unexplored. In the study presented 
here we have identified four embryonic stromal clones, two UG-, one GI- and one EL-
derived, that support a dramatic expansion of CFU-GM and CAFCw,,,6 during a twelve 
week co-culture with human CD34+ UCB cells in the presence of at least Tpo. This 
expansion was higher than that obtainable with the FBMD-1 stromal line known for its 
capability to maintain or expand HSC activity. Without addition of cytokines only one 
EL-derived cell clone maintained the CFU-GM generation for up to twelve weeks, while 
in the presence of at least Tpo to the stromal co-cultures a continuous HSC and progenitor 
production was supported by twelve out of nineteen stromal clones. The limited number 
of stromal clones analyzed does not allow identification of the embryonic region that 
best supports the maintenance and expansion of human HSC subsets. 
Five out of seven stromal clones that supported murine in vivo repopulating HSCs 
also supported the generation of human newborn HSCs and progenitors in vitro. This 
strongly suggests that the factors responsible for in vivo expansion of murine HSCs 
in E II AGM, GI and EL subregions also play an important role in the maintenance of 
newborn human HSCs in vitro and can be used to amplify the CFU-GM and CAFCw"'' 
from CD34+ UCB cells. In contrast, two stromal clones, UG15-1B7 and UG26-2D3, 
supported murine but not human progenitors in long-term co-cultures. It might therefore 
be speculated that one or more UG stromal factors involved in maintenance or expansion 
of human CAFCw"'' in extended LTC-CFC do(es) not have cross-species restrictions, 
or is( are) produced in sub-effective concentrations. Such factors could be derived from 
the murine stromal cells, but they could also be elaborated by the human progenitors and 
function to communicate with the stromal cells. In this context, it is of relevance to note 
that cytokine addition improved LTC-IC maintenance in part through interaction with 
progenitors and/or in part through interaction with stromal cells [31, 32]. Chemokines, 
such as the AGM-expressed WECHE, have been reported to inhibit the growth of 
progenitors [33, 34]. These data suggest that the ability of different AGM-derived 
stromal clones to support human HSCs and progenitors may be explained in part by 
proportionate differences in expression of stimulatory and inhibitory factors for HSC 
and progenitor expansion. 
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Although most of the embryonic clones used here were derived from different 
embryonic regions, we observed large variability in support of human HSCs and 
progenitors even between the clones derived from the same region. Such variability is 
most likely representative of the complex interplay between stroma and hematopoietic 
cells, regulated by adhesion molecules, extra-cellular matrix molecules, membrane-bound 
cytokines and cytokine receptors. Chemotactic factors such as SDF-1 a may additionally 
help to guide and maintain HSCs in their niches [35-37]. Previously, we showed that the 
presence ofTpo in long-term stromal co-cultures prolonged the hematopoietic activity and 
stimulated the generation of human progenitors for up to twentyfive weeks [38]. Recently, 
we demonstrated the synergistic role of stroma-cytokine combinations in expansion of 
human primitive progenitors [16]. In the present study, the addition of Tpo to different 
stromal co-cultures often dramatically prolonged the hematopoietic activity, indicating 
the importance of this cytokine in long-term stromal survival of human HSCs. These data 
support and extend the requirement ofTpo to maintain HSCs in stromal co-cultures [39]. 
We show that a significant proportion of human CAFC and CFU-GM in co-cultures 
with a majority of murine stromal clones is found in the non-adherent compartment. We 
have also shown that both the adherent and non-adherent HSCs and progenitors can be 
gradually lost during extended cultures due to medium changes and that consequently 
the support of stromal clones for maintenance of HSCs and progenitors can be 
dramatically underestimated. In general, different methods are applied for maintenance 
of long-term stromal co-cultures. These include (a) half-medium changes each week and 
removal of half of the non-adherent cells as is the case in a part of our experiments, (b) 
medium changes without discarding cells, or (c) maintenance by splitting and refeeding 
the cultures with seeding the total number of harvested adherent and non-adherent cells 
on newly established stromal layers without discarding cells. All these methods will 
affect the number ofHSCs and progenitors obtained after extended LTCs. It is generally 
assumed that in primary long-term co-cultures the majority of the most primitive stem 
cells adheres to the stromal layer. For example, Mauch et al. showed that about one 
third of murine spleen colony forming cells (CFU-S) was contained in the non-adherent 
compartment of stromal co-cultures, however, the adherent CFU-S had greater 'self-
renewal' capacity than did non-adherent CFU-S [ 40]. Whether our stromal cell lines 
differentially affect the extent of self-renewal in our extended LTC is presently under 
investigation. Our findings that a large proportion of HSCs and progenitors was present 
in the non-adherent fraction of extended LTCs demonstrate that the ability of stromal 
cell lines to sustain HSC and progenitor production cannot be evaluated on the basis of 
the adherent or non-adherent fraction alone. 
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In tbe present study, we describe a set of embryo-derived stromal cell lines capable of 
sustaining human hematopoiesis in extended cultures. These stromal cells provide us with 
tools to investigate factors required for in vitro maintenance of human hematopoiesis as 
well may assist in establishing of culture systems that may mediate numerical expansion 
ofHSCs in vitro. 
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Abstract 
Studies of hematopoietic cell interactions with their microenvironment have resulted 
in establishment of many stromal cell lines from adult bone marrow (BM), fetal liver, 
aorta-gonad-mesonephros (AGM) region and yolk-sac. In the studies presented here we 
examine chemoattractive activities of stromal cell lines derived from several of these 
tissues using human hematopoietic cells as targets in a transwell migration assay. In 
addition, we examine the effect of exogenous cytokine addition on the chemotactic 
activity elaborated by these stromal cells, as well as on the proportion of adherent or 
non-adherent human umbilical cord blood (UCB)-derived colony forming cells (CFCs) 
in stromal co-cultures. Our results demonstrate that varying chemotactic activities are 
present in media conditioned by different stromal cell lines (SCM). The presence of 
Flt3-L and/or Tpo during the conditioning phase modulated this activity in a stromal cell 
specific way. Flt3-L or Tpo increased the chemotactic activity of marrow-derived MS-
5 and FBMD-1 stromal cells, whilst they inhibited the release of chemotactic activity 
by AGM-derived stromal cells. Furthermore, the cytokine combination increased the 
chemotactic activity of embryonic dorsal aorta!mesenchyme(AM)-derived stromal cells. 
A strong decrease in the migration of HL60 cells towards SCM was observed in the 
presence of a CXCR4 antagonist, indicating that CXCR4/SDF-l interaction is involved 
in the migration of HL-60 and CD34+ UCB cells towards SCM produced by various 
stromal cells. Since non-adherent CFU-GM in stromal co-cultures could be modulated 
by addition of cytokines, these results suggest that chemotactic activities are regulated 
through the interactions of cytokines with stromal cells. 
Introduction 
The microenvironment of hematopoietic tissues regulates embryonic and adult 
hematopoiesis in vitro and in vivo via direct cell-cell contact, membrane-bound 
presentation of cytokines and extracellular matrix components. The use of Dexter-type 
long-term cultures closely mimicking the in vivo hematopoietic microenvironment 
allowed in vitro maintenance of progenitors for extended periods and analysis of stroma-
dependent hematopoiesis [1, 2]. In these stromal co-cultures the primitive progenitors 
present in the inoculum are assumed to adhere to and migrate into the stromal layer, 
i.e. the adherent compartment, where they may quiescently survive or proliferate 
and release colony-forming cells (CFC) in the supernatant, i.e. the non-adherent 
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compartment. Although the non-adherent CFC are routinely assayed as an indicator of 
the hematopoietic activity in stromal co-cultures, there are indications that the majority 
of primitive progenitors are located in the adherent compartment [l-5]. Thus, although 
spleen colony forming cells (CFU-S) and CFC have been described to localize in both 
the adherent and non-adherent compartments [6-8], the majority of primitive progenitors 
can be recovered from the stromal layers [9, 10]. Although there is a close association 
between progenitors and stromal cells, their direct interaction appears not to be required 
for the maintenance of long-term in vitro hematopoiesis [ll]. 
To examine the interactions of hematopoietic cells with their microenvironments, 
many stromal cell lines and clones from adult, fetal and embryonic hematopoietic sites 
have been established and demonstrated to maintain in vitro and in vivo repopulating 
hematopoietic cells [ 12-19]. On the other hand, stromal cells have been shown to 
increase expansion oflong-term culture-initiating cells (LTC-ICs) [20] and lineage(Lin)· 
CD34+ [21] cells and extend maintenance of graft quality [22]. Our preliminary data 
indicate that the majority of primitive human progenitors (CAFCw"k6) localizes in the 
non-adherent compartment of co-cultures with stromal cell lines from adult murine BM 
and embryonic AGM region-, liver- and gut mesentery-derived stromal cells [23]. We 
speculated as to whether stromal elaboration of chemoattractant activities contributes 
to the establishment of a distribution of (primitive) progenitors over adherent and non-
adherent fractions in co-cultures. One potential chemoattractant for progenitors is the 
stromal cell-derived factor-! (SDF-1, CXCL12), a ligand for the G-protein coupled 
CXCR4 receptor, produced by BM stromal cells and osteoblasts. This chemokine has 
been shown to strongly attract CD34+ and the more primitive CD34+ CD38· hematopoietic 
cells. It activates j3l-integrins, which induce gelatinase B (MMP-9) expression on 
hematopoietic progenitors, probably allowing these cells to migrate through endothelial 
cell layers [24-30]. 
We also wished to know whether changing environmental factors modulates the 
chemoattractive activity of stromal cells. Thus, we evaluated whether the early acting 
cytokines Flt3L and Tpo, which enhance maintenance of (primitive) progenitors in 
extended long-term cultures, would modulate the chemoattractive activity of stromal 
cells. To this purpose, we have prepared stromal cell-conditioned medium (SCM) in the 
absence or presence of Flt3-L and/or Tpo, and tested these for their ability to stimulate 
both chemotaxis and chemokinesis [31] of a human leukemic cell line (HL-60) and 
human CD34+ UCB cells. We here demonstrate that different stromal cells produce in 
their supernatants different levels of chemotactic activities and that Flt3-L and/or Tpo 
can modulate these activities by stromal cells. Our results suggest that these chemotactic 
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activities are involved in the localization of (primitive) progenitors in the adherent 
compartment of stromal co-cultures. 
Material and methods 
Human umbilical cord blood cells. Human UCB samples were collected from umbilical 
cord vein after full-term delivery by the nursing staff of the Department of Obstetrics 
and Gynecology at the Sint Franciscus Gasthuis (Rotterdam, The Netherlands). UCB 
was collected in sterile flasks containing I 0 ml citrate-glucose as anticoagulant, stored 
at room temperature and processed within 24 hours of collection. Low-density cells 
were isolated using Ficoll Hypaque density centrifugation (1.077g/cm2, Lymphoprep, 
Nycomed Pharma, Oslo, Norway). After centrifugation at 600 g for 15 minutes, the 
mononuclear cells (MNCs) at the interface were collected, washed twice with Hanks 
Balanced Salt Solution (HBSS, Gibco, Breda, The Netherlands) and resuspended in 
Iscove's modified Dulbecco's medium (IMDM, Gibco, Breda, The Netherlands). The 
MNCs were stored in 10% FCS, 20% DMSO in IMDM in liquid nitrogen until use. 
Isolation of CD34+ cells. In all experiments human UCB were positively selected 
for the expression of CD34 using either Variomacs or Automacs Immunomagnetic 
Separation System (Miltenyi Biotech, Bergisch Gladbach, Germany) according to the 
manufacturers instructions. After thawing and before the CD34+ hematopoietic cells 
were isolated we pooled 2 to 21 different UCB samples. The purity of the CD34 selected 
cells from UCB, as determined by FACS after staining witb a CD34 antibody, was 
>90%. The progenitor and stem cell numbers in the input and output suspensions were 
determined by CFC and CAFC assays. The absolute number of progenitors present in 
uncultured material was 14,194 ± 6,504 and 2,942 ± 1,047 per 105 CD34+ cells for CFU-
GM and CAFCw"''' respectively. 
Hematopoietic growth factors. The following cytokines were used: recombinant 
human stem cell factor (SCF), recombinant human FT3-L and recombinant human Tpo, 
all kindly donated by C. Saris from Amgen (Thousand Oaks, CA, USA); recombinant 
human interleukin-6 (IL6), recombinant human granulocyte-macrophage colony 
stimulating factor (GM-CSF), recombinant human granulocyte colony stimulating 
factor (G-CSF) and recombinant murine stem cell factor (SCF), all gifts from Genetic 
Institute (Cambridge, MA, USA); recombinant human erythropoietin (Epo, Boehringer, 
Mannheim, Germany) and recombinant human IL3 (Gist Brocades, Delft, The 
Netherlands). 
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Stromal cells. The FBMD-1 cells were cultured as previously described [32]. MS-5 
was kindly provided by Dr. L. Coulombe!, Paris, France and cultured as FBMD-1 cells. 
The embryonic stromal clones were generated from subdissected AGM regions, livers 
and gastrointestinal tracts from EIO and Ell embryos of transgenic for LacZ inserted 
into the first intron of the Ly-6E.l locus or transgenic for temperature-sensitive mutant 
SV 40 large T antigen. Details about the establishment of these stromal clones have 
been described elsewhere [33]. The embryonic stromal clones were cultured in 25 or 
75 cm2 flasks (Costar, Cambridge, MA, USA) with 5 or 15 ml IMDM containing 10% 
fetal calf serum (FCS, Summit, Fort Collins, CO) and 10% horse serum (HS, Gibco), 
supplemented with penicillin (100 U/ml, Gibco), streptomycin (0.1 mg/ml, Gibco), ~­
mercapto-ethanol (I O·' M, Merck, Darmstadt, Germany). The stroma cells were grown 
to confluency at 33°C and 10% C02 and irradiated with 40 Gy prior to stromal cultures, 
or not as was the case with SCM. 
Stromal cocultures. Irradiated confluent layers of different stromal cells in 25 cm2 
flasks were overlaid with 1.5 x I 04 or 2 x I 04 CD34+ UCB cells. These cells were cultured 
in 5 ml IMDM-cocktail containing 20% FCS supplemented with penicillin (1 00 U/ml), 
streptomycin (0.1 mg/ml), ~-mercapto-ethanol (104 M), cholesterol (15 1-1M, Sigma), 
linolic acid (15 1-1M, Merck), iron-saturated human transferrin (0.62 g/1, Intergen, 
Uithoom, The Netherlands), nucleic acids (cytidine, adenosine, uridine, guanosine, 
2'-deoxycytidine, 2'-deoxyadenosine, thymidine, 2'-deoxyguanosine (all at 10·3 g/ml, 
Sigma)). Cultures were fed with the cytokine combination Flt3-L (50 ng/ml) and/or 
Tpo (1 0 ng/ml). Cultures of each group were set up in two-fold and maintained at 33° C 
and I 0% C02 for two weeks with half medium change and removal of half of the non-
adherent cells at week 1. At week 2 the CFC outputs of the adherent and non-adherent 
fractions from two co-cultures with FBMD-1, EL08-ID2, UG26-!B6, UG26-3D4, 
GI29-2B4, AM30-2A4, AM30-3A3, AM30-3F4, and AM30-1C6 were determined. In 
addition, we also determined the CAFCw"'' outputs from the co-cultures with FBMD-1, 
EL08-1D2, UG26-IB6, UG26-3D4, GI29-2B4. In a second series of experiments 1.5 x 
104 or 2 x 104 CD34+ UCB cells were cultured on FBMD-1, MS-5, GI29-2B4 and EL08-
1D2 in the absence or presence of Flt3-L (50 ng/ml) and evaluated for their adherent 
and non-adherent CFC fractions at week 2 of culture. In two additional experiments 1 
x 104 or 2 x 104 CD34+ UCB cells were deposited on UG-26-1B6 and evaluated in the 
presence ofFlt3-L (50 ng/ml), Tpo (10 ng/ml), SCF (100 ng/ml), IL6 (lOOng/ml) alone 
and in various combinations of these cytokines for the balance between CFCs in the 
adherent and non-adherent compartments of the cultures. These experiments were also 
performed with the cytokine combination G-SCF (20 ng/ml) and IL3 (10 ng/ml) and 
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without addition of any cytokines. The cultures were maintained for two weeks under 
the same conditions as above mentioned. To harvest the adherent layer, the non-adherent 
cells were first collected and the layer washed with phosphate-buffered saline (PBS, Life 
Technologies, Breda, The Netherlands) and subsequently incubated with trypsin-EDTA 
(Life Technologies, Breda, The Netherlands) at 37°C for 5-10 minutes. The digestion 
was stopped by adding I ml FCS. 
Stroma-conditioned medium. Confluent layers of different stromal cells in 75 cm2 
flasks were washed twice with PBS and incubated for 7 days with 15 ml IMDM and 
0.25% BSA supplemented with penicillin (I 00 U/ml), streptomycin (0.1 mg/ml) and 
~-mercapto-ethanol (104 M): IMDM/BSA. The conditioning was also performed in the 
presence of either Flt3-L (50 ng/ml) and Tpo (10 ng/ml) alone or a combination of both 
cytokines. The conditioned media were harvested, centrifuged at 315 g for 5 minutes to 
get rid of non-adherent cells and used subsequently in migration assays. 
In vitro migration assays. Migration of cells were performed using two chamber 
transwells (6.5 mm diameter, 24-well clusters, Costar, Cambridge, MA) with 5 [J.m pore 
size. The pore filter were pre-coated overnight with 20 [l.g/ml bovine fibronectin (Sigma 
F 1141). The HL-60 leukemic cell line (CCL-240, American Type Culture Collection, 
Manassas, USA) was cultured in IMDM with 20% FCS. For migration assays, either 
105 to 3xl05 HL-60 or 105 CD34+ UCB cells cells were washed twice with PBS and 
resuspended in either 100 [.tl IMDM/BSA or SCM and placed in the upper chamber of 
the transwell. In the lower chamber, 600 [l.i of IMDM/BSA with or without the ligands 
SDF-1 (R&D Systems Europe, Oxon, UK), Flt3-L (50 ng/ml) and Tpo (10 ng/ml) alone 
or in combination was placed. In additional experiments 600 [J.l of cytokine-absent or 
cytokine-induced SCM was placed in the lower chamber. Finally, in one experiment 
the effect of CXCR4 antagonist (Becton & Dickinson, Alphen aan den Rijn, The 
Netherlands) on migration was evaluated. Herefore, HL-60 cells were incubated with 
or without 10 [l.g/ml for 30 minutes in culture medium at room temperature prior to 
migration assay. After 4 hours of incubation at 37° C 10% C02 the upper chamber 
was removed and the number of migrated cells was assessed using a CASY® 1/TTC 
cellcounter (Schiirfe System GmbH, Reutlingen, Germany) for HL-60 cells and Symex 
microcellcounter (Charles Goffin, !Jsselstein, the Netherlands) for CD34+ UCB cells. 
Percentage of migration was determined by calculating percentage of input cells 
migrated into the lower chamber. 
Clonogenic assay. Granulocyte-macrophage colony forming unit (CFU-GM) and 
burst forming unit-erythroid (BFU-E) progenitor cells were assayed using a semisolid 
culture medium (1.2% methylcellulose), containing IMDM supplemented with 30% 
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FCS, f:l-mercapto-ethanol (5 x 10-s M), penicillin (100 U/ml), streptomycin (0.1 mg/ml), 
hu-Epo (I U/ml), hu-IL3 (20 ng/ml), hu-GM-CSF (5 ng/ml), hu-G-CSF (50 ng/ml) and 
mu-SCF (100 ng/ml). Duplicate cultures were plated in 35 mm tissue culture dishes 
(Falcon) and incubated at 3rc and 10% C02 in a humidified atmosphere for 14 days. 
Colonies containing 50 cells or more were scored at day 14 using an inverted light 
microscope. 
Cobblestone area forming cell assay. Confluent stromal layers of FBMD-1 cells in 
fiat-bottom 96-well plates (Falcon) were overlaid with UCB cells in a limiting dilution 
set up as described [34]. Briefly, twelve successive two-fold dilutions were used for each 
sample with 15 wells per dilution. The percentage of wells with at least one phase-dark 
hematopoietic clone (cobblestone area) of at least five cells beneath the stromal layer 
was determined at week 6 (CAFCwcok6). At initiation of the cultures 250 CD34+ UCB 
cells per well were plated in the first dilution, while after cultures 857 CD34• input 
equivalent cells per well were used in the first dilution. The CAFC frequencies were 
calculated using Poisson statistics. 
Statistical analysis. The values are reported as mean ± I SD. The correlation 
coefficients are measured using Microsoft Excel 97 program_ 
Results 
High proportion of (primitive) progenitors is found in the non-adherent compartment 
of stromal cocultures. To determine the progenitor subsets in the two compartments of 
different stromal co-cultures, CD34+ selected UCB cells were seeded on confluent layers 
of irradiated ( 40 Gy) stromal cells and maintained for two weeks. Interestingly, a high 
proportion of CAFCw"'' and CFU-GM were observed in the non-adherent compartment 
of stromal co-cultures (figure Ia). These proportions remained high and even increased 
when cultured for extended periods of twelve weeks [23]. Furthermore, the percentage 
of non-adherent CFU-GM generally reflected that of the non-adherent CAFCw"'' in 
these cultures (figure I b), suggesting that common factors determined their distribution 
and that measurement of CFU-GM would give sufficient information for both progenitor 
subsets. 
Effect of cytokines on the proportion of progenitor subsets in adherent and non-
adherent compartments of stromal cocultures. In order to elucidate whether cytokines 
could modulate the distribution of primitive progenitors over adherent and non-adherent 
compartments of stromal co-cultures, CD34+ UCB cells were cultured in the presence 
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Figure 1. The proportion of non-adherent CFU-GM and CAFCw~>< in cocultures of CD34. UCB cells and 
various stromal cells . Data represent the mean of two experiments with duplicate cultures. The cultures were 
maintained by half medium change at week 1 with removal of half of the non-adherent cells in the presence of 
Flt3-L + Tpo. In each experiment the cultured cells were assayed after pooling the corresponding cultures prior to 
CFC and CAFC assays. Bars represent the non-adherent CFU-GM fraction of several stromal cell lines at week 
2 of culture (a). Also the non-adherent CAFCweck6 fraction with respective CFU-GM fractions are plotted for five 
representative stromal co-cultures at week 2 (b). 
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of either single cytokines or combinations thereof for two weeks on UG26-1B6 stromal 
cells. The CFU -GM of the non-adherent compartment as percent of total is shown in 
table 1. Cytokine addition led to an increased proportion of non-adherent CFU-GM in 
the groups that contained exogenous Tpo, SCF, Flt3-L + Tpo + SCF, Flt3-L + Tpo + 
IL6, SCF + IL6 or IL3 + G-CSF, while the other cytokine groups did not significantly 
differ from the control cultures. This suggested that exogenous cytokine(s) can affect 
the distribution of CFU-GM over adherent and non-adherent compartments of stromal 
co-cultures. 
Chemotactic activity of medium conditioned by different stromal cells. To determine 
whether the presence of primitive progenitors in the non-adherent compartment was 
due to chemotactic factors released by stromal cells, we measured the in vitro migratory 
capacity of HL-60 cells towards media conditioned by different stromal cells. We first 
compared the spontaneous and ligand induced migration of HL-60 cells in a transwell 
system with fibronectin-coated filters. HL-60 cells, like CD34+ UCB cells, express 
CXCR4 receptor and migrate towards SDF-1 [31, 35]. Hardly any spontaneous migration 
was observed over these filters (figure 2), while increasing percentages of HL-60 cells 
migrated towards increasingly higher SDF-1 concentrations. Some cytokines including 
Tpo have been reported to act as chemoattractant [36], while other cytokines including 
Flt3-L are associated with mobilization ofCD34+ cells [37, 38]. Using the same cytokine 
concentrations as had been used under stromal co-culture conditions, the presence of 
the cytokines Flt3-L, Tpo or both in the lower chamber showed no additional effect on 
chemotactic activity (figure 2b). However, SDF-1 in combination with various cocktails 
including Flt3-L or Tpo showed consistent effects on chemotatic activity. 
We next investigated the migration-inducing activity of SCM in the presence or 
absence of cytokines. In the first set of experiments we evaluated the migration of HL-
60 cells in a positive chemoattractant gradient (directed movement, i.e. chemotaxis). 
The MS-5 stromal co-culture was used as reference because it produces high levels of 
SDF-1 [39]. The supernatant from the MS-5 cells attracted 10% of the HL-60 cells, 
while the FBMD-1 CM attracted 6.5%. The supernatants from the embryonic stromal 
cells showed similar chemoattractive activity (15-42%), except for three AM30 clones 
(-1C6, -2A4, and -3F4), which showed much higher chemoattractive activity for HL-60 
cells (figure 3a). 
We were interested to see whether the presence of Flt3-L and Tpo would affect the 
chemotactic activity in the medium of our stromal co-cultures. As shown in figure 3a, 
Flt3-L increased the chemotactic activity of the EM-derived stromal cells MS-5 and 
FBMD-1, whereas Tpo had no effect. In contrast, Flt3-L decreased the chemotactic 
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Table 1. Effects of exogenously added cytokines on the proportion of non-adherent CFU-GM in co-culture 
supported by UG26-1B6 stromal cells. 
Stromal co-culture 
conditions 
No cytokines 
Flt3-L 
Tpo§ 
SCF 
IL6 
Flt3-L + Tpo 
Flt3-L + Tpo + SCF 
Flt3-L + Tpo + IL6 
Flt3-L + Tpo + SCF + IL6 
SCF+IL6 
IL3 +G-CSF 
Non-adherent proportion ofCFU-GM 
as of total CFU-GM content 
64±6 
77±27 
88± 8 
85±7 
79 ±21 
73±23 
87±3 
79 ± 1 
68±2 
86 ± 1 
85 ± 1 
CD34+ UCB cells were cultured with UG26-1B6 stromal cells and maintained in the presence of cytokines 
for two weeks. A half medium change at week I was perfonned by removal of half of the non-adherent cells. 
Data represent the mean(± 1 SD) oftvvo independent experiments with duplicate cultures. Abbreviations: UG, 
urogenital ridge.§, mean of four experiments. 
a. b. 
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Figure 2. The effect of SDF-1, Flt3-L and/or TPO on migration of HL-60 cells. Data represent the mean 
(± 1 SD) percentage of one representative experiment performed in duplicate. Migration of HL-60 cells was 
determined in respons to various concentration of SDF-1 (a). The effect of Flt3-L (50ng/ml) and/ or Tpo (10 
ng/ml) with or without SDF-1 (250 ng/ml) were also determined (b). IMDMIBSA without any supplements was 
included as control. Abbreviations: F, Flt3-L; T, Tpo; S, SDF-1. 
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Figure 3. The chemotactic activity in SCM of adult, fetal liver and embryonic stromal cells measured using 
HL-60 cells. Data represent the mean(± 1 SD) percentage of migrating HL-60 cells in one experiment performed 
in duplicate or quadruplicate. Migration ofHL-60 cells in response to cytokine-absent or cytokine-induced SCM 
was determined after 7 days medium conditioning on different stromal cells in the absence or presence ofFlt3-L 
and/or Tpo (a). Effect of exogenous added cytokines on migration in response to SCM prepared in the absence 
ofcytokines (b) and the chemokinetic activity of this latter SCM group (c) were also determined. The mean 
percentage of migration towards control was 0.7 ± 0.3 and towards SDF-1 21.2 ± 19.5 in case of chemotaxis 
and 2.3 ± 1.6 in case of chemokinesis, respectively. Abbreviations: FL, fetal liver; AM, aorta-mesenchyme; UG, 
urogenital ridge; GI, gastrointestinal tract; EL, embryonic liver.** mean of2 experiments performed in four- or 
six-replicates. 
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activity of the AM30-1C6, -2A4, EL08-1D2, and GI29-1B4 embryonic stromal cells 
(figure 3a), as well as all of the embryonic stromal clones tested (not shown). Since 
both Flt3 and Tpo as single cytokine additions decreased chemotactic activity of the 
embryonic stromal clones, we were surprised to find that the presence of both cytokines 
during medium-conditioning induced a dramatic stimulatory effect on migration ability 
of all four AM30 clones (figure 3a). In control experiments, we evaluated whether 
Flt3-L or Tpo would directly affect the HL-60 migratory activity. As is shown in figure 
3b, exogenous addition of either Flt3-L, Tpo or both to the lower chambers during the 
chemotaxis assay did not affect HL-60 migration. Thus, the presence of exogenous 
cytokines in the stromal co-cultures strongly affects the secretion of chemotactic activity 
by stromal cells. 
We also tested whether the various SCMs induced chemokinetic activity (random 
movement, i.e. chemokinesis). We observed variable chemokinesis of HL-60 cells 
between CM from different stromal cells (figure 3c). Except for AM30 clones, no 
significant effect in random migration of HL-60 cells was observed as compared to the 
reference stromal activity ofMS-5. 
Table 2. Effects of blocking CXCR4 receptor on migration ofHL-60 cells towards stroma-conditioned medium. 
Conditions in Migration(% of input) %of migration 
the lower well inhibition 
Without CXCR4 WithCXCR4 
antagonist antagonist 
Control 1 ± 0.3 0.9 ± 0.7 6 
SDF-1 64±3 17 ± 3 74 
MS-5 20 ± 1 3±2 85 
FBMD-1 !0 ± 0.7 2 ± 0.3 85 
AM30-3F4 50±2 9 ± 0.4 82 
AM30-2A4 41 ± 6 5 ± 0.08 87 
AM30-!C6 15 ± 2 3 ± 0.3 78 
AM30-3A3 !! ± 3 5±0.6 52 
UG26-!B6 5±1 3±0.8 53 
UG26-3D4 4±0.2 3 ± 0.1 42 
EL08-!D2 5 ±0.7 3 ±0.3 48 
Gl29-2B4 6±0.9 3 ± 0.02 51 
Migration of HL-60 cells in response to medium conditioned by stromal cells in the absence of cytokines was 
determined in the absence or presence of a CXCR4 antagonist (10 ).lglml) in the upper well. Percentage of 
migration represents the mean of one experiment performed in duplicate. Abbreviations: AM, aorta~mesenchyme; 
UG, urogenital ridge; GL gastrointestinal tract; EL, embryonic liver. 
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Table 3. The chemotactic activity in Flt3·L and Tpo-induced SCM of adult and embryonic stromal cells 
measured using UCB CD34• cells. 
Conditions in Migration 
the lower well (%of input) 
Control 0.4 ± 0.04 
SDF-1 34± 14 
MS-5 14±0 
FBMD-1 8±0 
AM30-3F4 74±3 
AM30-2A4 65±3 
AM30-IC6 35±7 
AM30-3A3 31 ± 2 
UG26-IB6 13 ±2 
UG26-3D4 12 ±I 
EL08-ID2 8±1 
GI29-2B4 8±1 
Migration of CD34 ... UCB cells in response to medium conditioned by stromal cells in the absence of cytokines 
was determined. Percentage of migration represents the mean of one experiment performed in duplicate. 
Abbreviations: AM, aorta-mesenchyme; UG, urogenital ridge; GI, gastrointestinal tract; EL. embryonic liver. 
The chemotactic activity released by stromal cells can be partly blocked by CXCR4 
antagonist. To examine whether the chemotactic activity of SCM could be due to 
the presence of SDF-1, we added a CXCR-4 antagonist to the upper chamber of the 
chemotaxis chambers. Addition ofthis antagonist inhibited the SDF-1 induced migration 
of HL-60 cells by >70% (table 2). Indeed, the SCM-induced migration was suppressed 
to a great extent for all SCM elaborated from the various stromal lines (42% to 87%), 
indicating that the chemotactic activity of the different SCMs was largely due to the 
presence ofSDF-1 in these SCMs. 
Human CDJ4+ UCB cell migration towards SCMs. To validate some of the above 
findings obtained with the HL-60 culture line we also performed experiments with 
primary human CD34+ UCB cells. Since the stromal co-cultures testing for CFU-GM 
were performed in the presence of the cytokines Flt3-L and Tpo, we used Flt3-L + 
Tpo induced SCM to assess the chemotactic activity on CD34+ UCB cells. These cells 
showed hardly any spontaneous migration, whereas chemoattractant activity towards 
SDF-1 resulted in migration of 34% ± 14 of input cells (table 3). SCM from various 
stromal cell lines demonstrated a significant chemoattractive activity for CD34+ UCB 
cells, particularly the AM30 clones that showed the highest percentage of activity (31% 
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to 70%). The chemotactic activity of the various SCMs for the HL-60 cells and CD34+ 
cells showed a high correlation coefficient (figure 4a), strongly suggesting that the use 
of HL-60 cells as target cells in migration assays is predictive for CD34+ UCB cell 
migration. 
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Figure 4. Correlation between the non-adherent CFU-GM content of stromal cocultures and the chemotactic 
activity on HL-60 and UCB CD34' cells. CFU-GM data represent the mean(± 1 SD) with duplicate cultures and 
are measured as percentage of total at week 2 of culture (see figure lb ). The chemotactic data represent the mean 
(± 1 SD) percentage of migrating cells towards SCM in one experiment performed in quadruplicate for HL-60 
cells (data are the same as in table 2, first column) and duplicate for CD34+ UCB cells (data are the same as in 
table 3). The stromal co-cultures and the conditioning of stroma were performed in the presence of the cytokines 
Flt3-L and Tpo. The chemotactic activity of SCMs measured as migration of HL-60 or CD34' UCB cells are 
plotted (a). Also the non-adherent CFU-GM or CAFCwe.:k6 (b) proportions with corresponding chemotactic 
activity measured as migration of CD34+ UCB cells are depicted. The correlation coefficients are given as the 
Rsquares. 
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When we compared the migration results obtained with HL-60 cells (table 2) or 
CD34+ UCB cells (table 3) with the non-adherent CFU-GM fractions (figure Ia), 
we observe some relationship between these parameters (figure 4b ), suggesting that 
chemotactic activity plays a modest role in the distribution of progenitors over adherent 
and non-adherent compartment of stromal co-cultures. To test this, we added Flt3-L 
to co-cultures of C34+ UCB cells and four representative stromal lines and assessed 
CFU-GM in the non-adherent compartment. As shown in figure 5, the presence of this 
cytokine diminished the non-adherent CFU-GM percentage in cultures with GI29-2B4 
and EL08-ID2 stromal cells and increased its percentage with MS-5 and FBMD-1 
(figure 5). Although these changes are similar to, but not as robust as, what we observed 
for chemoattractive activity (figure 3a), these data suggest that Flt3-L affects the 
chemotactic activity elaborated by stromal cells, which in turn affects the non-adherent 
progenitor fractions. 
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Figure 5. The non-adherent proportion of CFU-GM in the presence of Flt3-L. Data represent the mean of 
two experiments with duplicate cultures. The cultures were maintained by half medium change at week 1 with 
removal of half of the non-adherent cells in the presence of Flt3-L + Tpo. In each experiment the cultured 
cells were assayed after pooling the corresponding cultures prior to CFC and CAFC assays. Abbreviations: GI, 
gastrointestinal tract; EL. embryonic liver. 
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Discussion 
The interaction between hematopoietic stem cells and the microenvironment requires 
a close association of these entities. In order for the stem cells to home to the proper 
microenvironment, chemotactic factors are produced. The most potent of these factors 
is SDF-l. We here describe that embryonic stromal cells, particularly those derived 
from the dorsal AM, strongly elaborate chemotactic activities for HL-60 and UCB 
CD34+ cells. The presence of Flt3-L and/or Tpo during the stromal conditioning phase 
of medium modulated this chemotactic activity in a stromal cell specific way. Flt3-L or 
Tpo increased the chemotactic activity of MS-5 and FBMD-1 stromal cells, while these 
cytokines had an inhibitory effect on production of chemotactic activity by most other 
stromal cells. Surprisingly, the combination of Flt3-L and Tpo had the opposite effect, 
as it dramatically increased the chemotactic activity of AM30 clones. These effects were 
not due to residual Flt3-L and/or Tpo during the transwell migration assay, as addition of 
these cytokines to the medium in the migration assay did not affect HL-60 cell migration 
in the absence or presence of various SCM. 
In vitro culture systems with stromal cells from BM, yolk-sac, fetal liver or AGM 
region offer unique opportunities to investigate the interactions between progenitor 
subsets and stromal cells or factors. The mechanisms underlying these interactions have 
still not been clearly established. Most studies indicated that the majority of primitive 
progenitors, which appear to be multifactor-responsive for their survival, adhere 
directly to the stromal cells, presumably through mediation of various adhesion proteins 
[40, 41]. Murine and human stromal cells are capable of producing a large number 
of hematopoietic cytokines [42-47], some of which, like SCF and Tpo, have been 
shown to have chemoattractive capabilities in addition to their activity on progenitor 
growth. Other cytokines such as IL8 and MCPs function mainly as regulators of 
proliferation for progenitors [ 48-50], even though on mature blood cells they mainly act 
as chemoattractant and activating factors. In addition, various chemoattractant factors 
have been described to regulate (primitive) progenitor mobilization and homing. SDF-
1, which is released by BM stromal cells and osteoblasts [26, 28, 39], has been shown 
to be the major chemoattractant for progenitors. In our laboratory, somatostatin (ligand 
of somatostatin receptor-2) has also been identified as chemoattractant for normal and 
malignant hematopoietic progenitors [51, 52]. The role of other chemokines, like MIP-
313 and WECHE which are also expressed by marrow and embryonic stromal cells [53, 
54] in HSC and progenitor chemotaxis is less clear. Changing the growth requirements 
of stem cells is also likely to influence their homing behaviour. Indeed, it is known 
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that chemoattraction of progenitor and stem cells can be modulated by cytokines. For 
instance, CD34+ cells have been reported to show enhanced SDF-1 directed chemotaxis 
by either pre-treatment or co-incubation with IL3 or SCF [26, 31, 55]. Our data show 
that stromal cells from different origins produce different levels of chemoattractant 
activities. In particular the AM clones elaborate high levels of CXCR4-dependent 
chemoattractant activity. More interestingly, we found that Flt3-L inhibited the 
elaboration of chemoattractive activity by the majority of stromal cells. This effect was 
entirely due to an effect on the stromal cells, because the fresh addition ofthis cytokine 
in the lower chamber of the transwell cultures, in combination with SDF-1 (figure 2) 
or cytokine-absent SCM showed no significant additive effect on migration of HL-60 
cells (figure 3b ). The effect of Flt3-L may explain the results of recent clinical analysis 
of plasma Flt3-L levels in mobilization ofCD34+ cells, where high plasma levels of this 
cytokine were associated with poor mobilization outcome [37, 38]. 
The yolk-sac and intraembryonic area surrounding the dorsal aorta serve as the 
main hematopoietic tissues during early and mid-gestation. The intraembryonic AGM 
region autonomously generates the first adult HSCs at embryonic day 10.5 (E10.5), 
the number of which dramatically increases thereafter [56, 57]. At Ell the HSCs are 
generated only in the AM subregion, while the UGs contain HSC activity at E12 or 
after culture of Ell explants [58]. All these data suggest that AM cells may behave like 
a center for emergence of adult HSCs, and subsequently support their maintenance and 
expansion in their environment and surrounding tissues prior to their localization in the 
liver microenvironment. Our current results suggest that the localization of these adult 
stem cells at the ventral wall of the dorsal aorta may in part be due to the elaboration of 
chemotactic stimuli by the AM microenvironment, since the most highly chemotactic 
active stromal cells were derived from this particular region. However, it is still unclear 
as to whether these chemotactic factors act to attract or maintain stem cells following 
their emergence, or to attract cells from neighbouring regions. 
There is evidence that cytokines can modifY the chemotactic activity of SDF-1 on 
hematopoietic progenitors and cell lines. For example, preincubation of M07e and UT-
7/mpl cell lines and CD34+ UCB progenitors with Tpo led to a significant reduction in 
SDF-1 induced migration [59]. It has also been shown that the migration towards SDF-1 
was reduced for CD61 + cells and megakaryocytic progenitors when cultured in cytokine 
cocktails including IL6, ILl!, Flt3-L and/or IL3 in combination with Tpo + SCF as 
compared to Tpo + SCF alone [60]. In another study, progenitors from CD34+ UCB cells 
cultured in the presence of Tpo, Flt3-L and SCF had a chemotactic response equivalent 
to uncultured cells, while addition of IL3 reduced this response by 20-50% [61]. In 
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contrast to these migration-diminishing effects, other cytokines may in fact enhance the 
migratory capacity of cells. For example, a cooperative interaction between SCF and 
SDF-1 enhances chemotaxis ofCD34+ hematopoietic progenitors [31]. At present it is 
unclear how early-acting cytokines modulate SDF-1 responsiveness. One explanation 
might be that there are common downstream substrates where signaling pathways 
converge. For instance, it has been shown that the combined use of SDF-1 and SCF 
leads to a delayed activation of mitogen-activated protein kinase (MAPK) activation, 
suggesting that signaling pathways cooperate to enhance chemotaxis of progenitors 
[55]. In line with this, investigation of intracellular signaling pathways induced by SDF-
1 and Tpo revealed some overlapping patterns of protein phosphorylation/activation 
(MAPK, protein kinase B) and some that were distinct or even opposite for Tpo and 
for SDF-1 [62]. In addition, simultaneous activation of three signals through c-mpl, c-
kit and CXCR4 has been reported to induce in vitro proliferation and differentiation of 
megakaryocytic progenitors by signaling through protein kinases phosphatidyl-inositol 
3-kinase, protein kinase C and MAPK [63]. All these data show that cytokines can 
interact functionally in modulating cell proliferation and migration. Thus, it is likely that 
treatment of stromal cells with Flt3-L and Tpo, which are produced by both stromal cells 
and hematopoietic progenitors [45, 64] may affect adhesion molecule expression, local 
cytokine and/or chemokine production. In fact, our observations would support such a 
view. However, though we have evidence that both Tpo and Flt3-L are produced by the 
AM cells [33], it is unclear whether their respective receptors, c-mpl and Flk2/Flt3, are 
also expressed. We are currently investigating this issue. 
In conclusion, we have shown that marrow- and embryonic subregion-derived 
stromal cells elaborate factors, probably SDF-1, which chemoattract HL-60 and UCB 
CD34+ cells. More importantly, we show that treatment of stromal cells with early-
acting cytokines alters their ability to elaborate chemotactic factors. This interesting 
observation demonstrates that stromal cells not only make early-acting cytokines, but 
also respond to those factors, revealing another layer of interactions between stem cells 
and the microenvironment. 
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General discussion 
Rational for HSC expansion 
Adult HSC transplantation (SCT) has achieved significant therapeutic success over the 
last decades, providing a viable treatment option for many previously incurable diseases. 
However, several inherent limitations of the procedure have restricted its widespread 
use. These include lack of sufficient donors for all recipients, period of BM aplasia 
leading to severe and prolonged neutropenia and thrombocytopenia, and the potential for 
tumor contamination in autologous SCTs. Experimental studies suggest that umbilical 
cord transplantation might help eliminate the issue of donor availability and some post-
transplant complications. Despite its theoretical advantages over SCT from adult donors, 
the lower number ofHSCs in single UCB samples and the preliminary data showing the 
importance of cell dose for the outcome of UCB transplantations have been of major 
concern in adult patients. Indeed, as a consequence of limited HSC numbers, UCB 
transplants have a tendency for delayed time to platelet recovery as compared to adult 
ones. While the time required for myeloid recovery was similar in children receiving 
transplantation with UCB or unrelated BM, platelet reconstitution was significantly 
delayed, being 51 days for sibling and 75 for unrelated UCB transplants in comparison 
to 23 days for unrelated BM transplants [1-7]. These limitations of UCB raised a 
considerable interest in the development of ex vivo HSC and progenitor expansion 
strategies. In addition, the need for large-scale marrow harvesting could be reduced by 
ex vivo increase of sufficient number of HSCs and progenitors from a single marrow 
aspirate. Also small MPB grafts from heavily treated cancer patients might benefit from 
ex vivo expansion of these cells before clinical application. In another setting, expansion 
studies can contribute to the development of culture conditions that permit efficient gene 
transfer into primitive HSCs. 
Which hematopoietic cell population should preferentially be expanded? 
Depending on clinical applications, expansion of different hematopoietic cell subsets 
can be required. It is thus important to define culture conditions that are relevant to 
the particular cell type being expanded. The relevant properties of cells in each of the 
different hematopoietic compartments can be summarized as (a) primitive HSCs for 
long-term engraftment and gene replacement therapy; (b) progenitors for intermediate 
and short-term engraftment; and (c) mature cells such as dendritic cells, and different T-
and NK-cell subsets for immunotherapy. It is essential to define the aim ofhematopoietic 
cell expansion and to adapt the experimental conditions to obtain the required cell subset. 
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Defining such cell-based culture systems and elucidating the molecular events, which 
permit the ex vivo expansion of HSCs from various sources, is additionally important 
to pursue. The major aim of this study is to address the conditions in which LTR HSCs 
derived from UCB can be expanded ex vivo. 
The ex vivo expansion studies ofHSCs and progenitors have used either total CD34+ 
cells or CD34+ cell subsets. Liquid cultures established either under stroma-free or 
exogenous cytokine lacking stroma-supported conditions clearly demonstrated that 
primitive subsets of CD34+ cells possess greater expansion potential than their more 
mature counterparts. CD34 antigen has been used as a convenient positive selection 
marker to enrich HSCs and progenitors, which in turn were used in SCT and research. 
However, new findings have added to the growing evidence that some HSCs in the BM 
do not express CD34. The capacity of human CD34· HSCs to give rise to large numbers 
of CD34+ cells that can mediate reconstitution [8-12], and raises the possibility that 
we may inadvertently discard significant number of stem cells by CD34+ selection of 
human samples. Several studies indicate that CD34 expression reflects the activation! 
kinetic state of HSCs and that it is reversible (reviewed in [13-15]). Injection of 150 
mg/kg fluorouracil to mice showed that both CD34· and CD34+ populations of the BM 
may contain stem cells [8] and that CD34· stem cells can become CD34+ after ex vivo 
incubation [8], indicating that activated stem cells express CD34. Also the reversal of 
the phenotype from CD34+ to CD34· has been demonstrated in a in vivo model [16]. 
Thus the most appropriate cell population for clinical transplantation is an extremely 
important but controversial issue. Whether the CD34· cells should be included in clinical 
transplantation, or whether the CD34 expressing cells are enough, remains to be seen. 
Expansion of HSCs and progenitors with in vitro repopulating ability 
Previous attempts emphasized the role of early acting cytokines Flt3-L, Tpo, SCF and 
IL6 in regulation of HSC and progenitor growth and survival in vitro [17-23]. In line 
with this, considerable progress in ex vivo expansion of hematopoietic progenitors 
has been obtained when these early acting cytokines were used in combinations [24-
26]. These four cytokines have also been reported to support primitive HSC and 
progenitor proliferation with maintenance of LTR ability [17-19, 21, 23]. Only one 
group has reported dramatic expansion of LTC-ICs and SRCs during stroma-free ex 
vivo propagation of more than three months, however, other laboratories to date have 
not reproduced these observations. Using the long-term production ofCD34+CD38· and 
LTC-IC subsets as a stringent endpoint for HSC expansion, Piacibello and colleagues 
have uniquely achieved a dramatic expansion of primitive CD34+ UCB cells over periods 
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as long as thirty weeks under cytokine-supplemented stroma-free conditions [25, 26]. 
These authors additionally demonstrated that the SRCs were markedly expanded using 
Flt3-L, Tpo, SCF and IL6 under the same conditions after ten weeks of culture [27]. 
The supportive capacity of the hematopoietic microenvironment on the maintenance 
of HSCs and their ability to generate progenitors in in vitro cultures has also been 
explored [28-30]. Initially, stromal support was evaluated in the absence of exogenous 
cytokines, which failed to significantly expand the in vitro and in vivo LTR cells in 
co-cultures [31-34]. The inclusion of Tpo in such stromal co-cultures has dramatically 
increased the longevity ofhematopoietic activity and maintenance of repopulating ability 
ofHSCs [35, 36]. Additionally, stroma-supported cultures ofUCB and MPB HSCs have 
been reported to maintain and even moderately expand their numbers when at least Flt3-
L and Tpo were included [37-39]. Ex vivo expanded UCB cells have also been shown 
to maintain their ability to differentiate along myeloid and lymphoid progenitors after 
two to five weeks under stroma-contact or non-contact conditions in the presence of 
at least Flt3-L and Tpo [39, 40]. Lastly, we have shown that stromal support was also 
required for optimal maintenance and transplant quality of CD34+ selected MPB cells 
in short-term cultures [41, 42]. All these studies demonstrate only maintenance or a 
slight increase of HSCs after culture and suggest that at least both stromal cells and 
the exogenous cytokines Tpo and/or Flt3-L together might be required for expansion of 
HSCs and progenitors ex vivo. 
Because a short culture period is favorable in a clinical setting, we firstly tried to 
expand UCB HSCs and progenitors during two-week stroma-free and stroma-supported 
cultures. A more than 10-fold expansion of CAFCw"k' and of the potential of CD34+ 
UCB cells to multilineage engraft the BM of sublethally irradiated NOD/SCID mice 
was obtained in the presence of at least Flt3-L + Tpo. Under stroma-free conditions, the 
results following two-week cultures showed Flt3-L + Tpo + SCF + IL6 to represent an 
optimum cytokine combination for expansion of early and late progenitors. Addition 
of SCF = IL6 to Flt3-L + Tpo enhanced expansion of CFU-GM and CAFC subsets, 
indicating a synergistic effect. This is in contrast to the data ofPiacibello and colleagues, 
which show no difference in the extent of HSC and progenitor expansion with addition 
of SCF ± IL6 at the early stage of the culture period [25, 26]. The sources of cytokines, 
the purification procedures of cell populations or the presence of uncharacterized factors 
in the sera may reflect these differences. In these two-week cultures, the stromal support 
could be replaced by adding additional SCF ± IL6 to the Flt3-L + Tpo stimulated short-
term stroma-free cultures. In contrast to stroma-free cultures, addition of SCF = IL6 
to F!t3-L + Tpo in stroma-supported cultures did not substantially modify the extent 
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of CAFC and SRA. This observation suggests that the SCF and IL6 elaborated by the 
FBMD-1 stromal cells were sufficient to compensate for the exogenously added SCF 
and IL6. 
Using combinations of early acting cytokines Flt3-L, Tpo, SCF and IL6 we observed 
synergistic effects in support of early HSCs and progenitors for extended periods often 
weeks. As can be seen in detail in chapter 3 we were able to dramatically improve the 
expansion ofCAFC subsets in cultures exceeding a time period of two weeks and showed 
that stromal support with exogenous addition of at least Flt3-L + Tpo was required to 
do this. Stromal support expanded the CAFCw"'' subset maximally from !!-fold to 89-
fold, as compared to stroma-free conditions in the presence of the cytokine combination 
Flt3-L + Tpo + IL6. Also the CD34.CD38-CXCR4+ cells representing SRCs required 
both stromal support and cytokines to expand over a time period of five weeks. These 
data contrast with the previous data published by Piacibello and colleagues indicating 
no stromal requirement in expansion of LTC-ICs for more than six months and of SRCs 
for ten weeks. These authors used initially FCS in stroma-free LTCs for evaluation 
of optimal conditions, which resulted in massive and prolonged ex vivo expansion of 
(primitive) progenitors from CD34+ UCB cells. Subsequently, they switched to pooled 
human serum as a substitute for FCS and assessed whether the cytokine combination 
Flt3-L + Tpo + SCF + IL6, which gave the best expansion results ofLTC-ICs and CFCs, 
could maintain and amplify SRCs. This latter condition gave an increase of >70-fold 
the input SRCs after a culture period of nine to ten weeks. Therefore, the differences 
observed between these and our extended long-term data might be in part attributable 
to the culture conditions used with special reference to serum batches or the source of 
serum used. 
We then studied the effect of a new fusion protein ofiL6 and soluble IL6R, H-IL6, on 
the expansion ofUCB CD34• cells. The addition ofH-IL6 to Flt3-L + Tpo substantially 
increased CD34+ generation and enhanced the proliferation ofCFC and CAFCwook6 during 
six-week stroma-free cultures of CD34+ or AC133+ UCB cells. This fusion protein also 
acted synergistically with Flt3-L + SCF and Flt3-L + Tpo + SCF for the expansion of 
CD34+ cells and CAFCwook6 both under stroma-free and stroma-supported conditions. 
These data support and extend the studies of two groups [43, 44], who tested a complex 
of the soluble IL6R and IL6 (IL6/siL6R) in combination with SCF or Flt3-L in three-
week stroma-free cultures and semisolid clonal assays and demonstrated an increased 
proliferation of multipotential and committed progenitors from UCB- and EM-derived 
CD34+ cells. In addition, Zandstra et a! [ 45] reported a higher LTC-IC expansion in 
one-week serum-free cultures of CD34.CD38· UCB cells stimulated by Flt3-L and IL6/ 
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siL6R complex when compared to the combinations ofFlt3-L + Tpo or Flt3-L, SCF, IL6, 
IL3 + G-CSF. Under the same conditions, stimulation of CD34+ UCB cell subsets with 
IL6/siL6R instead ofiL6 resulted in a higher expansion of erythroid progenitors, mixed 
colonies (CFU-GEMM) and LTC-ICs [43, 46, 47]. In contrast, though the H-IL6 fusion 
protein enhanced the expansion of ACJ33+ hematopoietic progenitors with a variety 
of cytokine combinations, IL6 synergized more potently than the fusion protein with 
Flt3-L and Tpo for the expansion of CD34+, CD34+AC133+ cells as well as CAFCs in 
our culture system. This may in part be due to the use of AC133+ cells, which have been 
found to possess a lower expansion potential in our culture system than CD34+ cells. 
AC133 is expressed on a subfraction of CD34+ cells, containing committed progenitors 
and LTC-ICs as well as LTR cells. However, CD34+ cells lacking AC133 antigen have 
no LTR ability and are enriched for erythroid progenitors [48, 49], which have been 
shown to be IL6Ra· [46]. Therefore, it might be that AC133 selection results in an 
enrichment of IL6Ra+ cells which in turn gives an enhanced response to IL6. Stromal 
support greatly enhanced the progenitor expansion induced by Flt3-L + Tpo or Flt3-L + 
Tpo + H-IL6. However, the highest proliferation was again obtained in the presence of 
IL6, whereas addition of SCF in these stroma-supported cultures resulted in increased 
differentiation. 
Expansion of the ability of the cells to multilineage repopulate the EM ofNOD/SCID mice 
Several data support the contention, that in contrast to CFU-GM, SRC are difficult to 
expand, and are rapidly lost in stroma-free cultures for five to nine days [50-52]. It 
is at present unclear whether the loss of SRC following culture is due to loss of their 
proliferative ability, or to decreased ability to home to the murine BM. In the present 
study, the expansion of the ability of CD34+ UCB cells to multilineage engraft the BM 
of sublethally irradiated NOD/SCID mice following two-week stroma-free cultures was 
observed in the presence of various cytokine permutations including Flt3-L + Tpo and 
SCF + IL6. Remarkably, addition of SCF ± IL6 to the cytokine combination Flt3-L + 
Tpo showed no significant effect on the estimated expansion of the engraftment ability. 
In addition, Piacibello and coworkers showed that more than 70-fold SRC increase 
could be obtained after nine to ten weeks culture ofCD34+ UCB cells under stroma-free 
conditions in the presence of the cytokines Flt3-L, Tpo, SCF and !L6 [27]. However, it 
is not clear from these studies whether SRC were expanded after two weeks of culture. 
Another study showed that two-week expanded CD34+ UCB cells retain their ability 
to support long-term hematopoiesis in serum-free cultures containing Flt3-L + Tpo + 
SCF + G-CSF as shown by their in vivo engraftment of the NOD/SCID mice and ability 
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to undergo multilineage differentiation along all myeloid and B-, NK, and T-lymphoid 
pathways in vitro [40]. Increase of SRA after culturing CD34+ UCB cells may be very 
likely due to an increase of the total SRC number, however, it is also possible that 
quiescent SRC, or pre-SRC, are activated or recruited, respectively. Alternatively, it 
could be that cultured cells show an increased ability to home either to, or expand in the 
BM of NOD/SCID mice, or that there is a numerical or functional gain of facilitating 
cells that is possibly required for engraftment of the NOD/SCID BM by SRC. According 
to previously published data [53], the use of at least SCF "' IL6 in our culture system 
might have caused increased homing potential of the CD34+ UCB cells by upregulation 
of CXCR4 receptor on expanded cells, which in tum contributed to the increased 
SRA. Interestingly, our results (chapters 2 and 3) also indicated that the stromal 
microenvironment has a significant capacity to improve the SRA expansion in two-week 
cultures with at least Flt3-L + Tpo. These data contrast with several previous studies 
indicating that proliferation ofHSCs in the presence of stroma is associated with loss of 
most in vivo repopulating ability [31, 33]. It should, however, be realized that Flt3-L and 
Tpo were not exogenously added to the stroma-supported cultures in the latter studies. 
In agreement with our findings, stromal cells and a combination ofFlt3-L + Tpo and/or 
SCF resulted in 13- to 80-fold expansion oflate CAFCs and at least several fold-increase 
of SRA in two to four-week cultures [54, 55]. Also the type of stromal cells used in 
these cultures can contribute to variable results as it has been demonstrated that the type 
of stromal cells used in LTC-IC assay affected the frequency assessment of primitive 
progenitors [56]. Recently, Lewis eta!. demonstrated that AFT024 stroma non-contact 
cultures with addition ofFlt3-L + Tpo + SCF + IL7 or Flt3-L + Tpo can also maintain 
long-term engrafting cells, defined by their ability to engraft secondary or tertiary hosts 
[57]. However, while at week 2 the expansion of SRA was similar under our stroma-free 
and stroma-supported conditions, after five weeks of culture cells were hardly or not at 
all able to give detectable levels of human engraftment in the mice. Possibly, this low 
SRA might be due to a) loss of SRCs; b) differentiation of SRCs; c) dilution of SRCs 
as limited numbers of input equivalent cells were infused at five- and ten-week cultures 
when compared with two-week time point, or d) decreased ability to home to and to 
expand in the BM ofNOD/SCID mice when cultured for extended periods. 
Role of embryonic hematopoietic microenvironment on HSC and progenitor expansion 
The microenvironment of the AGM region, where definitive adult HSCs first appear 
during mammalian embryonic development, has been proposed to play an important role 
in HSC recruitment, maintenance and/or expansion [58]. A few stromal cell lines from 
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the AGM region have been reported to maintain HSCs with competitive repopulating 
activity [37, 59] in vitro. However, this support did not seem to be better than that of 
earlier established stromal cell lines from fetal liver or adult BM ([60, 61], chapters 2 
and 4). As the co-culture of HSCs with stromal cells has been shown to promote the 
hematopoietic activity and expansion of human HSCs and progenitors in vitro and in 
vivo, our second main topic in this thesis was aimed at analyzing whether our previous 
adult stromal support data could be improved by stromal cells derived from different 
embryonic regions. It is very likely that the neonatal HSCs and progenitors collected 
from UCB, which are a step closer to the fetal hematopoietic system, might also benefit 
from co-cultures with stromal cells derived from an earlier stage in the development 
than adult microenvironment. In the study presented in chapter 5 we have identified four 
embryonic stromal clones that support a dramatic expansion ofCFU-GM and CAFCw"k' 
during a twelve-week co-culture with human CD34+ UCB cells. This expansion was 
higher than that obtainable with the well established stromal line FBMD-1 known for 
its capability to maintain or expand HSC activity. As was the case in our previous co-
cultures with FBMD-1 (chapters 2-4), the majority of these embryo-derived stromal 
cells also required additional addition of cytokines, i.e. Tpo +/- Flt3-L, to achieve 
maintenance or expansion of human HSCs and progenitors. The addition of Tpo to 
different stromal co-cultures often dramatically prolonged the hematopoietic activity, 
indicating the importance of this cytokine in long-term survival of human HSCs. These 
data support and extend the requirement of Tpo to maintain murine HSCs in stromal 
co-cultures [35, 36]. We observed also a large variability in support of human HSCs and 
progenitors not only between clones derived from different embryonic regions, but also 
between clones derived from the same region. Such variability is most likely a reflection 
of the complex interplay between stroma and hematopoietic cells, regulated by adhesion 
molecules, extra-cellular matrix molecules, membrane-bound cytokines and cytokines 
receptors. Chemotactic factors such as SDF-la may additionally help to guide and 
maintain HSCs in their niches [ 62-64]. 
Stroma-specific distribution of HSCs and progenitors over adherent and non-adherent 
compartments 
We found that the majority of primitive human progenitors (CAFCwook6) localize in the 
non-adherent compartment of co-cultures with stromal cells derived from adult murine 
BM or embryonic AGM region-, liver- and gut mesentery (chapters 5 and 6). This is 
in contrast to co-cultures with primary EM-derived stroma, in which the majority of 
primitive progenitors can be recovered from the adherent stromal compartment [65, 66]. 
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Our finding is in line with several previous studies suggesting that FBMD-1, M2-l OB4 
and AFT024 stroma non-contact support of LTC-ICs/CAFCs as assessed in transwell 
experiments differed between co-cultures supported by different stromal cells [ 42, 67]. 
In another study a direct interaction between progenitors and stromal cells appeared 
not to be required for the maintenance of long-term in vitro hematopoiesis [ 68]. All 
these data indicate that the distribution of (primitive) progenitors over adherent and 
non-adherent compartments in stromal co-cultures might very likely depend on the type 
of stromal cells used. In our case we investigated whether this distribution could be in 
part due to the secretion level of chemotactic activity by stromal cells. Indeed, different 
stromal cells contained variable levels of chemotactic activities in their supernatants that 
could be modulated by Flt3-L and/or Tpo. Various chemoattractant factors have already 
been described to regulate (primitive) progenitor mobilization and homing. Stromal cell-
derived factor-! (SDF-1, CXCLI2), a ligand of the G-protein coupled CXCR4 receptor, 
produced by BM stromal cells and osteoblasts [64, 69, 70], has been shown as the major 
chemoattractant for progenitors. In our laboratory somatostatin (ligand of somatostatin 
receptor-2) has also been implicated in chemotaxis of normal and malignant hematopoietic 
progenitors [71, 72]. A new chemoattractant, WECHE, expressed amongst others in 
dorsal aorta, yolk-sac, fetal liver and umbilical vein, has recently been identified [73]. 
Additionally, it is known that chemoattraction of cells can be modulated by cytokines. 
For instance, CD34+ cells have been reported to show enhanced SDF-1 chemotaxis by 
either pre-treatment or co-incubation with IL3 or SCF [69, 74, 75]. Thus, in view of the 
existence of many chemokines and seven-transmembrane G-protein coupled receptors, it 
is reasonable that the interaction of human cytokines or human hematopoietic cells with 
stroma could result in release of chemoattractants or other yet unidentified factors by 
stromal or hematopoietic cells which in synergy with cytokines might affect (primitive) 
progenitor motility and guide them in the proper stromal environment, i.e. either in the 
adherent or non-adherent culture compartments. Our results obtained with the CXCR4 
antagonist suggest that the chemotactic activity in SCMs is to, a great extent, due to the 
interaction of this receptor and its ligand SDF -I. 
Which factors contribute to maintenance and/or expansion under stromal conditions? 
At present it is largely unknown which mechanisms are involved in the supportive effect 
of stroma on ex vivo maintenance and expansion ofHSCs and progenitors. Cell adhesion 
molecules and extracellular matrix molecules most likely contribute to a specific 
contextual interaction between stem cells and the stromal environment, and chemotactic 
factors as SDF-1 and specific lipids help to guide and maintain HSCs and progenitors 
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in their niches [62-64, 76, 77]. HSCs and progenitors are usually in a quiescent or slow 
cycling state under stroma-supported conditions and TGF-~ has been indicated as a 
candidate for controlling this quiescence. Indeed, it has been observed that primitive 
CD34•CD38· cells show a high sensitivity to cell-cycle inhibition by TGF-~, whereas 
more mature CD34+CD38+ cells are hardly affected or are even stimulated by TGF-~ 
[78-80] . MIP-1 a, interferon (INF) and tumor necrosis factor (TNF) have also been 
shown to inhibit hematopoiesis in in vitro assays, and in some cases when administered 
to mice they inhibited the cycling activity of progenitors in vivo [78, 81-84]. In addition, 
our group emphasized the use TGF-~ antagonist in expansion ofMPB cells. Exogenous 
addition of IL3, SCF, IL6 and anti-TGF-~ gave expansion of CAFCwook6 in one-week 
FBMD-1 stroma-supported cultures. One possible explanation might be that the addition 
of neutralizing antibodies directed against TGF~ could have abrogated the proliferation 
inhibition of stroma-contact, because TGF-~ is an important inhibitor of primitive stem 
cell proliferation and is produced by FBMD-1 stromal cells [85]. 
Whether HSCs require direct contact with stromal cells for their survival and/or 
proliferation or are regulated by stroma-derived factors exclusively remains unclear. 
While Verfaillie and coworkers reported an inhibitory effect of stroma-contact on 
CFC and LTC-IC proliferation as compared to stroma-noncontact conditions [68, 86-
88], Bennaceur-Griscelli et al. demonstrated that MS-5 stromal cells counteracted 
differentiation events triggered by cytokines and promoted self-renewal divisions [89]. 
Different stromal cells may vary in the extend with which molecules are elaborated 
into the medium or in their expression of adhesion molecules or chemotactic molecules 
affecting the ability of HSCs and progenitors to co-localize and adhere to stroma. 
Unpublished observations in our lab show that stromal cells differed in their protein 
expression of various cell adhesion molecules (CAMs), membrane-bound cytokines 
and cytokines receptors. No correlation of these parameters with stromal support for 
HSCs and progenitors was observed. It should be noted that these latter experiments 
were performed in the absence of human HSCs and progenitors. The presence of 
hematopoietic cells might very likely result in higher or lower expression of proteins 
affecting hematopoietic-stromal cell interaction, and in turn affecting hematopoietic 
cell maintenance or expansion. It is also reasonable that this interaction might result 
in induction or release of factors from either stromal cells or themselves differently 
affecting the support provided by different stromal cells. Among many cytokines and 
chemokines that could be possibly involved, murine IL6, ILl 0, EGF, GM-CSF, LIF, 
IFN-~ and y and M-CSF do not cross-react with human cells, while human IL-4, IL-
9, IL-12, EGF, GM-CSF and IFN-~ and-y are not able to activate the corresponding 
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receptors on mouse cells. In this context the study of Punzel et a! is of relevance [ 67]. 
These authors showed that addition of human SCF, G-CSF, GM-CSF, LIF, MIP-la 
and IL-6 in concentrations found in human bone marrow stroma-conditioned medium 
significantly increased LTC-IC maintenance. Other factors as 0-sulphated GAGs have 
been shown to aid the long-term maintenance of LTC-IC under stroma non-contact 
conditions [90], while exogenous addition of LIF have been suggested to be responsible 
for maintaining and expanding transplantable CD34+Thyl + cells in stroma-supported 
cultures through an action on the stroma [91]. We also observed that while the use of 
cytokines alone expanded early progenitors for twelve weeks and the use of stroma alone 
decreased their numbers within the same time period, the combination of stroma and 
cytokines greatly increased the maintenance and production ofHSCs and progenitors for 
extended periods. The effect of cytokines can thus partly be explained by a direct effect 
on HSCs and progenitors. However, they are also likely to act indirectly by an effect 
on stroma, indicating that the addition of cytokines may have reversed the proliferation 
block in stroma-contact cultures. Human Flt3-L, Tpo and IL6 are known to exhibit 
cross-species activity on mouse cells. Unpublished observations in our lab indicate that 
the murine adult EM-derived FBMD-1 stromal cells and embryonic stroma cells do not 
express murine c-kit (receptor for SCF) and Flt3 (receptor for Flt3-L). However, they 
express the murine IL6Ra and c-mpl (Tpo receptor), and human Tpo down modulates 
this IL6Ra expression on these cells. These data substantiate our contention that at 
least the cytokines Tpo and IL6 used in the present study might have reacted on both 
hematopoietic cells and stroma. Of further interest was the observation that in SCF + 
IL6 stimulated extended LTCs, stroma decreased the expansion magnitude of CD34+ 
and CD34+CD38· cells, CFU-GM and CAFC subsets as compared to the stroma-free 
conditions. A possible explanation for this observation is that the exogenous soluble 
ligand SCF may compete with the stroma membrane-bound SCF for c-kit receptors on 
HSCs and progenitors, assuming that the interaction with the membrane-bound SCF, 
rather than soluble SCF, results in the modification of the most effective signaling 
pathways in maintaining these cells. 
Jncongruency of surrogate HSC and progenitor assays after prolonged cultures 
Characterization of expanded cells for HSC and progenitor function is currently based 
on both in vivo (SRC and fetal sheep assays) and in vitro (CAFC, LTC-IC, and CFC) 
surrogate models. We found that important differences existed between the HSC 
and progenitor assays that have been used to quantitate their expansion after culture 
(chapters 3 and 5). Especially, the enumeration of CD34+ subsets and CFC generation 
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greatly overestimated the expansion of CAFC or SRA at the time points analyzed, 
confirming that the different surrogate methods to quantitate HSCs and progenitors are 
unlikely to detect identical populations after culture. These results were in agreement 
with previously published data indicating a dissociation between primitive CD34+CD38· 
phenotype, LTC-IC and SRC during cultures ofUCB or BM cells [34, 38, 92]. We have 
subsequently wondered whether the dramatic CD34+CD38· expansion during culture 
arose from the input CD34+CD38· cells or by downregulation ofCD38 antigen expression 
within a population of cultured CD34+CD38+ cells that no longer contained any LTR 
ability, both in vitro and in vivo. Remarkably, we found that although before culture the 
CD34+CD38· cells were all Lin·, after culture the majority of the CD34+CD38· cells co-
expressed lineage-restricted markers resulting in an overestimation of the expansion of 
the CD34+CD38· population. Additionally, Von Lear et al demonstrated that the purified 
CD34+CD38+ cell population lost their CD38 antigen while remaining CD34+ during a 
four days stroma-free culture [93]. Very recently, Danet et al. demonstrated that a loss of 
CD38, HLA-DR and c-kit surface expression led to a dramatic increase in phenotypically 
primitive MPB progenitors indicating that the relationship between stem cell phenotype 
and function is also altered in cultured CD34+ MPB cells [94]. These observations 
clearly indicate that this phenotype is not a reliable indicator for HSC assessment after 
culture. Thus one must be careful when interpreting data on HSC expansion, as it is 
possible to generate increased numbers of cells that may have phenotypic properties of 
primitive HSCs but do not functionally meet the criteria for HSCs. 
Clinical drawbacks in ex vivo expansion of HSCs and progenitors 
It requires a relative long time to increase the number of primitive cells by ex 
vivo manipulation [95-97]. Prolonged cultures may inherently cause exhaustion of 
proliferative and lineage potential of most primitive cells [50, 98]. In addition, ex vivo 
manipulation may reduce the efficiency of specific migration and homing of in vivo 
repopulating cells to the BM, as it is known that this homing process can be affected 
by cytokine exposure [50, 51, 53, 99, 100]. Thus, an effective culture system in which 
primitive cells can be rapidly expanded is required for clinical settings. Rapid expansion 
is also economical, less time consuming and labour intensive while limiting the risk of 
infections and transformation than a long process. 
As we and others show that cytokines and stomal cells are required for ex vivo 
expansion, the contamination of stromal cells into cultured hematopoietic cells is a 
potential clinical limitation of this culture system. It is also difficult to harvest cultured 
hematopoietic cells completely, since a number of cultured cells migrate under stromal 
189 
Chapter 7 
layers. Several groups looked for ways to circumvent these problems by the use of non-
contact and low or high pore density culture systems [87, 101, 102]. In these experiments, 
human hematopoietic cells were physically separated from the stromal layer in culture 
inserts. Whether such a system will be applicable in a clinical setting remains a question 
and a future challenge. In addition, the use of murine stromal layers for ex vivo expansion 
of human primitive cells is another problem for clinical application. Although the murine 
stromal cells can produce a large quantities of cytokines with cross-species activity, the 
availability of human stromal cell lines would allow a more stable and better defined 
tool to study the mechanisms of the support and manipulation of human hematopoiesis 
in vitro. Recent developments in this area are promising. Two human stromal cell lines 
have been reported to allow proliferation and differentiation of primitive hematopoietic 
cells from human UCB [103]. 
Current clinical status in ex vivo expansion of HSCs and progenitors 
The goal of improving the rate of engraftment, as well as speeding the time to recovery 
of marrow function, has spurred investigation of methods to numerically increase the 
HSCs and progenitors, not only from UCB but also with other sources. The potential 
clinical utility of ex vivo expanded HSCs and progenitors no longer remains a debate 
but has become feasible. On the basis of experimental findings and the development of 
automated closed-system for cell growth [I 04, I 05], human clinical trials have began. 
Several studies have been performed using teflon bags containing defined media [ 106-
1 09] or a perfusion culture system called the Aastrom system [11 0]. The human trials 
indicate the clinical benefit in post-transplant rate of the neutrophil recovery after the 
use of expanded cells, while the effect of expansion on long-term engraftment ability 
remains unanswered [106-116]. In the majority of the cases, ex vivo expanded cells 
were infused in combination with conventional cells. After infusion of these cells no 
prohibitive unfavorable immunological problems have been observed, demonstrating 
the feasibility of the expansion procedures and the clinical safety of the approach. 
In addition, no additional effect on platelet recovery was observed after infusion of 
expanded cells independent of their source. Possible explanations therefore may be that 
the culture conditions do not support progenitors that differentiate into platelets and/or 
that expanded cells need substantial cytokines as Tpo for platelet development. More 
interestingly, successful engraftment with solely expanded BM HSCs was also achieved 
using a stroma-based continuous perfusion method with addition of the cytokines GM-
CSFIIL3 fusion protein, Flt3-L and Epo or Tpo [112, 115], verifying the importance 
of the combination stromal cells and cytokines in order to ex vivo expand clinically 
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transplantable HSCs. Previously, our group demonstrated the requirement of stromal 
support and cytokines for optimal maintenance of the graft quality during ex vivo 
expansion of CD34+ MPB cells [ 42]. These observations extend the results described in 
this thesis in which we emphasize the role of stroma and cytokines for ex vivo expansion 
of UCB-derived HSCs and progenitors. Although we know that our expansion system 
requires an extended culture period, a combination of stroma and cytokines may allow 
sufficient increase for HSCs and progenitors with maintenance of the single stem cell 
quality that solely can be used as a graft without infusion of conventional cells. 
The regulation of homing, migration, engraftment and hematopoiesis is a complex 
process that presumably depends on microenvironmental factors, which are related to 
functional presence of stromal cells. It is very likely that the myeloablative regimens 
prior to SCT can affect the in vivo hematopoietic microenvironment of the recipient. The 
limitations on donor cell engraftment can thus be related to an inadequately receptive 
microenvironment. The cotransplantation of stromal cells might increase the level of 
engraftment by providing the necessary supportive microenvironment for hematopoiesis 
during the time when a relative abundance of donor HSCs is circulating. Indeed, 
cotransplantation of adult human stroma has been reported to result in increased human 
cell engraftment in a xenogeneic sheep transplantation model [ 11 7]. Also improved 
recovery of hematopoiesis after irradiation was demonstrated after stromal cell 
transplantation [118]. In addition to these functional effects of donor stroma infusion, 
homing of stromal cells has been demonstrated in other studies [119-121], however, 
many studies including BM transplantation in humans have suggested that the effectivity 
of stromal cell transplantation is very limited, if demonstrable at all [122-125]. 
Conclusions and future directions 
The results of this thesis research concerning the expansion of HSCs in vitro, show a 
maximal 825-fold expansion of UCB-derived CAFCw~k6 and 14-fold expansion in the 
ability of cells to engraft the BM ofNOD/SCID mice dependent on the culture conditions 
and/or time of culture, with particular reference to the cytokine combination Flt3-L and 
Tpo and/or the stromal layer used. In contrast to our demonstration for presence of 
stromal cells, Piacibello and coworkers demonstrate a more than 70-fold SRC increase 
after nine to ten weeks culture of CD34+ UCB cells under stroma-free conditions in the 
presence of the cytokines Flt3-L, Tpo, SCF and IL6 [27]. Despite these data, there is 
some evidence to suggest that cytokine exposure in vitro may reduce the efficiency of 
specific migration and homing of in vivo repopulating cells to the BM [50, 51, 53, 99, 
100]. Thus, at this stage it is not safe to extrapolate these preclinical findings to clinical 
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UCB transplantation in general. Expansion of UCB cells in the clinical setting should 
only be undertaken in highly specialized centers. 
We also demonstrate that the combination of cytokines and stromal cells are required 
for ex vivo expansion of primitive progenitors exceeding a time period of two weeks. 
These data suggest that this combination may also be required for maximal engraftment 
and self-renewal of transplanted cells in vivo. Thus, it is important to assess the use 
of stromal cells to enhance the engraftment rate and quality of the graft. A combined 
cytokine and stromal cell strategy will potentially maximize engraftment and vastly 
improve therapeutic outcomes. Another option, which at present remains technically 
challenging, will be the use of genetically engineered cytokine producing stromal 
layers to create a continuous level of cytokine production throughout the LTC in order 
to optimize the ex vivo expansion. Also, the membrane-bound form of cytokines, such 
as SCF, may play an important additional role in the cell-cell interactions observed 
between stromal and hematopoietic cells in these cultures. 
In summary, the results described in this thesis provide information regarding 
regulation of hematopoiesis within its microenvironment. However, it is still unclear 
which stromal factor(s) is (are) involved in HSC and progenitor expansion. As we 
continue to functionally characterize several stromal cell-lines derived from AGM-
region, further investigations may include the identification of (novel) molecules/genes 
by subtractive analysis using genomics and/or proteomics. 
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Summary 
Umbilical cord blood (UCB) is a most recent source of hematopoietic stem cells (HSCs) 
and progenitors, which has been used to treat especially young patients with malignant 
and nonmalignant hematological diseases and other severely ill patients whose immune 
systems have been decimated by high dose chemotherapy. However the reconstitution of 
hematopoiesis after transplantation with UCB cells is slower as compared to the use of 
BM or mobilized peripheral blood (MPB) grafts, which is most probably due to the low 
number of transplanted HSCs per kg bodyweight. This limited number of HSCs from 
one UCB unit may especially pose a problem when transplanting adult patients. In view 
of these existing limitations, there is a strong need for ex vivo culture systems allowing 
numerical expansion of UCB HSCs and progenitors prior to their transplantation in 
order to facilitate rapid and durable engraftment. 
The aim of this thesis was to define conditions that allow rapid and extensive 
numerical expansion of UCB HSCs and progenitors ex vivo without a concomitant loss 
of the ability for long-term repopulation. The surrogate in vitro and in vivo long-term 
repopulating cell assays were used to allow quantitative analysis of uncultured and 
cultured UCB HSCs and progenitors. 
In chapter 2 we tested whether HSC expansion would alter the in vitro and in vivo 
long-term repopulating potential ofCD34+ UCB under stroma-free and stroma-supported 
culture during two weeks. Our data showed a more than I 0-fold numerical expansion of 
cobblestone area forming cells (CAFC)w"k' and of the potential of CD34+ UCB cells to 
multilineage engraft the bone marrow (BM) of sublethally irradiated NOD/SCID mice in 
the presence of at least Flt3-L + Tpo. Among the cytokine combinations tested, stroma 
significantly improved the maintenance of CAFCw"k' with the cytokine combination 
Flt3-L + Tpo. 
The experiments described in chapter 3 were designed to investigate whether HSC 
expansion could be improved when the UCB cells were cultured for more than two 
weeks, and whether the presence of BM -derived stromal cells, and combinations of 
specific cytokines, could affect the maintenance or expansion of the in vitro and in vivo 
long-term repopulating potential of CD34+ UCB cells. In these studies stromal support 
enhanced the expansion of CAFCw,,k6 (maximally 89-fold the input at week 10) in the 
presence of Flt3-L + Tpo + IL6. Cultures stimulated with at least Flt3-L + Tpo gave an 
estimated 10 to 14-fold expansion of the ability of CD34+ UCB cells to multilineage 
engraft the BM of sublethally irradiated NOD/SCID mice at two weeks of stroma-free 
and stroma-supported cultures, while at week 5 and later the estimated SRA decreased 
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to low or undetectable levels in all groups. Shortly, our results show that stroma and 
Flt3-L + Tpo greatly increase the long-term generation of HSCs and progenitors as 
measured by in vitro assays. However, the different surrogate methods to quantifY the 
HSCs and progenitors (CD34+CD38·, colony forming cells (CFC), CAFCwookG and NOD/ 
SCID repopulating ability (SRA)) showed increasing incongruency with increasing 
culture time. Especially, the enumeration of CD34+ subsets and CFC generation greatly 
overestimated the expansion of CAFC or SRA at the time points analyzed, confirming 
that the different surrogate methods to quantitate HSCs and progenitors were unlikely to 
detect identical populations after culture. 
In chapter 4, the effect of a designer fusion protein of IL6 and the soluble IL6R, H-
IL6, on the ex vivo expansion of UCB progenitors was evaluated. This protein binds to 
Gpl30, a transducer unit shared by a series of receptors including IL6, ILl!, oncostatin-
M and leukemia inhibitory factor. Gpl30 is ubiquitously expressed on blood progenitors 
whereas the expression of IL-6R is limited to only 30-50% of CD34+ UCB cells. As a 
single agent, the fusion protein failed to induce the generation of UCB-derived CD34+ 
cells and CAFC, but synergized effectively and in a dose-dependent fashion with Flt3-L 
and Tpo for the expansion of hematopoietic progenitor cells under both stroma-free and 
stroma-supported conditions. We additionally showed that IL6 was more potent than 
the fusion protein in supporting the long-term generation of UCB CD34+AC!33+ or 
CD34+ cells and CAFC in the presence ofFlt3-L and Tpo under stroma-free and stroma-
supported conditions. 
In the embryo hematopoietic cells emerge and rapidly expand in the ventral wall of 
the dorsal aorta. To investigate the presumptive unique characteristics of the embryonic 
hematopoietic microenvironment and its surrounding tissues, we have generated stromal 
clones from subdissected day 10 and day !! AGMs, embryonic livers (ELs) and gut 
mesentery, and tested many of them for their support of murine blood progenitors. 
Subsequently, nineteen newly established murine embryonic stromal clones were 
selected and investigated for their ability to sustain human UCB HSCs and progenitors 
in extended LTCs of CD34+ UCB cells in the absence or presence of the cytokines Flt3-
L and Tpo. These embryonic stromal clones differed greatly in their support for human 
progenitors. Four embryonic stromal clones, two urogenital ridge (UG)-, one gastro-
intestinal tract (GI)- and one EL-derived, were identified that support a high numerical 
expansion of human UCB CFU-GM and CAFCwookG in the presence of at least Tpo. This 
expansion was higher than that obtainable with the FBMD-1 stromal cell line known 
for its capability to maintain or expand HSC activity. Without addition of cytokines 
only one EL-derived cell clone maintained the CFU-GM generation for up to twelve 
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weeks, while in the presence of at least Tpo to the stromal co-cultures a continuous 
HSC and progenitor production was supported by twelve out of nineteen stromal clones. 
Overall, the limited number of stromal clones analyzed did not allow identification of 
the embryonic region that best supports the maintenance and expansion of human UCB 
HSCs and progenitors. 
The interaction between hematopoietic stem cells and the microenvironment requires 
a close association of these entities. In order for the stem cells to home to the proper 
microenvironment, stromal cells produce chemotactic factors. The most potent of these 
factors is stromal derived factor-!. We found that embryonic stromal cells (chapter 6), 
particularly those derived from the dorsal AM, strongly elaborate chemotactic activities 
for HL-60 and UCB CD34+ cells. The presence ofFlt3-L and/or Tpo during the stromal 
conditioning phase of medium modulated this chemotactic activity in a stromal cell 
specific way. Flt3-L or Tpo as single factors increased the chemotactic activity ofMS-5 
and FBMD-1 stromal cells, while these cytokines had an inhibitory effect on production 
of chemotactic activity by most other stromal cells. Surprisingly, the combination of 
Flt3-L and Tpo had the opposite effect, as it dramatically increased the chemotactic 
activity of AM30 clones. These effects were not due to residual Flt3-L and/or Tpo 
during the transwell migration assay, as addition of these cytokines to the medium in the 
migration assay did not affect HL-60 cell migration in the absence or presence of various 
stroma-conditioned medium. 
The studies outlined in this thesis demonstrate that in vitro and in vivo long-term 
repopulating cells from UCB can be expanded ex vivo. However, this numerical 
expansion required at least I 0 weeks of culture. Another point of attention is that 
the human progenitors are co-cultured with murine stromal cells that can not be fully 
depleted from the cultured graft to allow clinical use. At the moment the clinical utility 
of this approach remains to be fully defined as it is not feasible to perform these cultures 
on a routine basis for use in clinic. Expansion ofUCB cells in the clinical setting should 
only be undertaken in highly specialized centers. 
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Sam en vatting 
Navelstrengbloed (NB) is de meest recente bron van hematopoietische stamcellen 
(HSC) en voorlopercellen, die gebruikt worden voor de behandeling van met name 
jonge patienten met maligne en non-maligne hematologische aandoeningen, en andere 
emstig zieke patienten met een defect immuunsysteem veroorzaakt door hoge-dosis 
chemotherapie. Het herstel van de bloedvorming na conditionering en daaropvolgende 
transplantatie met NB cellen is echter langzamer in vergelijking tot het gebruik 
van beenmerg (BM) en gemobiliseerd perifeer bloed (MPB) cellen. Dit is hoogst 
waarschijnlijk het gevolg van het !age aantal HSC dat wordt getransplanteerd per kg 
lichaamsgewicht. Door het !age aantal HSC nit een enkele NB verzameling kunnen zich 
met name problemen voordoen wanneer een volwassen individu ermee getransplanteerd 
wordt. Vanwege deze beperking is er een sterke behoefte aan ex vivo kweeksystemen 
die HSC en voorlopercellen nit NB numeriek kunnen vermeerderen alvorens ze te 
transplanteren teneinde een snel en duurzaam herstel te kunnen bewerkstelligen. 
Het in dit proefschrift beschreven onderzoek was gericht op het definieren van 
omstandigheden die een snelle en omvangrijke numerieke expansie van NB HSC en 
voorlopercellen ex vivo mogelijk maken zonder daarmee samengaand verlies van het 
lange-termijn repopulerend vermogen. Voor kwantitatieve analyse van ongekweekte en 
gekweekte NB HSC en voorlopercellen zijn er bekende kweekmethoden gebruikt voor 
in vitro en in vivo lange-termijn repopulerende cellen. 
In de experimenten beschreven in hoofdstuk 2 hebben we bestudeerd of HSC 
expansie onder stroma-vrije en stroma-ondersteunde omstandigheden het in vitro and in 
vivo repopulerend vermogen van NB CD34+ ce!len kan wijzigen gedurende twee weken 
kweek. In aanwezigheid van tenminste Flt3-L en Tpo werd er een meer dan 10-voudige 
numerieke expansie verkregen van CAFCw'"'' en van het vermogen van CD34+ cellen 
om een multi-lineage herstel te geven van de bloedvorming in het BM van subletaal 
bestraalde NOD/SCID muizen. Naast de verschillende groeifactoren die gebruikt zijn 
bleek stroma in combinatie met Flt3-L en Tpo het behoud van CAFCw"'' verder te 
stimuleren. 
De experimenten in hoofdstuk 3 waren ontworpen om te onderzoeken in hoeverre 
HSC expansie kan worden verbeterd wanneer de NB cellen Ianger dan twee weken 
waren gekweekt, en in hoeverre de aanwezigheid van stroma en bepaalde groeifactor 
combinaties het behoud of de expansie van het in vitro en in vivo lange-termijn 
repopulerend vermogen van CD34+ NB cellen konden belnvloeden. In deze studies 
werd gevonden dat stromale ondersteuning de expansie van CAFCw'"'' versterkt met op 
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week I 0 een maximale 89-voudige toename in aanwezigheid van Flt3-L + Tpo + IL6. 
K weken die op zijn minst gestimuleerd waren met Flt3-L + Tpo resulteerden na twee 
weken in een geschatte I 0 tot 14-voudige expansie van het vermogen van CD34+ cell en 
om het BM van subletaal bestraalde NOD/SCID muizen (SRA) te herstellen, terwijl 
na 5 weken en later de geschatte SRA fors daalde, zelfs tot ondetecteerbare niveaus in 
aile groepen. Kortom, onze gegevens Iaten zien dat stroma en Flt3-L + Tpo de lange-
termijn productie van HSC en voorlopercellen (bepaald met in vitro kweekmethoden) 
enorm doet toenemen. Maar de verschillende kweekmethoden die gebruikt zijn om HSC 
en voorlopercellen te kwantificeren (CD34+CD38·, kolonie vormende cellen (CFC), 
CAFCwookG en SRA) Iaten onder ling een toenemende incongruentie zien met toenemende 
kweektijd. Met name de bepalingen van CD34+ subpopulaties en CFC productie 
hebben de expansie van CAFCwookG en SRA sterk overgeschat. Deze gegevens Iaten 
zien dat na kweek de verschillende kweekmethoden waarmee HSC en voorlopercellen 
gekwantificeerd worden geen identieke populaties identificeren. 
In het onderzoek beschreven in hoofdstuk 4 werd het effect onderzocht van een in 
ontwikkeling zijnd fusie eiwit van IL6 en de oplosbare IL6 receptor (IL6R), H-IL6, op 
de expansie van NB voorlopercellen. Het H-IL6 eiwit bindt aan Gpl30, een 'transducer 
unit' dat als subunit fungeert in een aantal receptoren o.a. IL6, ILl!, oncostatine-M en 
'leukemia inhibitory factor'. Gp 13 0 wordt hoog geexpresseerd op bloedvoorlopercellen, 
terwijl de expressie van IL6R beperkt is tot 30-50% van de CD34+ NB cellen. In de 
aanwezigheid van aileen het fusie eiwit wordt de productie van CD34+ cellen en CAFC 
uit NB niet gestimuleerd, maar het verhoogde synergistisch en in een dosis-afhankelijke 
wijze met Flt3-L en Tpo de expansie van hematopoietische voorlopercellen onder 
stroma-vrije en stroma-ondersteunde omstandigheden. In aanvulling hierop hebben 
we Iaten zien dat IL6 meer doeltreffend werkte dan het H-IL6 fusie eiwit bij de 
ondersteuning van de lange-termijn productie van NB CD34+ACJ33+ of CD34+ cellen 
en CAFC in aanwezigheid van Flt3-L en Tpo onder stroma-vrije en stroma-ondersteunde 
omstandigheden. 
Hematopoietische cellen in het embryo ontstaan en expanderen heel snel in de 
ventrale wand van de dorsale aorta. Om de vermoedelijk unieke karakteristieken 
van het embryonale hematopoietische micromilieu en zijn omringende weefsels te 
onderzoeken, hebben we stromale klonen ontwikkeld uit dag I 0 en 11 aorta-ganado 
mesonephros (AGM), embryonale lever (EL) en darm mesenchym, en vee! ervan zijn 
onderzocht op hun mogelijke ondersteuning van muize bloedvoorlopercellen. Volgend 
op deze experimenten zijn negentien van deze nieuw ontwikkelde muize embryonale 
stromale klonen geselecteerd en onderzocht op hun vermogen om humane NB HSC 
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en voorlopercellen te handhaven of the expanderen in verlengde lange-termijn kweken 
van CD34+ NB cellen in af- of aanwezigheid van de groeifactoren Flt3-L en Tpo. Deze 
embryonale stromale klonen verschilden grotendeels in hun support voor humane 
voorlopercellen. Vier embryonale stromale klonen, twee ervan afkomstig van urogenitale 
tractus (UG)-, een van gastro-intestinale tractus (GI)- en een van EL, zorgden voor een 
hoge numerieke expansie van humane NB CFU-GM and CAFCwook6 in de aanwezigheid 
van tenminste Tpo. Deze expansie was boger dan die welke verkregen werd met de 
FBMD-1 stromale cellijn die bekend staat om zijn capaciteit om HSC activiteit te 
handhaven of te expanderen. Terwijl zonder toevoeging van groeifactoren een stromale 
celkloon uit de EL in staat was om de CFU-GM productie voor ongeveer twaalf weken 
te onderhouden, konden in aanwezigheid van tenminste Tpo twaa!f uit een totaal van 
negentien stromale klonen dit bewerkstelligen. Vanwege het beperkt aantal onderzochte 
stromale klonen waren we statistisch niet in staat een embryonaal gebied met de beste 
ondersteunende capaciteiten voor het handhaven en expanderen van humane HSC en 
voorlopercellen uit NB aan te wijzen. 
De interactie tussen HSC en micromilieu vereist een nauwe samenhang. Om ervoor 
te zorgen dat de HSC zich via het homingsproces (het proces van migratie van HSC 
via de bloedbaan naar het beenmerg) in het juiste micromilieu vestigen, worden 
er chemotactische factoren geproduceerd. De meest potente van deze factoren is 
'stromal derived factor-!'. We hebben gevonden dat embryonale stromale cellen, met 
in het bijzonder de stromale cellen afkomstig van dorsale aorta (hoofdstuk 6), sterke 
chemotactische activiteiten produceren die HL-60 en NB CD34+ cellen aantrekken. De 
aanwezigheid van Flt3-L en/of Tpo tijdens de stromale conditioneringsfase reguleerde 
deze chemotactische activiteit in een stromale eel specifieke wijze. Het enkel gebruik 
van Flt3-L of Tpo deed de chemotactische activiteit van MS-5 en FBMD-1 stromale 
cell en toenemen, terwijl deze groeifactoren een inhibitoir effect hadden op de productie 
van chemotactische activiteit van de meeste andere stromale cellen. Onverwachts liet 
de combinatie van Flt3-L en Tpo een tegengesteld effect zien op de chemotactische 
activiteit van AM30 klonen door deze sterk te Iaten toenemen. Deze effecten waren niet 
het gevolg van overgebleven Flt3-L en/ofTpo tijdens de transwell migratie experiment, 
omdat de toevoeging van deze cytokinen aan het medium in het migratie assay de HL-
60 eel migratie niet be'invloedde in de af- of aanwezigheid van verschillende stroma 
geconditioneerd media. 
De studies die in dit proefschrift staan beschreven, demonstreren dat in vitro en in vivo 
lange-termijn repopulerende cellen uit NB geexpandeerd kunnen worden ex vivo. Deze 
numerieke expansie vraagt echter tenminste I 0 weken kweek. Een ander aandachtspunt 
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is dat de humane voorlopercellen gekweekt zijn samen met muize stromale cellen, welke 
niet volledig verwijderd kunnen worden bij een eventuele klinische toepassing. Op dit 
moment dient het klinische gebruik van deze toepassing nog beter worden beschreven 
omdat het routine basis gebruik van deze kweekmethoden in de kliniek niet haalbaar is. 
Expansie van NB cellen voor het klinisch gebruik zal hierbij aileen kunnen plaatsvinden 
in hoog gespecialiseerde centra. 
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Abbreviations 
AM 
AGM 
APC 
BFU-E 
BM 
BSA 
CAFC 
CD 
CFC 
CFU-C 
CFU-GM 
CSF 
EL 
Epo 
FACS 
FBMD-1 
FCS 
FITC 
Flt3-L 
G-CSF 
GM-CSF 
HS 
HSC 
HSPC 
IL 
IMDM 
GI 
Lin-
LTC 
LTC-CFC 
LTC-IC 
LTR 
MNC 
MPB 
aorta/mesenchyme 
aorta gonad mesonephros 
allophycocyanin 
burst forming unit-erythroid 
bone marrow 
bovine serum albumin 
cobblestone area forming cell 
cluster of differentiation 
colony forming cell 
colony forming unit in culture 
colony forming unit-granulocyte macrophage 
colony stimulating factor 
embryonic liver 
erythropoietin 
fluorescent activated cell sorting 
flask bone marrow dexter-clone 1 
fetal cald serum 
fluorescent iso thio cyanate 
fms-like tyrosine kinase-3 ligand 
granulocyte-colony stimulating factor 
granulocyte-macrophage-colony stimulating factor 
horse serum 
hematopoietic stem cell 
hematopoietic stem and progenitor cell 
interleukin 
Iscove's modified Dulbecco's medium 
gastrointestinal 
lineage marker negative 
long-term culture 
long-term culture colony forming cell 
long-term culture initiating cell 
long term repopulating 
mononuclear cells 
mobilized peripheral blood 
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NC 
NOD/SCID 
PB 
PBS 
PE 
SCF 
SCM 
SCT 
SD 
SDF 
SRA 
SRC 
Tpo 
UCB 
UG 
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nucleated cells 
nonobese-diabetic/severe combined immunodeficient 
peripheral blood 
phosphate buffered saline 
phycoerythrin 
stem cell factor 
stroma conditioned medium 
stem cell transplantation 
standard deviation 
stromal derived factor 
NOD/SCID repopulating ability 
NOD/SCID repopulating cell 
trombopoietin 
umbilical cord blood 
urogenital-ridge 
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kwijtraakt. Bedankt voor jouw aanwezigheid, medeleven en onuitputtelijke vriendschap. 
Ik wens jou aile succes met de voorbereidingen van jouw proefschrifL Or han en Hiiseyin 
ik wil jullie bedanken voor jullie steun, ik heb vee! van jullie twee geleerd. Aysel 
Terkivatan, jou ben ik ook niet vergeten, ik zal mijn best doen om onze vakantie met de 
meiden nog een keer te regelen. 
Nahim Avc1, mijn muziekleraar, jou wil ik bedanken voor je geduld met mij als 
leerling en voor het verruimen van mijn blik in muziek. Toen ik je uitlegde wat voor 
een idee ik over de kaft van dit proefschrift had wist jij precies het muziekstuk wat erbij 
hoorde. 
Ik wil de cardiologen dr. Pels, dr. Stoel, dr, Ten Kate, de longarts dr. Van Uffelen, de 
!eden van CCU, echo-cor, CAG en de afdeling cardiologie van het Albert Schweitzer 
ziekenhuis locatie Amstelwijck (kortom het Amstelwijck clubje) bedanken voor hun 
gezelligheid en hulp tijdens mijn eerste stappen van het artsenleven. Ik heb het werken 
nooit zo leuk gevonden als toen. 
Tiirkan, een van mi jn paranimfen, als ik moet opschrijven waarvoor ik jou moet 
bedanken heb ik meters papier nodig. Chirurgen houden van kort en bondig, daar jij een 
toekomstige chirurg bent zeg ik aileen maar bedankt. 
Casanova, dit had jij niet gedacht maar ik ga het toch doen, bedankt dat jij een veilige 
haven bent geworden waar ik in aile rust kan verblijven. Ik wens jou aile goeds. 
Mijn ouders, de eerste onderwijzers van mijn Ieven, wat ik van jullie heb geleerd kan 
ik nooit elders leren. Anne ve baba, hayattaki ilk 6gretmenlerim, sizden 6grendiklerimi 
baska hi~ bir okul 6gretemez, sayg1yla ellerinizden opiiyorum. Salim, Deniz, Emin en 
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Hila!, broers en zus, ik weet niet hoe ik jullie moet bedanken voor alles. Zander jullie 
zorg, steun en lief de was dit proefschrift nooit waardevol geweest. Ik wil ook ons jongste 
familielid Fatma, mijn schoonzus, bedanken voor haar vriendschap en gezelligheid. 
Verder mijn grootouders, aile ooms en tantes, neefjes en nichtjes, kusjes. 
Macht ik iemand vergeten zijn ... bedankt! 
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